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INTRODUCTION 
 The word “Siddha” comes from the word “siddhi”, which means an object to 
attain perfection or heavenly bliss.  Siddha generally refers to Attama siddhi that is the 8 
super natural powers those who attained or achieved the above said powers are know as 
“Siddhars”.Siddhars were saintly figures. There were eighteen important siddhars in 
olden days and they developed this medicine. 
Origin : 
 The origin of siddha system of medicine, traces back to the submerged Lemurian 
continent. Its was conceived and crafted by the ancient siddhars who’s principle 
Language was Tamil.  The origin of the system and the usaged of medicinal plants 
belongs to the age of the Sangam Literatures as early as 3000 B.C. “Tholkappiam”  
and“Thirumanthiram” stands as a proof to this.  
Basic principles : 
 Siddha system of medicine is based on “Saiva Siddhantha” .  The prime principle 
of saiva siddhantha is to become one with the gods almighty and that is determined  as a 
goal of life.  The goal of life can be achieved by keeping the health of our mortal body.  
The could be known by Thirumoolar in line, which says,  
clk;ghh; mopapy; capuhy; mopth;; ; ; ; ;; ; ; ; ;; ; ; ; ; 
jplk;gl nka;Qhdk; NruTk; khl;lhh;; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ; 
clk;ig tsh;f;Fk; cghak; mwpe;Nj ; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;  
clk;ig tsh;j;Njd; caph; tsh;e;NjNd ! ; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ;  
 jpUke;jpuk;  
 Siddha science considers nature and man as essentially one.  Nature is man and 
man is nature. Man is said to be the microcosm and universe is the macrocosm because 
what exists in the world exists in man. Man is nothing but a miniature  world, containing 
the five elements of various principles which constitute the minerals plants, and animal 
kingdom .  
According to siddha medical science, the universe originally.  Consisted of atoms  
which   contributed to the five basic elements. Viz., 
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Prithivi -  Earth 
Appu  -  water  
Theyu  -  Fire 
Vayu   -  Air  
Agayam  -  Sky 
Among these elements. 
 Earth – gives fine shapes to the body includes bones tissue, muscles, skin, hair, 
etc, 
 water – represents for blood secretions of the gland, vital fluid etc.          
 Fire – gives motion, vigor and vitality to the body.  
These three elements  are primarily responsible for the formation of three 
humours, 
 Vatham   
 Pitham  
 Kabam.  
 These are the three fundamental functional constituents of human body and these 
are supposed to be in the proportion of 1: ½ : ¼ in a healthy individual and are known as 
“Muthathukkal”(Kj;jhJf;fs;).But when this equilibrium is disarranged these are known 
as mukkutrangal  (Kf;Fw;wq;fs;)  which lead to disease.  This principle is quoted by  
Thiruvalluvaras  
kpfpDk; FiwapDk; Neha;nra;Ak; E}Nyhh; ; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;  
tspKjyh vz;zpa %d;W; ;; ;; ;  
-jpUf;Fws; ; ;; ;; ;  
The Fundamental subjects of Siddha methodology 
1.Vadham (Alchemy )  
2.  Vaithiyam (medicine)  
3. yogam (yoga) 
 4. Gyanam or Thathuvam (philosophy)  
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Meateria  Medica : 
 The siddha system has three classifications over the sources of the drug.  They are  
 Mooligai vaguppu – plant sources. 
 Thathu Vaguppu – metal and mineral sources  
 Jeeva Vaguppu- animal sources.  
 
CHEMISTRY IN SIDDHA SYSTEM: 
In siddha system, chemistry had been found well developed into science auxilliary 
to medicine and alchemy. It was found useful in the preparation of medicine as well as in 
transmutation of basic metals into gold.  The siddhars were aware of several chemical 
operations divided into several process such as : 
 Calcination 
 Sublimation 
 Distillation  
 Fusion   
 Separation 
 Fermentation  
 Exaltation etc.    
  With the help of these,various medicines are prepared to cure the various 
diseases.According to the siddha literature,there are 4448 diseases.Among them 80 vadha 
diseases. 
  In that, Thandaga vatham is one of the most common degenerative joint disorder 
causing health problems for backache to neurological problems. Yugimunivar has 
classified“Thandaga vatham” as one among the 80 types of vatha disease. The disease 
Thandaga vatham (Yugi vaidhiya chinthamani Page No. 109-110) can be correlated to 
Lumbar spondylosis.Age 45-64 years identified 85.5% of Osteophytes within the lumbar 
spine. 
27-37% of symptomatic population internationally Lumbar spondylosis can begin 
in person as young as 20 years. 
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10% of women age 20-29 to have evidence of disc degeneration, lumbar 
spondylosis while affecting 80%  older than 40 years nevertheless was found 3% of 
individuals aged 20-29 years.  
Approximately 84% of men and 74% of women have vertebral osteophytes, most 
frequently at T9-10 and L3 levels. Approximately 30% of men and 28% of women aged 
55-64 years have lumbar osteophytes. Approximately 20% of men and 22% of women 
aged 45-64 years have lumbar osteophytes. 
 All of the symptoms may disappear when the patient ceases walking even though 
he remains in the standing position at times however the symptoms may be exacerbated 
by prolonged standing and relieved by only sitting or lying down.Sitting for prolonged 
periods of time may cause pain and other symptoms due to pressure on lumbar vertebrae. 
Repetitive movements such as lifting and bending (eg: manual labour) may increase pain.  
It commonly affects different sects of people like tailors, drivers, clerks, etc. most 
recent additions are IT sector people. 
  Treatment is usually conservative in nature; the most commonly used treatments 
are non-steroidal anti-inflammatory drugs (NSAIDs), analgesics (rarely steroids and 
opioids), physical modalities, and lifestyle modifications. Surgery is occasionally 
performed.Hence there is an immense gap between the disease and its management and if 
an alternative medication is proved, there is much hope, that this gap can be reduced 
greatly. Hence the author has taken “Thandaga vatham” comparable with lumbar 
spondylosis as research topic. 
          Numerous Siddha drugs are available to treat this disease and many of them have 
been tried already and have shown good results. Yet the author has chosen a new drug, 
from the classical text. This is because, as lumbar spondylosis is mostly degenerative 
disease, a special combination with rejuvenating drugs, from a classical textbook of 
medicine, could give excellent prognosis. 
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The author’s choices of medicines for the clinical study are  
INTERNAL DRUG: KUSTATHI CHOORNAM (1 GRAM WITH HOT WATER) 
                                      (ANUBOGA VAITHIYA DEVARAGASIYAM)Pg No., 424 
EXTERNAL MEDICINE: ERANDA THYLAM (30 ml). 
(SARABANTHIRA VAITHIYA MURAIGAL- VATHAROGA CHIKKICHAI) 
Pg No., 12 
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AIM AND OBJECTIVE  
AIM :  
  Phase II criteria based clinical study of THANDAGAVATHAM (Lumbar 
spondylosis) and the drug choice KUSTATHI CHOORNAM (internal) and ERANDA 
THYLAM (External) 
  
OBJECTIVE : 
Primary objective : 
 To evaluate the clinical efficacy of KUSTATHI CHOORNAM (internal) and 
ERANDATHYLAM (external)  for the treatment of THANDAGA VATHAM  
(LUMBAR SPONDYLOSIS). 
 
Secondary objective:   
• To study the Siddha basic principles like envagaithervukkal including neerkkuri 
and neikkuri. 
• To evaluate the safety profile of the trial medicine. 
• To Evaluate the pharmacological study of trial medicine  
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REVIEW OF LITERATURE 
SIDDHA ASPECTS 
jz;lf;;; thjk;;;; 
‘A+fp itj;jpa rpe;jhkzp” E}ypy; thj Neha;fs; 80 tifahf tptupf;fg;gl;L 
cs;sJ. ,jpy; xd;W jz;lfthjk;; ;; ;; ;. 
Definition : 
  mtatq;fis nraywr; nra;J clk;ig jz;lfj;ijg; Nghy; tPo;j;jp 
ePl;ly; klf;fy;> mirj;jy; Kjypait ,y;yhky; rtj;ijg; Nghy; fplf;fr; 
nra;Ak; thj NehahFk;. 
  A kind of rheumatism chareterised by great prostration in which the body is 
rendered like a log of wood , unable to stretch of fold the limbs and pass motion or urine. 
The whole body assumes a thorough rigidity as the stiffness appearing after death. 
-T.V.Sambasivapillai agarathi IV. 
Etiology: 
  The etiological factors of thandaga vatham are similar to that of the common 
etiological factors of Vadha diseases. They are, 
A+fp itj;jpa rpe;; ;; ;; ;jhkzp - 800 : 
‘vd;dNt thje;jh ndz;gjhFk; 
,fj;jpNy kdpju;fSf; nfa;AkhW 
gpd;dNt nghd;jidNa NrhuQ;nra;J 
ngupNahu;fs; gpuhkziuj; J}lzpj;Jk; 
td;Njtr; nrhj;jpy; NrhuQ;nra;J 
khjh gpjh FUit kwe;j Ngu;f;Fk; 
fd;dNt Ntjj;ij epe;ij nra;jhy; 
fhaj;jpw; fye;jpLNk thje; jhNd.”!
‘jhndd;w frg;NghL Jtu;g;Giwg;G 
 rhjfkha; kpQ;RfpYk; rikj;j tz;zk; 
Mndd;w thwpdJ Grpj;jhYk; 
 Mfhaj; NjwyJ Fbj;jyhYk; 
ghndd;w gfYwf;fk; kpuh tpopg;G 
 gl;bdpNa kpfTWjy;  ghunka;jy; 
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Njndd;w nkhopahu; Nkw; rpe;ijahjy; 
 rPf;fpukha; thjkJ nrdpf;Fe; jhNd.” 
 
‘Mdhd tud;widNa kjpahkhe;ju; 
 mfjp guNjrpau;fl;F md;d kPahu; 
 Nfhdhd FUnkhopia kwe;j Ngu;fs; 
 nfhiyfsT ngha;fhkq; Fwpj;j Ngu;f;F 
 Cdhd rle;jd;dpy; thjk; te;J 
 cw;gtpf;Fk; Ntjj;jpd; cz;ikjhNd.” 
‘thjtu;j;jp jidfhy NkNjh ntd;dpy; 
 kUTfpd;w thdpfu;f; flfkhFk; 
                Mjitg; grpNahL fhu;j;jpif jd;dpy; 
 mlUNk kw;wkh jq;fs; jd;dpy; 
                 NghjNt rkpf;Ffpd;w fhykhFk;.” 
guuhrNrfuk;:; ;;  
‘ghupdpw; gag;gl;lhYk; gyUld; Nfhgpj;jhYk; 
fhnudf; fUfpNahbf; fOkuj;Juj;jpdhYk; 
 VHngW jdJ neQ;rpd; kpfj;Jf;fkile;jpl;lhYk; 
ghupa fhw;wpdhYk; gluPDk; thjq;fhZk;”!
mfj;jpau; Fzthflk;:; ; ;; ; ;; ; ;  
‘tptuklh mrjp rd;dp %is NehT 
 tpupthd %isaJ kpUJthfp 
mtdpjdpy; jplkhfg; NghtjhYk; 
 mg;gNd %j;jpu Fz;bf;fha; tpahjpahYk; 
jtKdptu; jPu;f;fhf;if Nkf Nuhfk; 
 jd;ikAs;s Kj;jz;L nfhbtpahjp 
mtkpyhg; gupr euk;gOj;jq; fz;lhy; 
 mZFklh thjNeha; MFk;ghNu.” 
mfj;jpau; fd;k fhz;lk;:; ; ; ; ;; ; ; ; ;; ; ; ; ;  
‘E}nyd;w thjk; te;j tifjhNdJ 
 Ez;ikaha;f; fd;kj;jpd; tifiaf; NfS 
fhypNy Njhd;wpaJ fLg;gNjJ 
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 iffhypy; Klf;fpaJ tPf;fNkJ 
 NfhypNy gLfpd;w tpUl;rkhd 
 Foe;ij kue;jd;id ntl;ly; Nky;Njhy;rPty; 
ehypNy rPtnre;J fhy;Kwpj;jy; 
 ey;ynfhk;G jioKwpj;jy; eypj;jy; fhNz.” 
To sum up: 
Diet: 
• Excessive bitter, astringent, pungent taste foods. 
• Harmful combinations like milk and greens. 
• Eating tubers. 
• Drinking polluted water. 
• Previously cooked items. 
 
Lifestyle: 
• Day time naps. 
• Overnight toil. 
• Excessive physical strain. 
• Walking long distances. 
• Exposure to excessive cold. 
• Mental fluctuations. 
Seasonal changes: 
• Precipitation of Vadha diseases generally occur during the winter season ( Aani to 
Karthigai). 
Siddha literature states that since the soul is immortal, the imprints of sins would 
be carried over from life to life and expressed via diseases. This theory of kanmam should 
be extensively studied and further analyzed. 
Neha; tUk; top:; ;; ;; ;  
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        czthjp nray;fshYk; fhy - Njf epiy khWghLfshYk; fd;k 
tpidahYk; thjk; mjpfupj;J gpj;j - fgq;fis nfLj;J gpd; VO 
clw;jhJf;fis gw;wp Neha; Vw;gLfpwJ/ 
THE TYPE OF ALTERATIONS OF VATHA ARE 
1. THANNILAI VALARCHI )!jd;dpiy tsh;r;rp*!
DEFINITION 
   A Kutram, which is provoked in its own location, is called Thannilai Valarchi. 
 
LIMITATION 
  Hatefulness of the things, which are causing thannilai valarchi, and likeness 
of things, which, are getting opposite properties are the limitations of Thannilai Valarchi. 
 
DURATION 
Vatha gets "Thannilai Valarchi" during Mudhuvenil Kaalam (Aani andAadi]. 
 
2. Vetrunilai Valarchi )Ntw;Wepiy tsh;r;rp*!
DEFINITION 
  A kutram, which is provoked to other locations, is called "Vetrunilai Valarchi". 
 
LIMITATION 
  Signs and symptoms of the affected kutram and the pathological conditions of 
the Udal kattugal give details of the limitations. 
 
DURATION : 
  Vatha Gets "Vetrunillai Valarchi" during Kaar Kaalam [Aavani and Purattasil. 
 
3. THANNILAI ADAITHAL )jd;dpiy miljy;)!
DEFINITION 
  A provoked Kuktram, which is neutralizing in its own property, is called 
Thannilai Adaithal. 
 
DURATION 
  The provoked vatha neutralizes during Koodhir Kaalam (lyppasi and Kaarthigaij. 
  Mdp> Mb> Mtzp> Gul;lhrp> Ig;grp> fhh;j;jpif ,k;khjq;fspy; thjk; 
kpFe;J Ntjid jUk;. kw;w khjq;fspy; thjk; rkdilAk;. 
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FACTORS WHICH ALTER VATHA 
1. When hot foods are mixed with vayu, vatha gets "Thannilai Valarchi”. 
2. When cold is mixed with vayu, vatha gets "Vetrunilai Valarchi”. 
3. And when oilyness mingles with hotness and gets are mixed with vayu, vatha 
neutralizes in its own property that means healthy conditions. 
 
CHARACTERISTICS OF VATHA THEGI : 
ACCODING TO SIDDHA MARUTHUVAANGA SURUKKAM ;!
• thj clypdDf;Fj; jPAk; IaKk; Fiwe;J tsp kpFe;jpUg;gJkd;wp> 
nkype;J cah;e;j clYk;> 
• gUj;j mbj; njhilfSk;> ele;jhy; fPy;fs; 
nel;ilapLjYk;> 
• jbj;j ,ikfSld; tl;lkhf tpfhhpj;Jr; rhf;fz; Nghd;W 
RuRug;ghAk;> 
• Fsph;e;jghh;itAk;> rpWJ fWik ntz;ik fye;jdthAkpUf;Fk; fz;fSk;> 
• rpWJntz;ik fye;J xspUk; cly; epwKk; mt;thW fWj;J Kid 
gpse;j jiykapUk;> 
• njspthd thh;j;ijiaAk; rpy Ntis kdf;fyf;fj;Jld; gl;Lk; 
glhikAkhd jLkhw;w thh;j;ijAk;> 
• jpj;jpg;G Gspg;G> cg;G> #L cs;s nghUs;fspy; rpWJ tpUg;gKk;>Fsph;r;rp 
nghUe;jpa nghUs;fspy; ntWg;Gk;>kpf;f cz;bAk;> kpf;f cz;bnadpDk; 
mw;g td;ikAk;> 
• ngz;fsplj;jpy; mw;gtpUg;Gk;> 
• tPhpa tsh;r;rpf; FiwTk;> 
• Gj;jpu ngUf;fKk;> Mz;ik czh;r;rp 
mwpT ,it epiyapd;idAk;> 
• tpisahl;L> ,ir mtkjpr;rphpg;G> njhf;fzk;> 
Ntl;ilahlypy; tpUg;Gk;> 
• jFjp ,d;ik> gifik><ifapd;ik> nghd;dhyhd 
nghUs;fis fth;jypy; epidg;G Kjypa gz;GfSk; Gfopd;ikAk;> 
• miuf;fz; %ba rpW J}f;fKk;> mj;J}f;fj;jpy; tPz;> kiy> fhL 
,itfspy;jhd; elg;gjhff; fhZfpd;w fdTk;> Gyikj; jpwikiaAk; 
cz;lhapUf;Fk;. 
-rpj;j kUjJ; thq;fr; RUf;fk; 
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According to Sidha Maruthuvaanga Surukkam, 
Vatha thegi has an appearance of 
• Thin, tall built 
• Large thighs 
• Thickened eyelids 
• Round, small, white, mixed eyes 
• Cool sight Black and white coloured skin complexion 
• Black, diverten hairs 
• Clear Speech – some times slurring, digressing speech etc 
 
Pathophysiology: 
           Diet, Seasonal changes, Lifestyle variations and Psychosocial factors  causes 
imbalance in the basic elements altering the ratio of three humours and leads to the 
derangement of seven udal thaathus producing the disease symptoms. 
The five basic elements: 
Earth: 
• It represents the Solidity. 
• It gives shape to the body and releases its energy.  
• Bones, muscles, nerves, skin, hair represent the Earth in the body. 
• Stability, strength, growth, firmness, sturdiness are its characters. 
Water: 
• It represents Fluidity. 
• Makes the Earth supple and helps in the transmission of energy. 
• Serum, lymph, saliva, sweat, semen represent it in the body. 
• Smoothness, gracefulness, volatility, agility, flexibility are its characters. 
Fire: 
• It represents warmth. 
• It gives vigor and stimulation to the body. 
• Hunger, fear, anger, irritation represent it in the body. 
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• It controls digestion. 
• Heat, dryness, sharpness, illumination, are its characters. 
Air: 
• It represents gas atmosphere. 
• It works as a life carrier.  
• Respiration and nervous system are controlled by it. 
• Walking, running, standing, sitting, jumping like postures represent it in the body. 
• Aridity, parchedness, wryness, sadness are its characters. 
Ether: 
• It is the eternal space and creator of life. 
• The eight indispensible passions represent it in the body. 
• Infinitesimal nature, clarity, subtleness, delicacy, refinement are its characters. 
The derangement of FIVE ELEMENTS in Thandaga Vatham is as follows. 
S.No. Element 
Nature of 
derangement 
Effect 
 
1. 
 
Earth 
 
 
Osteophytes 
 
2. 
 
Water  
 
 
Giddiness (Decrease blood supply). 
 
3. 
 
Fire 
 
 
Breaking the Cartilage Fragments. 
 
4. 
 
Air 
 
 
Swelling and Pain, Mental Depression. 
 
5. 
 
Ether 
 
 
Joint Space Narrows. 
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Three humours: 
Vadham: 
• Formed by air and ether. 
• Construction, dryness, cool, minuscule, hardness, movement, buoyancy are its 
properties 
• Skin, bone, muscles, nerves, joints are the seats of vadham. 
• It controls the senses, respiration, emotion, speech, etc. 
• It causes pain, numbness, spasticity, flaccidity, tremors, muscle wasting, 
inflammation, thirst, constipation, dryness, loss of movements, loss of integrity, 
hyper pigmentation etc if affected. 
Pitham: 
• Formed by fire. 
• Protection, warmth, sour, liquidity, transparency are its properties. 
• Blood, lymph, eyes, stomach are it seats. 
• It performs the functions of digestion and controls taste, hunger, thirst etc. 
• It also controls intellect. 
• If deranged it causes giddiness, anorexia, fever, jaundice, anaemia etc. 
Kabam: 
• Formed by earth and water. 
• Destruction, softness, sweetness, frothiness, flimsiness are its properties. 
• Intestine, liver, brain, thorax are its seats. 
• It gives lubrication to the joints, strength to joints. 
• Its derangement leads to loss of strength and steadiness, vertigo, palpitation etc. 
 VATHAM: 
• Improves the sensory organ
• Improves the speech
• Stabilizes the mind
• Controls respiration and gives more energy.
CITATION: 
• Abanan 
• Faeces 
• Idakalai 
• Below the umbilicus
• Lumbar spine 
• Skin  
• Nerves 
• Joints and hair follicles
• Muscles 
    It represents vayu, mind, dryness, pain, flatulence, sensitiveness and lightness.
Pranan: 
• Regulates respiration
• Controls mental function and 
 
KABAM
Aran
15 
 
 
 
 
 
 
 
special senses. 
 
VATHAM
Ayan
PITHAM
Arhi 
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Abanan: 
• Excretes urine and faeces 
• Expulsion of semen and fetus 
Viyanan: 
• Promotes circulation and strengthens the nervous system 
• Responsible for the recognition of various sensation 
Uthanan: 
• Responsible for the functions of the speech 
• Reflexes like vomiting, hiccough, cough etc., 
Samanan: 
• Assimilation process 
Nagan: 
• Responsible for intelligence 
• Movement of eyeball 
Koorman: 
• Responsible for the sensory functions of eyes 
• Promotes lacrimination 
Kirukaran: 
• Increases salivation in the oral cavity and mucous secretion in the nasal cavities 
• .Increases appetite and helps in concentration 
Thevathathan: 
• Responsible for laziness. 
• Eyeball movements. 
Thananjeyan: 
• Escapes after death from body 
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In thandaga vatham Abanan, Viyanan, Samanan , Thevathathan may be affected. 
PITHAM: 
Analagam: Responsible for digestion 
Ranjagam: Gives nutrition to blood 
Sathagam: Responsible for willful activities. 
Prasagam: Gives luster to skin. 
Alosagam: Gives strength to eyes 
Sathagam is affected in thandaga vatham 
KABAM: 
Avalambagam: Controls other kabams 
Klethagam: It lubricates the food. 
Bothagam: Responsible for taste sensation 
Tharpagam: It acts as a coolant for eyes. 
Santhigam: It maintains the integrity of joints. 
Avalambagam and Santhigam are affected in thandaga vatham. 
UdalThathukal: 
 There are seven udal thathukkal in human body. 
Saram 
 
Strengthens the body and mind 
 
          Affected 
Senneer 
 
Preserves brightness, boldness, power 
and knowledge. 
 
Not Affected 
Oon Gives structure and shape to body. Represents the tissues. 
Early stage – not affected. 
Later stage – Affected 
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THANDAGAVATHAM: 
Thandagavatham is one among the 80 vatha diseases with the clinical symptoms of: 
 Pain starts at the lower back gradually it moves upwards due to causative 
factor the Vayu travels in such a way. 
 Excessive sweating 
 Reduced range of movements 
 Anaemia 
 Yellow discoloration of urine and faeces 
 Aggrevating factor affects the bones and nerves,not able to walk. 
 
ACCORDING TO YUGI VAITHIYA CHINTHAMANI : 
 
‘tOj;jNt %yhjhuj;ijg; gw;wpNa 
kUtpNa NkNywp KJF kl;lha; 
tpOj;jNt rpurpy; te;J tpah;Tkhfp 
tpFthf Nehthfp Nkdp fd;wp 
gOjj; Nt clk;ngq;Fk; gQ;R Nghyhk; 
ghq;fhd kyry kQr;shFk; 
FOj;jNt njz;lfkhk; thje;jd;idf; 
$wpNdhq; Fznky;yhq; $h;e;J ghNu” 
-A+fp itj;jpa rpe;jhkzp ghly; 288 
 
‘$h;e;j;pl;l kyryq;fs; Jhpjkhdhy; 
nfhz;llf;fpg; gpd;Gjhd; nfhbjha; js;sp 
Ch;e;jpl;l rhPuj;jp Yjpu kPwp 
Cwj; Nja;j;J jiyajdp nyz;nza; thh;f;fpy; 
Thh;j;jpl;l top elf;fpy; nkj;j Te;jhd; 
Thje; jhDwg; tpj;J eil nfhlhky; 
Kozhuppu 
 
Lubricate the joints. 
 
Affected 
      Enbu 
 
         Physical bone structure. 
 
            Affected 
Moolai 
 
It is present in the bones and gives 
strength to them 
 
Affected 
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ehh;e;jpl;l euk;NghL vYk;gpw; #oe;J 
eZfpNa Nahb neQ;rp NtWe; jhNd 
-A+fp itj;jpa rpe;jhkzp ghly; 289 
 
Nahfj;jpd; Kjy; epiyapy; EioAk; NghJ cz;lhFk; Nfl;lhy;> KJFj; 
jz;bd; fPo;g;Gw kpUe;J jiy tiuapYk; fpsk;gpa thAtpdhy; Vw;gLk; NehahFk;. 
,e;Nehapy; tpah;j;jy;> cly; ,WFjy;> typj;jy;> cly; gOj;Jg; gQ;R Nghy; 
ntSj;jy;> kyKk; rpWePUk; kQ;rshjy; vd;Dk; Fwp Fzq;fis fhl;Lk;. 
 
jz;lf thAtpYz;lhFk; fopr;riy mlf;fp tUtjyhy; rpd;dhl;fs; 
nrd;w gpd;G mf;fopr;ry; mlf;f Kbahj mstpy; kpFe;J fopaj; njhlq;Fk.; 
 
mjdhy; cly; KOikAs;s FUjp jd;dstpy; kpFe;J ghAk;. md;wpAk; 
,e;Neha; KOikAk; NghfhjpUf;ifapy; jiy KOfy;> mjpf njhiyTelj;jy; 
,tw;iw Nkw;nfhs;spy; tspf;Fw;wk; kpFe;J euk;G> vYk;Gfis gw;wpr; #o;e;J 
elf;f Kbahkw; nra;J mt;thA neQ;R tiuAk; ghAk;. 
 
CAUSATIVEFACTOR: 
 Due to wrong yogic practices at the joint level,vayu gets started from lower back 
andreaches the head and causes the disease. 
 
AGGREVATING FACTOR: 
 Head bath 
 Walking for a long distance 
 
ACCORDING TO ROGA NIRNAYASARAM : 
‘Njfk; jz;lj;ijg; Nghy; tpOe;J mirtpy;yhky; ,Uf;Fk;” 
-Nuhf eph;za rhuk; 
Body is rendered like a log of wood. 
ACCORDING TO THANVANTHIRI VAITHIYAM : 
“Nlgm<m!keiz<!uiB!ukqglib<s<!sqOzx<!hek<jkk!<!
K~lgm<migs<!Osi<k<Kk<!kck<kqMR<s<!sivQ!olz<zil<!
Ofilg<!gm<mie!Oleq!Fuzqjth<!ohbi<h<Hk<!Okie<Xl<!
Kilg<!gm<mie!Ovigf<!k{<mg!uikliOl”!
.ke<uf<kiq!juk<kqbl<!
! !
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Nlk<Kme<!uiB!nkqgiqk<K!ghk<Kme<!Osi<f<K!siQvk<jk!^<K~zqg<gs<!
osb<Bl</!siQvl<!uim<mljmBl</!
• Generalized odema 
• General weakness 
 
ACCORDING TO JEEVARATCHAMIRTHAM :- 
thAthdJ vz;nza; t];J> ke;jt];J> rPu tPhpa t];J> japh; 
mjpfytzk;> gfy; epj;jpiu> gjpdhd;F Ntfq;fis kwpj;jy; Mfpatw;why; 
gpwe;Jrg;jjhJf;fspYk; tpahgpj;J mitfisf; fiyj;Jtpl;L 
Mkhra];jhdj;ijmDrhpj;Jr; rpNyj;k gpj;jq;fisj; jd;Dld; Nrh;j;Jf; 
nfhz;Lmtatq;fspd; nraiy khw;wptpLk;. ,jdhy; urhjp jhJf;fspy; 
kuj;jy;>rPjsk;> cs;nshpr;ry;> rhPuq; fdj;jy;> Qhgfkwjp> gpuik> Royy; 
NghypUj;jy;>,isg;G> mjpf Ntjid> ePh;f;fl;L vd;Dk; ,f;FwpFzq;fNshL 
NjfkhdJjz;lj;ijg; Nghy tpOe;J mirjYk; ePl;ly; Kf;fYk; 
vOjYk;,y;yhjpUf;Fk;. ,J Njfj;ij jz;ilg; Nghy ePl;b tpLjyhy; jz;lf 
thjk;vdg; Ngh; ngw;wJ. 
-mD Nghf itj;jpa Njtufrpak; (Kjy; ghfk;) 
• Numbness 
• Burning sensation 
• Loss of memory 
• Giddiness 
• Dyspnoea 
• Body pain 
• Unurea 
• Body is rendered like a log of wood 
• Restricted movements 
 
PINIYARIMURAIMAI - DIAGNOSIS 
Pini yari muraimai means method of finding the diseases. 
Piniyari Muraimai - Pini + Yari + Muraimai 
Pini Means - The disease which catch the body 
Yari means - Identifying the diseases 
Muraimai means- Rules and methods 
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As per siddha literature, the diagnosis is based upon three main principles. 
1. Poriyalarithal 
2. Pulanal arithal 
3. Vinaathal 
Poriyalarithal and pulanalarithal: 
Poriyal means five organs of perception pulangal means five objects 
Porigal Pulangal 
1. Nose - Smell 
2. Tongue - Taste 
3. Eyes - Vision 
4. Skin - touch 
5. Ear - Sound 
The application of poriyalarithal and pulanalarithal form the fundamental stepin 
the diagnosis of a disease. 
Vinaathal: 
It is asking questions concerned with the history of disease, and its clinical 
symptoms etc., to the patient (or) asking to his neighbour, when the patient is not able to 
speak, or the patient to be a child' These three principles are affected through the Envagai 
thervugal. 
The diagnosis is made through a proper examination of human body known as 
Envagai thervu. They are, 
‘ehbg; guprk; ehepwk; nkhoptpop 
kyk; %j;jpukpit kUj;Jt uhAjk;” 
                  - Neha; ehly; ghfk;I 
• Na - Examination of the tongue 
• Niram - Examination of skin colour 
• Mozhi - Examination of oral cavity and speech 
• Vizhi - Examination of eye 
• Malam - Examination of faecal matter. 
In thandagavatham there is constipation. 
• Moothiram - Urine analysis 
 
22 
 
‘mUe;Jkhwp ujKk; mtpNuhjkha; 
m/fy; myu;jy; mfhyT+d; jtpu;e;jow; 
  Fw;wstUe;jp cwq;fp itfiw 
  Mbf; fyrj; jhtpNa fhJnga; 
njhU K$u;j;jf; fiyf;Fl;gL ePupd; 
epwf;Fwp nea;f;Fwp epUkpj;jy; flNd”; 
- Neha; ehly; ghfk; I 
1. Neerkuri- The four aspects of this are, 
o Colour 
o Odor 
o Specific gravity 
o Deposits  
!!!!!!‘te;j ePu;f;fupvil kzk;Eiu vQ;rnyd; 
iwe;jpaYstit aiwFJ KiwNa” 
2. Neikuri – 
  This is special technique for diagnosing specific for Siddha system of medicine. A drop 
of oil is dropped inurine; the shape in which it spreads is noted and compared with 
standard list provided by the Siddha literature. 
o Sparisam - Analysis of texture, temperature through touch 
Finally the most important  
o Naadi or pulse examination. 
The three Uyir thaadhus are formed by the combination of 
Idagalai + Abanan - Vadham 
Pingalai + Pranan  - Pitham 
Suzhumunai + Samanan - Kabam 
 Derangement in the ratio leads to various diseases. The naadi can be felt one inch 
below the wrist on the radial side by means of palpation and percussion with the tip of the 
index, middle and ring finger corresponding of Vatham, Pitham and Kabam respectively. 
The normal ratios of three humours of the body are 1:1/2:1/4 respectively. 
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‘fhpKfdbia tho;j;jp ifjdpy; ehb ghh;f;fpy; 
  ngUtpuyq; Fyj;jpy; gpbj;jb eLNt njhl;lhy; 
  xU tpuNyhby; thjk; cah; eLtpuypy; gpj;jk; 
  jpUtpuy; %d;wpNyhby; rpNyj;Jk ehbjhNd” 
                               -Neha; ehly; ghfk;I 
InThandaga vatham the Naadi is either Vadha Pitham or   Pitha Vadham. !
Geographical, Seasonal and Personal variations (nilam, kalam, theganilai) are 
taken into consideration for the diagnosis of the diseases. 
GEOGRAPHICAL VARIATION: 
The geographical distribution of the land is classified into five types. 
• Kurunji – Kabha diseases and liver diseases are common. 
• Mullai –  Pitha and Vadha diseases are common. 
• Marutham – Safest place to reside. 
• Neithal – Vadha diseases are common. 
• Paalai – All the three humours may be affected. 
SEASONAL VARIATIONS: 
• Kaar kalam – August 16 – October 15. 
• Koodhir kalam – October 16 – December 15. 
• Munpani kalam – December 16 – February 15. 
• Pin pani kalam – February 16 – April 15. 
• Ilavenil kalam – April 16 – June 15. 
• Mudhuvenil kalam – June 16 – August 15. 
PERSONAL VARIATIONS: 
• Vatha thegam 
• Pitha thegam 
• Kabha thegam 
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DIFFERENTIAL DIAGNOSIS: 
Other vatha disease, which resembles thangaga vatham are mentioned 
below.Caution of patient history taking and examination will help to diagnosis the 
diseasewithout any doubt. 
 
They are 
1. Aasuva thamba vatham 
2. Ooruthamba vatham 
 
1. MRtjk;g thjk; : 
‘thjkh Aly;n tSj;J tonty;yh Neuk; 
Kaf;fNkh bUkyh A+id Az;lhk; 
Nejkha; neQr;ilj;jg; nghwp fyqF;k; 
neUgg;hf cly; fhZ neL%r;Rz;lhk; 
NfhJjhd; kaf;fj;jpy; kUe;jpl;hy; 
Fsph;r;rpaha;f; Nfhgpf;Fq; $r;r Yzl;hk; 
ghjej;hd; jpkpUzl;ha; KlN;ghyhFk; 
gLj;j MRtjk;gk; gfuyhNk 
gfuNt thjkJ Nfhgpj;jg;Ngh 
gz;ghf ];jphfh;b aJjhd; nra;apy; 
efuNt ntFJ}u top elf;fpyt; 
espuhd fhw;WNk gdpNky; gl;lhy; 
kpfuNt fha;fs; fdp fpoq;F jd;id 
kpftUj;jp kPwpNaa; japh;jhd; nfhz;lhy; 
KfuNt KJnfYk;ig KWf;fp nehe;J 
Koq;fhYq; fizf;fhYq; fLg;Gz;lhNl” 
-A+.fp.it. rpe;jhkzp 
The Clinical features are : 
1. Paleness of the body 
2. Cough 
3. Chest heaviness 
4. Numbness of both lower limbs. 
!
3/!CUj;jk;g thjk; :; ; ;; ; ;; ; ;  
‘Mnkd;w thjkJ cs;s lq;fp 
Mbj;Jiljhd; Fwq;fpuz;L kytha;g; gw;wp 
25 
 
fhnkdw; iffhypy; tpuY Rw;wpf; 
fdj;JNk rhzpaJ nghjpe;jhh; Nghyj; 
Njnkd;w rpue;jdpNy ghu Kz;lha;j; 
NjnkqF; %jpNa jpkpUz; lhFk ; 
ehnkd;w elf;nfhzu nthLf;f khfp 
eypA+Ue; jk;gkJ eDFq;fhNd” 
 
The clinical features are 
1. Heaviness in both thighs 
2. Feelings of cow waste applied over fingers of both hands and feet 
3. Numbness feel in whole body 
4. Difficulty in walking. 
 
LINE OF TREATMENT 
According to Siddha system of medicine, any disease management has three stages. 
• Kaapu or Prevention. 
• Neekam or Treatment. 
• Niraivu or Restoration. 
KAAPU OR PREVENTION: 
• Avoid excessive weight lifting. 
• Maintain proper posture while sitting. 
• Sleep without pillows. 
• Avoid watching television for a long period. 
• Avoid excessive cold exposure. 
NEEKAM OR TREATMENT: 
  The main aim of treatment in Siddha system is equlizing the lost equilibrium in 
three humours. Hence the below order is followed in the treatment of thandaga vadham. 
• Purgatives 
• Internal and external medicines. 
• Diet and advises. 
• Kanma neekam. 
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1. PURGATIVES: 
The purgatives are given to correct the deranged Vadham. 
‘tpNurdj;jhy; thjk; jhOk;”!
Mostly used purgatives are, 
• Vellai ennai – 10 – 15 ml 
2.INTERNAL AND EXTERNAL MEDICINES: 
      Internl and external medicines are given to cure the diseases. 
3. DIET AND ADVISES: 
     Pathiyam or dietary regulations should be strictly followed while taking internal 
medicines.  If not followed it may antagonize drug effect and can produce unwanted 
results. 
‘gj;jpaj;jhNy gyDz;lhFk; kUe;J 
gj;jpaq;fs; Nghdhy; gyd; NghFk;- gj;jpaj;jpy; 
gj;jpaNk ntw;wpjUk; gz;bjUf; fhjypdhw; 
gj;jpaNk tj;jpnad;W ghu;” 
                               -Njiuau; ntz;gh.   
4. KANMA NEEKAM: 
  To expiate the effects of kanmam, following measures are advised. 
‘italh nrt;te;jp KsupjhDk; 
thfhd fpzWfSk; rhiy Nrhiy” 
-mfj;jpau; fd;k fhz;lk; 
NIRAIVU OR RESTORATION: 
  Any residual effects of the disease should be cleared and the patient should return 
to his normal life.  To restore the activities of the life, special threapy is much essential.                                
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SIRAPPU MARUTHUVAM 
  All of the three stages of management of Thandaga vadham can be done by the 
application of SIRAPPU MARUTHUVAM (Special medicine), which is the unique 
feature in Siddha system of medicine. 
 KARPAM 
 YOGAM 
 VARMAM 
 THOKKANAM 
These are the specialty in SIRAPPU MARUTHUVAM. 
1.KARPAM: 
  Karpam or rejuvenator acts at molecular level and delays cellular ageing, thereby 
fights the progressive degeneration, is magnificent concept of Siddhars. It may be herbal, 
mineral or animal product. Some of the Karpam useful in Vadha diseases are  
• Inji (Gingiber officinalis) 
• Erukku (Calotrophis gigantea) 
• Seenthil (Tinospora cordifolia) 
• Amukura ( Withania somnifera) 
• Kodiveli (Plumbago zeylanicum) 
• Parangi pattai (Smilax chinensis) 
• Serankottai  (Semecarpus anacardium)  
2.YOGAM: 
  Yogam is defined as the union of the individual spirit with the universal spirit or 
attaining oneness with God. Astanga yogam defines eight steps of accomplishing 
enlightment. 
‘,ak epakNk vz;zpyh Mjdk; 
eaKW gpuhzhahkk; gpuj;jp ahfhuk; 
rakpF jhuiz jpahdk; rkhjp 
maKWk; ml;lhq;fk; MtJ khNk”!
.kqVlf<kqvl</!
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 Purity in thought. 
 Purity in action. 
 Proper postures. 
 Breathing exercises. 
 Restraining five senses. 
 Concentration. 
 Meditation. 
 Submission and attaining oneness with God. 
 
A. Asanam: (Proper postures) 
Asana means a state of being in which one can remain physically and mentally 
steady, calm, quiet and comfortable. Asana are specific body positions which opens the 
energy channels.  They are tools to higher awareness and provide the stable foundation 
for our exploration of the body, mind and the soul. 
Some of the asana useful in thandaga vatham are, 
 Chakrasanam – wheel pose 
 Thanurasanam – bow pose 
 Salabasanam – locust pose 
 Paatha hasthasanam 
 Ushtasanam  
MECHANISM OF PAIN RELIEF: 
1. Action on spinal muscles : 
  Asanam dampen the inflow of sensory impulses to the brain, which causes the less 
stimulation to the emotional brain.  Therefore, there are less visceral disturbances.  
Further reduction of sensory input creates a reciprocal chain, relaxing the muscle.  
Inhibition of synapses due to relaxed neuro muscular junctions in turn reduces the sensory 
input further.  
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2. Effects on tendons and ligaments: 
  The accentuated curve of the spine makes it supple and mobile.  The action on the 
ligaments and tendons of the spine has important effects on the nervous activity. 
3. Effects on nervous system: 
Asanam generate reflex actions in the vegetative functions and tones the chains of 
ganglions situated on both sides of the spine. 
 
B. Pranayamam: 
PRANAN means bioenergy. IYAMAM means control. Hence pranayama means control 
of bioenergy. 
‘Vw;wp ,wf;fp ,UfhYk; G+upf;Fk; 
fhw;iw gpbf;Fk; fzf;fwp thupy;iy 
fhw;iw gpbf;Fk; fzf;fwp thsu;f;F 
 $w;iw cijf;Fk; FwpaJ thNk”!
.jpU%yu;.!
USES OF PRANAYAMAM: 
 It improves the vital capacity. 
 Improves circulation. 
 Aids concentration. 
3.VARMAM: 
The points where the energy source resides and flows in the body of a living 
organism are known as varmam. If it is hurt in a particular manner, that forces some 
symptoms and signs in the human body, according to the site of injury. 
We can use these points in constructive way to cure diseases, relieve pain, 
preserve body etc. It can also be used defensive or attack stance, with techniques as in 
varma kalai, kalaripaayathu etc. 
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The varmam points useful in thandaga vatham are 
 Manibandha adangal 
 Komberi kaalam 
 Kuthikaal varmam 
 Kaaal kulasu 
 Kanpugaichal 
 Viruthi kaalam 
 Sevikutri kaalam 
 Mudichu varama 
 Nai iruppu varmam 
 Puratharai 
 Ulthodai varmam 
 Boomi kaalam 
4.THOKKANAM: 
Thokkanam or massage is a relaxation technique very much useful in vadha diseases. 
‘njhf;fzj;jp dhypuj;je; Njhy; Cdpitfl;F 
kpf;f rTf;fpaQ; rkPuDk; Nghk; - nka;f;fjpf 
 Gl;bAwf;fk; Gzu;r;rpapit fjpf;Fk; 
gl;l miyr;ryWk; ghu;”-Njud; jU. 
Benefits: 
 Improves blood and lymph circulation. 
 Reduces nerve irritation. 
 Refreshes the tissues. 
 It may also reduce the level of stress hormones. 
 Produces endorphins and gives happiness. 
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MODERNASPECTS 
AnatomyofVertebralColumn: 
The vertebral column forms back bone of the body. It forms a part of the axial 
skeleton. It is made up of 33 pieces of vertebrae and in intervening intervertebral discs. 
It is 60-70 cm length. 
AnatomyoftheSpine 
The spine is a complex structure that provides structural support for the body, 
transmits the weight, allows movement,protect the spinal cord and exiting nerve roots and 
act as an attachment site for the muscles and ligaments. 
CurvaturesofSpine: 
Normal curves present in sagittal plane with lordosis on the cervical and 
lumbar spine and Kyphosis in the thoracic spine. These normal curves allow for 
improved flexibility and load bearing capacity of the spine. 
The cervical and lumbar spine vertebrae are highly mobile as compared to the 
more rigid thoracic vertebrae that are restrained by the ribcage. 
IntervertebralDisc: 
  It is a fibro cartilaginous space found between the vertebral bodies. It is 
composed of inner nucleus pulposus and outer annular fibroses. 
LUMBARVERTEBRAE 
 It consist of 5 individual cylindrical boes that forms the spine in the lower back in which 
the first four are typical and the fifth is atypical. 
Typicallumbarvertebra: 
 Body is large and is wider from side to side than from before to backwards. 
 Vertebra foramen is triangular in shape and is larger than thoracic region. 
 Pedicles are short and strong. They project backwards from the upper part ofbody. 
 Laminae are short and thick board. They are directed and medially. 
 The spine form a vertical quadrilateral plate direct backwards and downwards. 
 The transverse processes are thin and taping, are directed laterally and 
slightlybackwards. 
 The superior articular processes lie farther apart than inferior. Each process 
bears a concave facet facing medially. Inferior articular process lies nearer to 
each other than superior. 
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FIFTHLUMBARVERTEBRAE 
 Body is largest of all lumbar vertebras.Anterior surface is deep. 
 Pedicles are directed backwards and laterally. 
 The spine is small and short. 
 The transverse processes are small short and pyramidal in shape. 
 The superior articular facets look more backward than medially and inferior 
articular facet look more forwards. 
 The distance between the inferior articular processes is equal or more than 
thedistance between the superior articular process. 
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ANATOMY OF LUMBAR VERTEBRAE: 
 These vertebrae carry all the upper body weight which provides the flexibility and 
movements to the trunk region. 
 The lumbar vertebrae make uo the region of the spine inferior to the thorax and 
superior to the sacrum and coccyx in the pelvis. 
 It connects the each vertebrae to its adjoining vertebra,it is called intervertebral 
disc,made up of tough fibrocartilaginous jelly like centre. 
 The outer layer of the intervertebral disc is annulus fibrosis which holds the 
vertebra together and provides the strength and flexibility to the back during 
movement. 
 The jelly like nucleus pulposus acts as a shock absorber to resist the strain and the 
pressure exerted on the lower back. 
 A cylinder of bone known as the vertebral body makes up the majority of the 
lumbar vertebral mass and bears most of the body weight. 
 Posteriorly the body is connected to a ring of bone known as the arch.The arch 
surrounds the hollow vertebral foramen and connects the body to the bony process 
on the posterior of the vertebra. 
 The vertebral foramen is a large,triangular opening in the centre of the vertebra 
thar provides the space for spinal cord,cauda eqina and meninges as they pass 
through the lower back. 
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The muscles around the lumbar spine can be divided into 3 group of muscles 
because of position and function: 
1. Psoas major attaches directly to the vertebral bodies anterolaterally and acts 
as a primary flexor muscles of the hip joint. 
2. Quadratus lumborum and the lateral intertransversarii attach to and 
covers the transverse process anteriorly.They act merely at lateral flexors. 
3. Interspinalis,anterior transversarii medialis, multifidi, lumbar erctor 
spinae (longissmus and iliocostalis).They attach directly to the lumbar 
vertebraeand acts as a extensor muscles. 
LUMBAR SPONDYLOSIS: 
SYNONYMS: 
 Lumbar arthrosis 
 Lumbar spomdylitis 
 Hypertropic arthritis 
 Osteoarthritis of lumbar spine 
DEFINITION: 
  Lumbar spondylosis defined as any or all degenerative conditions affecting the 
vertebral bodies, inter vertebral disc and associated joints of the lumbar spine. 
Nomenclature: 
Lumbar - Lower back region 
Spondylo - Vertebra 
Osis - Condition 
 
ABOUT LUMBARSPONDYLOSIS: 
 Arthritis of the spine is called spondylosis.It differs from arthritis in other joints 
because of the effect of the discs between the vertebra,not just the small facet 
joints that are in pairs between two vertevrae. 
 It is important to understand that arthritis does not mean pain.It is really just a 
wearing process in which some people can experience pain and in others there is 
no pain. 
 Spondylosis does not have to cause a pain.If you get pain, it is usually from the 
lower back region but it can sometimes affect the higher lumbar areas. 
 Symptomsusually relate to one main structure that is primary pain source, such as 
a facet joint. 
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 Occasionally, more generalized arthritis can cause pressure on to the spinal 
cord.This is called spinal stenosis.Because the spondylosis may result in pressure 
on the nerve going to the leg.It may not cause pain just numbness or pins and 
needles. 
 More advanced spondylosis will certainly causes stiffness in the spine and may 
alter the posture with scoliosis or commonly a flattening of the lumbar lordosis. 
Causes of lumbar spondylosis: 
• Aging , syptoms notice at age of 20-60 
• Genetic 
• Arthritis of other joints such as neck,knee shoulder 
• Injury history 
• Constant sitting for a long period of time, poor posture 
• Lifting heavy objects 
• Overweight and obesity 
Signs and symptoms: 
 Frequent lower back pain 
 Tenderness 
 Tingling and numbness 
 Motor weakness 
 Above symptoms radiate to the lower extremities 
 Restriction in lower back movements 
 After prolonged activities such as sitting,standing and walking 
 After inactivity, eg., getting up from bed after sleep 
 Stiffness in morning 
LOW BACKACHE: 
• It’s occurs common in second to fifth decade, disc disease and disc herniation 
occur in 3rd and 4th decade. 
• Symptoms of low back pain, radiating to the buttocks and reduced by rest andin 
squatting position. 
• Pain Increased while bending forward and sitting, weight lifting, coughing etc., 
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RADICULOPATHY: 
• Sciatica – Pain in supply of sciatic nerve and is regularly due to disc herniation 
• It is evidenced by the leg pain, equal to or more than the back pain 
• Pain radiating to sacroiliac region, buttocks and thighs. 
NERVE ROOT COMPRESSION: 
• About 95% of disc prolapse takes place through L4 - L5 region 
compressingL5 nerve root. 
• The other disc prolapse takes place through L3 – L4 and L5 - S1 L4 and S1. 
Epidemiology: 
Lumbar spondylosis is seen in 80% of population. 
Gender: 
Out of which Men - 84% 
Women - 74% 
Age: 
At the age between 55-64 yrs 30% of men and 28% of women are affected. 
At the age between 45-55 yrs, 20% of men and 22% of women are affected. 
 
Pathogenesis of Lumbar Spondylosis : 
Degenerative changes begin with intervertebral disc desiccation, which is 
associated with increase in the ratio of keratin sulfate to chondroitin sulfate. Along with 
desiccation, the nucleus pulposus shrinks, loses elasticity, and becomes more fibrous due 
the loss of water, protein and mucopolysaccharides during the aging process. Disc height 
is initially lost in the ventral portion of the disc, which results in a decrease in lumbar 
lordosis. Unfortunately, this process results in positive feedback cycle due to the increase 
in forces applied ventrally and eventually may lead to kyphotic deformity. 
  Another early degenerative change is the posterior longitudinal ligament 
beginning to pull away from the vertebral bodies near the end plates. Eventually,abnormal 
lumbar movement result either from the pain of disc herniation or annular protrusion, 
worsening degenerative changes, or increased ligamentous laxity. Where the PLL peels 
off the dorsal vertebral body, reactive bone formation begins forming spondylotic bone 
spurs, which may be as large as the width of the vertebral body. 
These osteophytic growths may project into the intervertebral foramina. The 
increase in joint motion causes an acceleration of osteophyte growth. The growth of 
37 
 
osteophytes, along with degenerative changes, leads to decrease in sagittal spinal canal 
diameter, the main pathophysiological process in Lumbar spinal spondylosis. 
In addition to the above-described osteophytic and degenerative changes, athird 
modality that causes spinal canal narrowing is congenital Lumbar stenosis. The average 
Lumbar spondolytic patient’s spinal canal is 3 mm smaller than the average population. 
More pronounced narrowing is observed in congenital stenosis patients. 
The average adult spinal canal diameter has been reported to be 17 to 18 mm 
 
Late Pathological Features : 
As discussed earlier, osteophytes originate from the vertebral bodies andextend 
into the spinal canal while some eventually progress to cross the intervertebraldisc space. 
When this occurs, the vertebral bodies may combine and fuse. 
 If thisautofusion occurs, patients may experience a paradoxical increase in 
stability of their Lumbar spine. This autofusion also results in decreased Lumbar motion 
and may be responsible for the improvement of symptoms in patients with mild or 
moderate myelopathy. However, this process occurs in the setting of relative kyphosis 
and may place additional stress on adjacent Lumbar levels and lead to progression of 
spondylotic abnormalities at the rostral and caudal levels. 
Degenerative changes begins with intervertebral disc desiccation Via Increase in 
the ratio of Keratin Sulfate , Nucleus pulposus shrinks, loses elasticity and become more 
fibrosus.Due toLoss of water, Protein,Mucopolysahcharide,result in loss of disc height. 
Osteophyte originate from the vertebral bodies due to abnormal movement, 
Osteophyte extend in to spinal canal results narrowing spiral canal and cord 
compression.Osteophyte extend in to intervertebral disc spaceresults auto fusion of 
vertebral bodies.Decreased Lumbar motion and improvementof symptoms. 
 
PATHOPHYSIOLOGY: 
  Intervertebral disks are believed to undergo a “degenerative cascade” of three 
overlapping phases. 
Phase I - Dysfunction Phase 
Phase II - Instability Phase 
Phase III - Stabilization Phase 
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Phase I - Dysfunction Phase 
 Seen between 15 to 45 years of age 
 Circumferential and radial tear seen in the disc annulus 
 Localized synovitis of the facet joints is seen 
Phase II - Instability Phase 
 Seen between 35 to 70 years of age 
 There is internal disruption of the disc 
 Progressive disc resorbtion takes place 
 Degenerative of facet joint with lax capsules, subluxation and joint erosions are 
seen. 
Phase III - Stabilization Phase 
 Seen over 60 years of age 
 Progressive development of hypertrophic bone above the disc and facet joints 
leading to segmental stiffening or frank ankylosis is seen. 
EXAMINATION: 
INSPECTION: 
Congenital are pathological skeletal deformities like scoliosis, lordosis or kyphosis. 
PALPATION: 
1. TENDERNESS: 
• Scatter tenderness over the low back. 
• Localized tender infilterates of the skin and subcutaneous tissue 
• Palpable tender induration of small intervertebral muscles 
• Tenderness at the level of posterior articulation and pain on percussion of affected 
intervertebral space. 
 
2. MOVEMENTS: 
Movementsofthisspine : 
1. Totestflexion : 
Instruct the patient to bend forwards as much as possible at the waist. 
Normalflexion is 80 degree or fingertips 3-4 inches from the floor. 
2. LateralFlexion : 
Instruct the patient to bend to the left and to the right as far as possible. Normal 
range is 35 degree on each side. 
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3. Extension : 
Instructs the patient to bend at waist as far backward as possible normal rangeis 20 
degree – 30 degree 
 
4. Rotation : 
Instructs the patient to rotate from the waist to the left and to the right as far 
aspossible. Normal range is 45 degree possible. 
  All the movements of the spine are tested and found to be controlled in all 
direction. 
 
3. CLINICALTESTS: 
i. Straight leg raising test (SLR) 
 With the patient lying supine, lift the foot to flex the hip passively with the knee 
kept straight. Measure the angle between the couch and the flexed leg to determine any 
limitations (normal 80-90 degree hip flexion). If the limit is reached, raise the leg to just 
less than this level and test for nerve root tension by dorsiflexing the foot.  
ii. Braggard’s test 
 A SLR procedure is done if positive the leg is lowered just below the point of pain 
and then the ankle is dorsiflexed. If pain increases pain is likely nervous in orgin whereas 
with no increase the source is presumed muscules. 
iii. Femoral nerve stretch test: 
  With the patient lying on the front, flex the knee and then extend the hip 
.This stretches the femoral nerve. A positive result is when pain is felt in the back or the 
front of thigh. 
iv. Schober’stest 
 Mark the skin in midline at the level of the dimples of Venus which overlies the 
sacroiliac joints (mark A). Using a tape measure, draw two marks, one 10 cm above(mark 
B) and one 5cm belowthis(mark C) 
 Place the end of the tape measure on the upper mark and ask the patient to touch 
the toes. The distance from mark B to mark C should increase from 15 to more than            
20 cm. 
v. Forward bending to touch the toes: 
vi. Flip test:  
  If a degree of functional overlay is suspected, ask the patient to sit on the end of 
the couch with hip and knee flexed to 90 degree. 
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 Examine the knee reflexes and then extended the knee, as if to examine the ankle 
joint. The genuine sufferer will lie back, otherwise you will have effectively demonstrated 
a difference between the SLR test when lying and when seated. 
vii.Lassegue test: 
 Inclusion of ankle dorsiflexation in the straight leg raising. 
viii. Bowstring sign: 
 Rise the leg to the point where pain is experienced. Now without reducing the 
amount of lift, bend the knee so as to near the saiatic nerve-buttock pain is immediately 
relieved. 
 Pain may then reinduced without extending the knee by simply pressing on the 
lateral popliteal nerve to tighten it like a bow string. 
ix. Buckling’s Sign: 
 Reflexive flexion of the patient’s knee during SLR. 
DIAGNOSIS: 
• History taking 
• Physical examination 
• X-ray 
• MRI scan 
• CT scan 
• Myelogram 
• Disco graphy 
• Nerve conduction studies 
• EMG 
DIFFERENTIALDIAGNOSIS: 
• Osteoporosis 
• Multiple myelomas 
• Multiple sclerosis 
• Extra dural tumour 
• Ankylosis spondylosis 
• Spino vascular insufficiency 
• Peripheral neuropathy 
• Herpes zoster 
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• TB Spine 
• Rheumatoid arthiritis 
• SLE 
COMPLICATIONS: 
• Severe spinal canal stenosis 
• Cauda equina syndrome 
• Neurogenic claudication 
• Paraplegia 
• Conus Medullaris. 
TESTS AND ASSESMENTS: 
• Clinical assessment 
• Siddha assessment 
• Laboratory Investigations 
• Radiological assessment 
CLINICAL ASSESSMENT: 
• Pain in lumbar region 
• Radiating pain to buttocks and lower limbs 
• Diffuse tenderness in lumbar region with limitation of movements 
• Stiffness of lumbar spine 
• Exacerbation of pain on movements 
• Pain increased on forward bending 
• Paraesthesia& sensory loss on affected area 
• Burning and tingling sensation in lower limbs 
PAIN ASSESMENT: 
Improvement assessed by following assessments: 
1. Pain assessment scale (17) 
      2. Restricted movement assessment scale 
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RESTRICTED MOVEMENT ASSESSMENT SCALE:  
GRADATION OF MOVEMENTS: 
Grade 1 :  Fit for all activities to do their work without support (Normal) 
Grade 2 :  Mild pain and mild restriction of movements. 
Grade 3 :  Moderate Pain with or without radiation to lower limbs and                                                                 
    moderate restriction of Movements 
Grade 4 :  Severe Pain with or without radiation to lower limbs and Severe  
     restriction of Movements 
SIDDHA ASSESMENT: 
EnvagaiThervu: 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
• Neerkkuri 
• Neikkuri 
LABORATORY INVESTIGATIONS: 
Blood: 
• TC 
• DC 
• ESR 
• Hb 
• Blood Sugar 
  Fasting 
  Post prandial 
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• Blood urea 
• Serum Creatinine 
• Serum Cholesterol 
Urine: 
• Albumin 
• Sugar 
• Deposits 
 
SPECIFIC INVESTIGATIONS: 
SEROLOGY: 
• CRP 
• RA factor 
• ASO titre 
RADIOLOGICAL INVESTIGATION: 
• X- Ray:  Lumbar spine AP and lateral view 
• MRI (If  required)  
Diagnosis: 
 The diagnosis was made by following Siddha diagnostic methods. Nilam, Kaalam, 
Poriyalaridhal, Pulanalarithal, Vinaadhal, Mukkutra Nilaigal, Udal Thathukal Nilai and 
Envagai Thervugal, and the diagnosis of Thandaga Vadham were obtained which 
correlated with modern diagnosis of lumbar Spondylosis by the X-Ray findings. 
THE BACK PAIN FUNCTION SCALE (BPFS) OF STRATFORD ET 
  Stratford et al developed the back pain function scale (BPFS) to evaluation 
functional ability in patients with back pain. The authors are from McMaster University 
Appalachian physical theraphy (Georgia) and Virginia common wealth university. 
Measure : 
1. Any of your usual work housework or school activities 
2. Your usual hobbies recreational or sporting activities 
3. Performing heavy activities around your home. 
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4. Bending or stooping 
5. Putting your shoes or socks (or stockings or pantyhose) 
6. Lifting a box of groceries from the floor 
7. Sleeping 
8. Standing for 1 hour 
9. Walking 1 mile 
10. Going up or down 2 flights of stairs (about 20 steps) 
11. Sitting for 1 hour 
12. Driving for 1 hour 
 
Responses Points 
Unable to perform activity 0 
Extreme difficulty 1 
Quite a bit of difficulty 2 
Moderate difficulty 3 
A little bit of difficulty 4 
No difficulty 5 
 Total score = sum (points for all 12 measure) 
Adjusted total score = total score / 60 
Interpretation: 
• Minimum score : 0 
• Maximum score : 60 
• Maximum adjusted score : 1 
• The higher the score the greater the patient’s functional ability. 
TREATMENT: 
  Vellai ennai 15ml at morning with hot water was given on the first day of 
treatment.All the patients were treated with the following medicines. 
1. KUSTATHI CHOORNAM – 1 gram thrice a day with hot water 
2. ERANDA THYLAM – 30 ml applied externally 
Varmam is applied as the complementary therapy for inpatients. 
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RESULTS AND OBSERVATION 
  For the clinical study 40 patients were selected and treated in PG-III Sirappu 
Maruthuvam Department, GSMC hospital Palayamkottai. Results were observed with 
respect to the following criteria. 
1. Sex 
2. Age 
3. Kalam 
4. Thega nilai 
5. Gunam 
6. Thinai 
7. Paruvakalam 
8. Socio-Economic Status 
9.  Etiological Factors 
10.  Occupation 
11. Clinical Presentation 
12.  Duration of Illness 
13.  Mukkutram 
14.  Udal Thathukkal 
15.  Envagai Thervugal 
16.  Pulse Reading 
17.  Neikkuri 
18.  Provocative Test 
19.  Number of Days Treated 
20.  Laboratory Investigations 
21.  Radiological Findings 
22. Pain scale Readings 
23. Effect of Varmam 
24. Over all curative effect.  
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1. Sex distribution 
Table 1: Illustrates sex distributions and its relative percentage 
 
 
 
 
INFERENCE: 
Out of 40 in patients, 47.5% were males and 52.5% were females.  
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SEX DISTRIBUTION
Male
Female
Sex OP Cases IP Cases TOTAL 
Male 11 8 19 
Female 9 12 21 
TOTAL 20 20 40 
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2. Age distribution 
Table 2: Illustrates the age distributions. 
AGE GROUP NO.OF.PATIENT PERCENTAGE(%) 
20-30 7 17.5 
31-40 3 7.5 
41-50 11 27.5 
51-60 19 47.5 
 
 
INFERENCE:: 
Among the 40 patients, in the highest incidence was in the age between 51-60 lowest 
incidence was in the age between  31-40. 
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3. Kalam: 
Table 3: Illustrates the kalam 
S. No Kalam 
Patients  
No of cases Percentage 
     1. 
2. 
3. 
Vadha Kalam(11-33YRS) 
Pitha Kalam(34-66YRS) 
Kabha Kalam(67-70YRS) 
7 
33 
- 
17.5 
82.5 
- 
 
 
INFERENCE : 
 Out of 40 Patients, 
       * 17.5% of cases were in the Vadha kalam 
        * 82.5% of cases were in the Pitha kalam. 
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4.Thinai (The habitat of the patients) 
Table 4: Illustrates the Thinai 
S. No Thinai 
 OP & IP Patients  
No. of cases Percentage 
 
1. 
2. 
3. 
4. 
5. 
 
Kurinji 
Mullai 
Marutham 
Neithal 
Palai 
 
- 
- 
34 
6 
- 
 
- 
- 
85 
15 
- 
 
 
INFERENCE:  
              85 % of the patients were from Marutha nilam  and 15% were from neithal. 
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5. Paruva kalam 
Table 5: Illustrates the paruva kalam and its relative percentage: 
 
 
INFERENCE:     
   Out of 40 patients,27.5% were come in munpanikalam,22.5% in 
pinpanikalam,17.5% in mudhuvenilkalam,12.5% came in karkalam and each 10% came 
in koothirkalam and elavenilkalam. 
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S. 
No. Paruva Kalam Months 
No. of 
Cases Percentages 
1.  Kar kalam Aavani, Purattasi(Aug.15 to Oct14) 5 12.5 
2. Koothir kalam Iyppasi, Karthigai(Oct.15 to Dec.14) 4 10 
3. Munpani Kalam Markazhi, Thai(Dec.15 to Feb.14)          11 27.5 
4. Pinpani Kalam Masi, Panguni(Feb.15 to Apr.14) 9 22.5 
5. Elavenil Kalam Chithirai, Vaikasi(Apr.15 to June.14) 4 10 
6. Muthuvenil Kalam Aani, Aadi(June 15 to Aug.14) 7 17.5 
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6.Socio – Economic status 
Table 6: Illustrates the socio-economic status 
S. No Socio-economic Status  No. of cases Percentage 
1. 
2. 
3. 
Rich 
Middle class 
Poor 
2 
27 
11 
5 
67.5 
27.5 
 
 
INFERENCE:  
  Out of 40 patients, 
                             67.5 % are middle class 
        27.5% are poor 
      5% are rich 
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 7. Distribution based on Etiological factors: 
Table 7: Illustrates etiological factors 
S. No. Precipitating Factors No. of cases Percentage 
1. Senility 12 30 
2. Occupation 26 65 
3. Trauma 2 5 
4. Metabolic - - 
5. Congenital - - 
 
 
INFERENCE: 
  Out of 40 patients, 65%  of thandagavatham are caused due to occupational cause 
and remaining 30% and 5% are caused due to senility and trauma respectively. 
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8. Occupation: 
Table 8: Illustrates occupation 
S.NO OCCUPATION NO.OF.PATIENTS PERCENTAGE(%) 
1. Beediworkers 2 5 
2. Farmers 9 22.5 
3. Sedentary 6 15 
4. Hotel workers 3 7.5 
5 Weight lifters 6 15 
6 House wives 14 35 
 
 
INFERENCE:  
  35% were housewives and 22.5 % were farmers,each 15 were from sedentary and 
weight lifters respectively and 7.5% from hotel workers. 
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9. Clinical Manifestations: 
Table9: Illustrates the Clinical Manifestations 
Sl.no Signs and symptoms No. of cases Percentage 
1. Low back ache 40 100 
2. Radiating pain to lower limbs 40 100 
3. Restricted movements 33 82.5 
4. Tenderness - - 
5. Numbness in lower limbs  26 65 
 
 
INFERENCE: 
 100% people have low back ache and radiating pain, 82.5% have restricted 
movements, 65% have numbness in the lower limbs. 
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10. Distribution According to the duration of illness: 
Table 10: Illustrate the duration of illness with their respective percentage: 
S. No. Duration of illness (Months) No. of cases Percentage 
1. 0-1 7 17.5 
2. 1-3 13 32.5 
3. 3-6 17 42.5 
4. 6-12 3 7.5 
5. 12-24 - - 
6. 24-36 - - 
 
 
INFERENCE:  
    In 40 patients, 42.5% have 3-6 month duration of pain , 32.5% have 1-3 
month of pain,17.5% have 1 month duration of pain and 7.5% have 6-12 month duration 
of pain. 
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10. Conditions of Mukkuttram 
a. Disturbance in Vadha: 
S. No. Disturbance In Vadha No of cases Percentage 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
Piranan 
Abanan 
Viyanan 
Udhanan 
Samanan 
Nagan 
Koorman 
Kirukaran 
Dhevathathan 
Dhananjeyan 
- 
6 
40 
- 
40 
- 
- 
- 
20 
- 
- 
15 
100 
- 
100 
- 
- 
- 
50 
- 
 
 
INFERENCE:  
  viyanan and samanan were affected in 100% of cases, devathathan affected in 
50% of cases 
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b. Disturbances in Pitha: 
S. No. Disturbances in Pitha No of cases Percentage 
1. 
2. 
3. 
4. 
5. 
Anar Pitham 
Ranjagam 
Prasagam 
Alosagam 
Sathagam 
- 
5 
- 
- 
40 
- 
12.5 
- 
- 
100 
 
 
INFERENCE:  
  Sathaga pitham was altered in all cases (100%) evidenced as difficulty in handling 
their regular duties because of pain in lumbar region & lower limb. Ranjaga pitham was 
affected in 12.5% patients having decreased RBC. 
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c. Disturbances in Kabha: 
 
 
 
 
 
 
 
 
 
INFERENCE:  
  Santhigam was found to be affected in all 40 cases (100%) 
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S. No. Disturbances in Kabha No. of cases Percentage 
1. 
2. 
3. 
4. 
5. 
Avalambagam 
Kilethagam 
Bothagam 
Tharpagam 
Santhigam 
0 
- 
- 
- 
40 
0 
- 
- 
- 
100 
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11. Involvement of Udal Thathukkal 
S. No. Udal Thathukkal 
No of cases 
affected 
Percentage 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Saram 
Senneer 
Oon 
Kozhuppu 
Enbu 
Moolai 
Sukkilam / Suronitham 
40 
40 
40 
40 
40 
40 
0 
100 
100 
100 
100 
100 
100 
0 
 
 
INFERENCE: 
   All the udal thathukkal were affected 100% in thandagavadham cases. 
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12. Condition of Envagai Thervugal 
S. No. En vagai thervu No of cases Percentage 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
 
Naa 
Niram 
Mozhi 
Vizhi 
Malam 
Moothiram 
Sparisam 
Naadi (Thontha naadi) 
- 
- 
- 
- 
6 
- 
- 
40 
- 
- 
- 
- 
15 
- 
- 
100 
 
 
INFERENCE: 
  15% were affected with the condition of malam and 100% affected with thontha 
naadi. 
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13. Naadi: 
Table 13:Illustrate for the pulse parameters: 
S. No. Parameters No. of cases Percentage 
1. Vatha pitham 22 55 
2. Pitha vatham 17 42.5 
3. Kaba vatham - - 
4. Vatha kabam 1 2.5 
 
 
 
INFERENCE:  
  Most of the cases were affected with 55% vathapitha naadi,42.5% were affected 
with pithavatha naadi and only 2.5% were affected with vathakabha naadi. 
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14. Neikuri: 
S. No. Inference No. of cases Percentage 
1. Spreading like snake 24 65 
2. Spreading like a ring 14 35 
3. Stands like a pearl 2 5 
4. Combination of ring and snake - - 
 
 
INFERENCE:  
  60% Patients having vatha neer which spreads like a snake,35% having pitha neer 
which spreads like a ring and 55 having kaba neer which soreads like a pearl. 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
INFERENCE
P
E
R
C
E
N
T
A
G
E
ILLUSTRATES THE NEIKURI 
ANALYSIS
SPREADING LIKE SNAKE
SPREADING LIKE RING
STANTS LIKE A PEARL
OTHERS
63 
 
 
14. Provocative test: 
S. No. Clinical features 
No. of cases 
Positive 
Percentage 
1 SLR 40 100 
2 Forward bending  40 100 
3 Femoral nerve stretch test 20 50 
4 Schober’s test 30 75 
5 Braggard test 7 17.5 
6 Lasegue test 5 12.5 
 
 
 
INFERENCE: 
  Based on modern aspect for the diagnostic purpose,provocative studies were 
done.In that SLR and foeward bending were affected 100%,50% femoral nerve test,75% 
schobler’s test were positive. 
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15.. No. of days  treatment: 
Table 15: Distribution According to the total number of days for treatment: 
S.No No. of days treatment 
No. of cases Percentage 
   Op,ip          %  
1 1–15           -           -  
2 15-30        14          35  
3 31-48        26         65  
 
 
INFERENCE: 
  Out of 40 patients,65% patients were treated 31-48ndays and 35% patients were 
treated 16-30 days. 
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16. Observations of other Clinical Laboratory Examinations: 
 At the time of admission and discharge routine laboratory examination were done and values were record 
 
   
s.no. OP No. 
TC(cells/cumm) DC(%) ESR(mm) Hb(gms%) SUG. ALB. DEP. 
BT AT BT AT 
BT AT 
BT AT BT AT BT AT BT AT 
 1 hr  1hr  
1 63877 7800 7900 64 29 7 66 31 3 18 14  11.4 11,6 Nil Nil Nil Nil NAD NAD 
2 65820 8200 8400 70 22 8 72 21 6 5  3  13 13.2 Nil Nil Nil Nil NAD NAD 
3 70870 7100 7400 64 32 4 65 31 2 8  6  12.1 12.4 Nil Nil Nil Nil NAD 1 – 2 pus cells 
4 72235 8900 8900 77 20 3 55 40 5 58  42  12.8 12.9 Nil Nil Nil Nil NAD NAD 
5 73846 6900 7100 64 33 8 65 33 2 14  12  12.6 12.7 Nil Nil Nil Nil NAD NAD 
6 74998 7600 7800 50 46 1 55 43 2 20  14  11.3 11.6 Nil Nil Nil Nil NAD NAD 
 
7 75064 7200 7300 53 40 7 67 27 6 4  2  16.5 16.2 Nil Nil Nil Nil NAD NAD 
8 81407 7600 7800 63 34 3 64 36 3 14  8  11.6 11.8 .Nil Nil Nil Nil NAD NAD 
9 111084 8100 8400 61 33 6 64 34 2 11  8  12.4 12.6 Nil Nil Nil Nil NAD NAD 
10 111088 7310 7700 61 34 5 64 33 1 12  8  10.6 10.9 Nil Nil Nil Nil NAD NAD 
11 112021 7500 7700 59 34 7 61 36 4 11  9  12.6 12.7 Nil Nil Nil Nil NAD NAD 
12 111983 9500 9700 70 22 8 71 24 5 6  4  10.9 11.1 Nil Nil Nil Nil NAD NAD 
13 112279 7200 7500 57 34 7 61 34 5 14  10  10.1 10.3 Nil Nil Nil Nil NAD NAD 
14 113753 6300 6900 63 34 3 58 38 4 5  5  11 11 Nil Nil Nil Nil NAD NAD 
15 114078 7200 7400 61 34 5 63 36 1 12  9  12,6 12.8 Nil Nil Nil Nil NAD NAD 
16 114372 7100 7100 63 33 4 62 32 6 8  8  10.4 11.2 Nil Nil Nil Nil 3 – 4 pus 
cells NAD 
17 17 348 7100 6500 68 28 4 50 46 4  14 12.3 12 Nil Nil Nil Nil NAD NAD 
18 297 8500 8700 70 25 5 72 24 4 10  8  12 12.2 Nil Nil Nil Nil NAD NAD 
19 991 8500 6800 53 43 4 63 34 3 6  5  12.4 12.6 Nil Nil Nil Nil NAD NAD 
20 2398 6600 7000 50 49 1 55 44 1 68  36  10.9 11.2 Nil Nil Nil Nil NAD NAD 
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SL.NO. OP No. 
SUG(mgs%) UREA(mgs%) CHOLESTEROL (mgs%) 
BT AT BT AT BT AT 
1 63877 85 83 17 16 148 145 
2 65820 92 90 50 43 191 185 
3 70870 94 93 29 26 176 170 
4 72235 128 88 27 25 195 160 
5 73846 90 88 31 29 168 165 
6 74998 103 99 27 24 169 165 
7 75064 102 97 21 18 176 159 
8 81407 97 95 34 33 158 154 
9 111084 93 91 29 25 164 159 
10 111088 96 93 27 24 152 150 
11 112021 97 95 29 26 178 173 
12 111983 96 93 26 24 120 117 
13 112279 92 90 27 24 138 135 
14 113753 76 76 19 15 144 130 
15 114078 89 80 25 23 159 154 
16 114372 88 101 21 19 152 112 
17 348 135 145 21 18 168 142 
18 297 95 94 26 23 154 150 
19 991 99 94 29 28 187 168 
20 2398 107 99 29 23 208 198 
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  HEMATOLOGICAL STUDIES URINE ANALYSIS 
s.no IP No. TC(cells/cumm) DC(%) ESR(mm) Hb(gms%) SUG. ALB. DEP. 
  BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 2174   7000 7100 64 32 4 61 38 1 10  11  9.3 10.1 Nil Nil Nil Nil NAD NAD 
2 3194 7300 7200 67 27 6 63 34 6 9  8  12.4 12.8 Nil Nil Nil Nil NAD NAD 
3 3251 7500 7900 61 36 3 63 36 1 13  9  11.8 12 Nil Nil Nil Nil 1-2 pus cells NAD 
4 3246 8600 8650 62 30 8 61 32 7 30  26  10.7 11 Nil Nil Nil Nil NAD NAD 
5 3244 7600 7400 62 35 3 67 30 3 25  16  13.3 13.9 Nil Nil Nil Nil NAD NAD 
6 3314 7000 7200 60 32 3 66 30 2 22  17  10.4 10.8 Nil Nil Nil Nil NAD NAD 
7 34 11200 10000 63 32 5 80 16 3 50  40  12.3 12.6 Nil Nil Nil Nil NAD NAD 
8 56 7000 7300 65 33 2 64 34 2 70  55  8.4 8.9 Nil Nil Nil Nil NAD NAD 
9  83  7300 7500 58 36 6 59 34 7 18  14  11.2 11.5 Nil Nil Nil Nil NAD NAD 
10 101 9400 9900 72 15 3 71 16 3 27  21  9.6 9.9 Nil Nil Nil Nil NAD NAD 
11 136 7000 7300 54 44 2 54 45 1 28  19  7.2 7.9 Nil Nil Nil Nil NAD NAD 
12 168 10000 8300 70 26 4 53 38 9 60  70  11.2 10.9 Nil Nil Nil Nil NAD NAD 
13 190 6900 7000 61 34 5 62 35 3 11  7  12.1 12.3 Nil Nil Nil Nil NAD NAD 
14 253 7900 8500 78 20 2 66 30 4 6  8  10.0 11.1 Nil Nil Nil Nil NAD NAD 
15 309 7600 8100 60 36 4 58 38 4 15  14  11.5 11.8 Nil Nil Nil Nil 3 -4 pus cells NAD 
16 587 7000 7100 54 44 2 52 43 5 63  34  9.0 9.2 Nil Nil Nil Nil NAD NAD 
17 836 7200 7400 61 33 6 62 34 4 17  11  11.2 11.5 Nil Nil Nil Nil NAD NAD 
18 837 8200 8500 74 18 8 73 21 6 13  9  13.0 9.0 Nil Nil Nil Nil NAD NAD 
19 865 13600 13600 65 33 2 66 333 1 30  15  12.1 12.3 Nil Nil Nil Nil NAD NAD 
20  932 7100 7500 51 46 3 53 42 2 11  8  12.1 12.3 Nil Nil Nil Nil NAD NAD 
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SL.NO. IP No. 
SUG(mgs%) UREA(mgs%) CHOLESTEROL (mgs%) 
BT AT BT AT BT AT 
1 2174 90 86 24 21 135 130 
2 3194 89 68 30 25 161 119 
3 3251 89 82 27 24 157 145 
4 3246 99 95 15 14 158 137 
5 3244 127 122 23 16 201 167 
6 3314 81 77 41 38 186 175 
7 34 142 90 24 22 214 221 
8 56 103 97 20 17 170 155 
9 83 114 98 38 29 280 260 
10 101 80 75 36 29 210 185 
11 136 108 91 30 26 160 135 
12 168 117 76 16 21 149 128 
13 190 101 98 25 21 184 173 
14 253 126 97 19 17 180 195 
15 309 120 99 23 20 188 185 
16 587 102 98 22 18 261 218 
17 836 101 97 29 21 189 165 
18 837 99 95 21 19 176 165 
19 865 131 125 38 32 139 128 
20 932 99 92 29 21 195 186 
 INFERENCE: 
Hematological studies: 
 Among the 40 patients, 5
Cholesterol and urea were normal.
WBC Count: 
 Total count was found in between 5000 to 100
were little higher. 
Erythrocyte sedimentation rate:
 ESR was increased at
may decrease at the time of discharge.
17. Radiological findings:
Sl. No. 
Radiological Findings
 
1. 
2. 
3. 
 
4. 
 
 
5. 
 
Degeneration 
Narrowing of IVS
Osteophytic
Changes 
Fusion of 
Osteophytes with
adjacent vertebrae
Loss of lordosis
 
INFERENCE: All of the patients 
patients (62.5%) having narrowing of IVS.
 
DEGENERATION
OSTEOPHYTES
NARROWING OF IVS
FUSION WITH ADJACENT VERTEBRAE
LOSS OF LORDOSIS
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 18. PAIN ASSESMENT SCALE
A. Back pain functioning scale:
Maximum adjusted score
0.2 - 0.4 
0.41 – 0.6 
0.61 – 0.8 
0.81 – 1 
  
INFERENCE: The higher the score, the greater the patient’s functional ability.
The maximum adjusted score before treatment was around 3 and after treatment
 
0
5
10
15
20
25
30
35
40
0.2 - 0.4
70 
: 
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0.41 - 0.6 0.61 - 0.8
Functioning scale
before after
 
0 
4 
34 
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 upto 8. 
0.8 - 1
 B. Restriction movement assessment scale:
Gradation 
Grade III –II 
Grade III – I 
Grade II – I 
Grade IV – III 
Grade IV – II 
 
INFERENCE: Before treatment most of the patients having grade iii restriction, after 
treatment it downs to grade ii and grade i.
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No. of op cases No.of i.p cases Total No. of cases
10 11 
5 4 
3 0 
1 2 
1 3 
 
 
GRADE II GRADE III
before treatment after tretment
 
21 
9 
3 
3 
4 
 
GRADE IV
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19. CURATIVE EFFECT OF VARMA ALONG WITH COMPLIMENTARY 
THRAPY(VARMAM): 
Clinical Cure: 
 No longer any clinical manifestations 
 Patient could work and live normally 
 No recurrence after 4 months 
Marked Effect: 
 Marked reduction of clinical manifestations 
 Slight pain after exertion 
Improvement: 
 Some improvement in the regional symptoms  
 With rela 
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S,NO EFFECT OF DRUG 
ALONG WITH VARMA 
NO.OF,PATIENT PERCENTAGE 
     (%) 
1. Marked effect 7 35 
2. Moderate effect 10 50 
3. Mild effect 3 15 
4. No effect - - 
    
 
INFERENCE: 
 When the patients are treated along with complementary therapy,50% patients 
have moderate effect ,35% have the marked effect and 15% have mild effect 
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20.EFFECT OF TRIAL DRUG ALONE IN OPD: 
Patients were treated only with trial drug medicine. 
S.NO 
EFFECT OF TRIAL 
DRUG ALONE 
NO.OF.PATIENT PERCENTAGE 
1. Marked effect 7 35 
2. Moderate effect 9 45 
3. Mild effect 4 20 
4. No effect - - 
 
INFERENCE: 
  45% patients have moderate effect,35% have marked effect and 20% have mild 
effect when treated with trial medicine alone. 
 
  
0
5
10
15
20
25
30
35
40
45
50
AFTER TREATMENT
P
E
R
C
E
N
T
A
G
E
CURATIVE EFFECT IN PATIENTS 
TREATED WITH TRAIL DRUG
MARKED EFFECT
MODERATE PAIN
MILD PAIN
NO EFFECT
 21.COMPARISON BETWEEN THE EFFECT OF TRIAL DRUG AND TRIAL 
DRUG DRUG ALONG WITH COMPLIMENTARY THERAPY:
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Table21: 
 
 
 
 
TRIAL 
DRUG 
ALONE 
 
 
 
OP % 
 7 35 
 9 45 
 4 20 
 - - 
 
MODERATE EFFECT MILD EFFECT NO EFFECT
 
TRIAL DRUG 
ALONG WITH 
VARMAM 
IP % 
7 35 
10 50 
3 15 
- - 
 
OP%
IP%
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22. Overall Curative effect (Based on number of cases treated): 
S.NO EFFECT OF THERAPY NO.OF.CASES PERCENTAGE 
1. Marked effect 14 35 
2. Moderate effect 19 47.6 
3. Mild effect 7 17.5 
4. No effect - - 
 
EFFECT OF THERAPY 
 
INFERENCE: 
     Thus from th end of the treatment,the data analysis says that the patient having 
moderate effect in 47.5%,marked effect in 35% and the mild effect in 17.5% 
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OUT PATIENT DEPARTMENT: 
Sl.no Op no. Name Age/sex occupation DOA DOD No. of days treated Result 
1 63877 Vijaya 54/F Housewife 26/07/17 22/09/17 45 Marked 
2 65820 Thangaraj 51/M Cooli 02/08/17 10/10/17 47 Marked 
3 70870 Peratchi 44/F Housewife 18/08/17 15/12/17 46 Moderate 
4 72235 Manikalakshmi 53/F Housewife 23/08/17 31/11/17 47 Moderate 
5 73846 Shanmugaraj 45/M Autodriver 28/08/17 01/11/17 48 Marked 
6 74990 Ramani 30/F Beedirolling 31/08/17 01/11/17 48 Marked 
7 75064 Rajsingh 34/M Teashop 31/08/17 01/11/17 48 Moderate 
8 81407 Krishnajeyanthi 44/F Housewife 20/09/17 12/11/17 42 Mild 
9 111084 Subramanian 42/M Cooli 16/12/17 10/02/18 48 Mild 
10 111088 Mytheenfathima 60/F Hosewife 16/12/17 31/01/18 40 Moderate 
11 112021 Fathima 25/F Housewife 19/12/17 01/02/18 48 Moderate 
12 111983 Maheshkumar 24/M Supervisor 19/12/17 04/02/18 44 Marked 
13 112279 Peratchi 60/F Cooli 20/12/17 02/02/18 41 Mild 
14 113753 Seyyad mahuth 52/M Beedirolling 25/12/17 01/02/18 40 Moderate 
15 114078 Karnamaharaja 29/M Police 26/12/17 10/02/18 43 Marked 
16 113357 Arul 54/M Sparepart 
shop 27/12/17 12/02/18 41 Mild 
17 348 Kanthasamy 58/M Farmer 02/01/18 11/02/18 40 Moderate 
18 297 K.S,Mani 52/M Accountant 02/01/18 28/02/18 44 Marked 
19 991 Prabhu 46/M Marketing 02/01/18 18/03/18 40 Moderate 
20 2398 Tamilselvi 50/F Farmer 06/01/18 01/03/18 48 Moderate 
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INPATIENT DEPARTMENT: 
Sl.no Ip  no. Name Age/sex Occupation DOA DOD 
No. of 
days 
treated 
Result 
1 2174 Subbaiah 58/M Cooli 02/08/17 18/08/17 17 Moderate 
2 3194 Kailasam 55/M Cook 06/12/17 03/01/18 29 Marked 
3 3251 Subbaiah 60/M Groceryshop 12/12/17 03/01/18 23 Mild 
4 3246 Thayammal 26/F House wife 12/12/17 03/01/18 23 Moderate 
5 3244 Rajkumar 39/M Supervisor 12/12/17 12/01/18 37 Marked 
6 3314 Petchammal 50/F Cooli 19/12/17 12/01/18 25 Moderate 
7 34 Malathi 36/F Housewife 04/01/18 21/02/18 48 Marked 
8 56 Gomu 60/F Cooli 10/01/18 06/02/18 28 Mild 
9 83 Lakshmanan 60/M Retd.VAO 17/01/18 16/02/18 31 Marked 
10 101 Subbulakshmi 60/F Farmer 18/01/18 20/02/18 34 Moderate 
11 136 Natarajan 55/M Plumber 22/01/18 18/02/18 34 Moderate 
12 168 Throwpathi 50/F Housewife 24/01/18 06/03/18 42 Marked 
13 190 Krishnammal 43/F Housewife 25/01/18 01/03/18 36 Moderate 
14 253 Vijayalakshmi 58/F Housewife 01/02/18 23/02/18 23 Marked 
15 309 Muthumari 49/F Housewife 06/02/18 01/03/18 24 Moderate 
16 587 Geethakumari 46/F Cooli 05/03/18 03/04/18 30 Moderate 
17 836 Ramalingam 60/M Supplier 27/03/28 23/04/18 28 Mild 
18 837 Nagammal 54/F Housewife 27/03/28 20/04/18 25 Moderate 
19 865 Pushpathai 60/F Housewife 30/03/18 19/04/18 21 Marked 
20 932 Samuvel 60/M Cooli 06/04/18 30/04/18 25 Moderate 
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DISCUSSION 
  According to the clinical features mentioned in the yugi vaithiya chinthamani 800, 
forty patients were selected.with the help of siddha method of diagnosis and the modern 
investigation, diagnosis was endorsed and finally treated with the trial drugs and Special 
therapies.  The observations are discussed here. 
Sex distribution: 
  Females were found to be affected more in females. 
Age Distribution 
 The significant statistical report shows that higher incidence was found to be with 
the age above 50 years, which is due to degenerative changes in the aging process is the 
important cause of lumbar spondylosis. Since this study is limited to patients below 60 
yrs, it was not possible to study the incidence in people above this age limit. 
Also most of the patients were known to be in Pitha kalam. 
 This information is bestowed by our Siddhars as the wordings. 
“Ou{<mi!Jl<hkil<!ubK!ke<eqz<!!
uqjvf<K!hqVkquqbqz<!nh<H!OlUl<!hiOv”!
 The target sites affected in lumbar spondylosis are generally bones, muscles 
nerves, hairs, blood, urine, fat which are the components of appu and prithivi boothas 
(Appu + Prithivi = Kabam – responsible for destruction).  Hence they starts degenerating 
above fifty years. 
Thega nilai: 
  All patients were Thondha thegis. 
Living Lands (Thinai) 
 The incidence of Thandagavatham is highest in people from Marutham. 
 Even though Siddha literatures mention Marutham as a disease free zone, most of 
the patients came from Marutham Nilam and few were from neithal thinai.  This may be 
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due to the altered lifestyle, environment and food habits. Since this is a single centered 
study, located in marutham, it may also have influenced the study. 
Socio Economic Status and occupation: 
       67.5% of people reported the signs and symptoms of Thandagavatham were middle 
class and this may be indirectly responsible for the higher incidence through their 
occupation. In contrast to much believed fact, considerable percentages of patients were 
housewives. 
Seasonal Distribution: 
 Most of the patients came during munpani kalam and pinpani Kalam. 
Precipitating Factors: 
             Eventhough the aging plays a major role in thandagavatham.the occupation may 
also precipates the major risk factor for the disease of low back ache. 
Clinical Manifestations: 
 Low back pain and radiating pain in one oe both lower limb presents in all forty 
cases (100%).Restricted movement presents in 33 cases (82.5%).Numbness presents in 26 
cases (65%) .These are the major clinical finding in thandagavatham. 
Derangement in Vatham: 
 Viyanan,Samanan were affected in all 40 cases (100%).Dhevadhathan also 
affected in few cases. 
Disturbances in Pitham: 
 Sathaga pitham was affected in all 40 cases (100%). 
Derangement in Kabam: 
 Santhigam was affected in all 40 cases (100%). 
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Eight Parameters in our System 
(Envagai Thervugal) 
 The analysis shows the efficacy of the envagai thervu and the prime significance 
of naadi. 
Clinical Laboratory Investigations: 
  ESR was raised in early stage in many patients and after treatment it was reduced. 
Incidence with reference to Radiological studies: 
 
From X-ray lumbar spine (AP & Laterial view) and   MRI, 100% cases shows the 
degenerative changes and osteophytic changes. 
Narrowing of intervertebral space was seen in 62.5% of cases. 
Treatment 
 The treatment was aimed to retain the deranged thoshas and providing relief from 
symptoms. Before treatment was initiated, the patients were advised to take Vellai ennai-
15 ml with hot water at morning in th empty stomach for first day of treatment. The 
patient was asked to take rest from internal medicine and other activities on that day. 
 From 2nd day onwards, the patient was treated with the trail drugs KUSTATHI 
CHOORNAM - 1gram with hot water and ERANDA THYLAM – 30 ml  
(EXTERNAL).During treatment, the patients were advised to follow pathiyam (avoid 
tamarind, tubers, etc) and advised to avoid pillows.But all aspect of pathiyam could not 
be followed due to practical difficulties. 
SIRAPPU MARUTHUVAM TECHNIQUES [METHOD] APPLIED IN 
THANDAGA VATHAM PATIENTS 
a) Varmam  
 Among the forty cases, 20 cases were treated by varmam regularly.These 20 
patients showed a positive quick response with their signs and symptoms when compared 
with other cases. 
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Pain Reduction and functional ability: 
  The back pain functioning scale and restricted movement assessment scale 
measurement recorded a significant reduction in pain, increase in range of motion and 
increase ability in daily activities. 
  The higher the score, the greater the patient’s functional ability. 
  The maximum adjusted score before treatment was around 3 and after treatment it 
went upto 8.  
 
  Pharmacological studies done in Pharmacology of KMCH college of pharmacy, 
Coimbatore revealed that Kustathi choornam bears significant effect of Analgesic, 
Acute and chronic anti inflammatory action.Eranda thylam has analgesic and anti 
inflammatory effect. 
 Bio chemical analysis of drugs was done in the department of Bio-chemistry of 
Government Siddha Medical College and Hospital, Palayamkottai.Kustathi choornam 
contains sulphate, ferrous iron,unsaturated compounds,reduced sugar and amino 
acid. 
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SUMMARY 
 40 cases of thandagavatham were diagnosed clinically based on Yugi vaithiya 
chinthamani 800 and admitted in inpatient and outpatient ward of post graduate 
department of Sirappu Maruthuvam, Government Siddha Medical College and Hospital, 
Palayamkottai and treated by the trial medicines. 
 Laboratory diagnosis of thandagavatham was done by Siddha diagnostic 
principles and endorsed by modern methods of investigations. 
 The various siddha principle of examinations were carried out and recorded in the 
proforma. 
 The trial medicine chosen for both internal and external treatment were kustathi 
choornam thrice a day with hot water internally and eranda hylam app;ied 
Externally. 
 The selection of patients and management of patients during admission and after 
treatment was carried out under the supervision of professor, reader, lecturer grade 
II of P.G. Sirappu maruthuvam department. 
 Before starting the treatment, patient’s history was taken and recorded for the 
selected forty cases. 
 During the period of treatment all the patients were put under pathiyam (A 
specific dietary regimen). 
 A periodical haematologocal investigation was made for all the cases. 
 Bio chemical analysis of Kustathi choornam showed. Presense of sulphate, 
ferrous iron, unsaturated compound, reducing sugar and amino acid.  
 The pharmacological evaluation of the Kustathi choornam had showed  the 
significant analgesic and anti inflammatory actions. No acute toxicity effects were 
noted. 
 The in patients are discharged after the prescribed time period as in protocol and 
advised to follow out patients ward. 
 The observations made during the clinical study shows that the internal drug 
Kustathi choornam is clinically effective. 
 Clinically the patient has marked reduction of low back pain with the radiating 
pain in the lower limb and restricted movements and decreases ESR was noted. 
 Though there was appreciable clinical improvement.The action of external 
application Eranda thylam with Varmam is also quite remarkable. 
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CONCLUSION 
Selected 40 patients were treated with internal trial drug Kustathi choornam 1 
gram with hot water and Eranda thylam 30 ml per day.Varmam is given for 20 
inpatients. Trial drug has the significant reduction of signs and symptoms. 
• The trial medicine has significant analgesic and anti-inflammatory. 
• Further follow up of all these patients showed the disappearance of signs and 
relief from symptoms. 
• The trial medicines were free from side effects, adverse effects and toxic effects. 
 
The effect of the drug were observed as: 
• Marked effect – 35% 
• Moderate effect – 47.5% 
• Mild effect – 17.5% 
           This result of the clinical trial illustrates the good clinical effect of the trial drug 
and the complementary therapy.   
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ANNEXURE I 
STANDARD OPERATING PROCEDURES THE PREPARATION OF 
KUSTATHI CHOORNAM AND ERANDA THYLAM: 
SOURCE OF RAW DRUGS : 
 The required raw drugs for preparations of KUSTATHI CHOORNAM and 
ERANDA THYLAM are purchased from a authorized centers and raw drugs are 
identified and authenticated by the Medicinal Botanist of Govt. Siddha Medical College, 
Palayamkottai, then they are purified and the medicine is prepared in the P.G.Gunapadam 
Practical hall of Govt. Siddha Medical College, Palayamkottai. 
INGREDIENTS : 
KUSTATHI CHOORNAM (internal): 
SL. 
NO 
DRUGS BOTANICAL NAME PART USED Amount 
1 Kostam  Saussuria lappa Root 1 palam (35gms) 
2 Vetpalaivirai Wrightia tinctoria  Seed 1palam (35 gms) 
3 Chukku Zingiber officinalae  Rhizome 1 palam (35gms) 
4 Chitramoolam  Plumbago indica  Root  1palam (35 gms) 
5 Athividayam  Aconitum heterophyllum Root 1 palam (35gms) 
6 Manjal  Curcuma longa Rhizome  1palam (35 gms) 
 
PURIFICATION OF RAW DRUGS  
KOSTAM   : Remove the adulterant and make it dry it on shade  
VETPALAI VIRAI : Remove the adulterant and make it dry it on shade  
MANJAL  : Wash with water a allow it to dry  
CHUKKU   : Peel off the outer layer and allow to dry  
CHITRAMOOLAM  : The root will be baked in a steam of milk 
ATHIVIDAYAM  :Wash with water and  allow it to dry    
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METHOD OF PREPARATION OF KUSTATHI CHOORNAM:  
 The above raw drugs are purified separatedly and allow it to dry in shade.The 
purified raw drugs are powdered separatedly and mix all together.Filter it with a white 
cloth.   
ERANDA THYLAM (External)  
S.No INGREDIENT BOTANICAL  PART USTP  MEASUREMENI 
1. Aamanakkuennai  Ricinus communis  Seed oil  1 Naali (1. 3litre) 
2. Milagu  Piper longum  Unriped fruit  ½ palam (17.5gm) 
3. Manjal  Curcuma longa  Rhizome  ½ palam (175 gm) 
4. Vellai Poondu  Allium sativum Bulb  ½ palam (17.5 gm) 
5. Kuppaimeni Saru Acalypha indica  Whole plant  ½ palam(720 ml) 
6. Kadugu  Brasica juncea  Seed ½ palam (17.5gm) 
 
METHOD OF PREPARATION OF ERANDA THYLAM  
Grind the above raw drugs to Kalkam mix the kalkam with kuppaimeni saaru.keep 
it in sunlight a day. At evening it will be mixed with oil and heat until ut reaches the 
required consistency. Filter it then kept in a airtight container.  
DRUG STORAGE : 
 The trial drug “KUSTATHI CHOORNAM” and “ERANDA THYLAM” is 
stored in clean and dry air tight containers. 
  The siddha literature of the trial drugs are as follows: 
DRUG REVIEW LITERATURE: 
INTERNAL DRUG: 
1.KOSTAM: 
BOTANICAL NAME: Saussurea lappa 
FAMILY: Asteraceae 
VERNACULAR NAME: 
Sanskrit: Pushkara 
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Bengali: Keu 
Tamil: Koestam 
Telugu: Kashmeeraamu 
Malayalam: Channak Koova 
Hindi: Kust 
HABITAT: An elegant climbing Plant found Plentifully in Bengal and Kashmir. 
PART USED: Root & Tuber. 
ACTION: Root is bitter, Astrigent, Stimulant & digestive, Anthelmintic, depurative and 
aphrodisiac. 
USES: Root is usefull in Catarrhal fevers, Coughs, Dyspepsia, Worms, Skin Diseases and 
Snake Bits. Tuber is cooked and made into a Cymys or presence which is very 
Wholesome. 
Ogim<ml<!< << << < - Kottam 
Costus speciosus  
OuX!ohbI;!!Ogi]<ml<?!Gvi?!yzq!
h/d;!OuI!
Sju;!jgh<H?!uqXuqXh<H! ke<jl!;!<<< ouh<hl<! hqiqU!;!giIh<H<<< !
!
osb<jg;!<<< !
! hsqk<kQk<K~{<c! ! Stomachic!
! Ogijpbgx<xq!! ! Expectorant 
! dvlig<gq! ! ! Tonic!
! ouh<hL{<mig<gq! ! Stimulant!
! uqbIjuh<ohVg<gq! ! Diaphoretic!
! fim<cZX!oum<jm!fMg<gl<!wEOfib<gt<!
! Ogim<moles<!osie<eiz<!GjzBr<gi{<!.!%m<cx<!
! SvOkimf<!oki{<jmOfib<!Okizik!hqk<kl<!
! hvOksl<!OhiOl!hxf<K/!
! !
! !
88 
 
kqm<cgUt<!ngMgtR<!ose<eq!fiuib<!!
! ! osxqhq{qouh<!hjkh<Hki!uIk<kl<!Djk!
! Lm<cobP!Ljtuqv{l<!Suis!gisl<!
! ! &cgk<Oki!mvUlv!uqmr<gt<!Olgg<!
! gm<cn\!gz<zquqm!higl<!H,k!
! ! g{l<hiz!gqvgoliM!kiK!fm<mR<!
! osim<cuV!hqvlqhqk<kl<!-juobi!Vr<Og!
! ! okijzBl<uqv!{iiqg<Gs<!Sgh<OhiOxiOl/!!
! !
! -k<OkiM!Oke<?!usl<H?!-jugt<!OsIk<Kg<!ogiMg<g?!ouxqOfib<!fQr<Gl</!
!
2.VETPALAIVIRAI: 
BOTANICAL NAME: Holarrhena Anticlysenterica 
FAMILY: Apocynaceae 
VERNACULAR NAME: 
Sanskrit: Kutaja 
English: Kurchi 
Tamil: Kashappu-Vetpalarishi 
Telugu: Ka Ka Kodise 
Hindi: Karchi 
HABITAT:  
   This is small tree is common in Forests of India, Indigenous to the tropical 
Himalayas, Assam, Up &Down To Travancore. There are two Varieties- White & Black. 
PART USED:  
  Bark, Seeds & Leaves. 
CONSTITUENTS: 
  Bark a seed Contains. 
  A non oxygenated alkaloid-Wrightine or Conessine or Kurchisine and 
Holarrherine. 
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ACTION: (SEEDS) 
  Seeds which resemble oats, are very bitter 
  Astrigent, Febritage, anticlysenteric, anthelmintic, carminative and also 
antiperiodic in combination with other antiperiodics like cocculus cordifolius. 
oum<hijz<<< !– Vetpalai 
Wrightia – tinctoria (Roxb) R.Br 
OuX!ohbI!;gqiqlz<zqjg?!Gmsl<?!ux<sl<!
h/d;!-jz?!hm<jm?!uqk<K!)niqsq*!
uqk<K<<< !
Sju!;!-eqh<H!! ! ! ke<jl!;!<<< km<hl<! ! hqiqU!;!-eqh<H!
osb<jg;!<<< !
uqk<K<<< !
! dvlig<gq! ! ! Tonic!
! -K?!kQ!utqg<!%m<ce<!ohVg<jgBl<?!gMue<?!Gmz<!uiB?!ubqx<Xh<!ohiVlz<?!
gpqs<sz<!ujg!Lkzqbjugjth<!Ohig<Gl</!!
! oum<hijz!ke<eiqsq!uQXhqk<k!uikoliM!
! ogim<hiI!gvh<hie<!Gmz<uik!.!dh<hqsk<jkg<!
! gi{il!OzfiTr<!g{<cg<Gr<!gisqeqbqx<!
! H,{iI!Ljzbi!Hgz!
4/CHUKKU: 
BOTANICAL NAME: Zingiber officinale 
FAMILY: Zingiberaceae 
VERNACULAR NAMES: 
    Eng: Dried ginger 
    Tel: Sonti 
    Kan: Ona shunti or sunti 
    Sans: Nagaram 
Hindi : Sonth 
HABITAT:Widel distributed in tropical asia,cultivated in many parts of india on large 
scale.A herbaceous,rhizomatous perennial reaching upto 90cm in height under 
cultivation. 
PART USED:Rhizome 
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CONSTITUTIONS: 
  Dried ginger contains 1-2% volatile oil, camphene, zingiberene, 
zingiberoleucalyptol, yellow oil gingerol, phenols, resins, zingerone. 
ACTION: Analgesic and anti-pyretic activity. 
 
Sg<G<<< .Chukku 
Zingiber Officinale, Rosc 
OuX! ohbI<;< << nVg<ge<?! nkgl<?! NIk<vgl<?! dhGz<zl<?! dzIf<k! -R<sq?! gMhk<kqvl<?!
Sg<G?!S{<c!osi{<c?!osthe<el<?!ostuI{l<?!fuSX?!figvl<?!loft]kl<?!uqs<u!
Oh]\l<?!uqm&cb!nlqIkl<?!OuIg<ogil<H/!
h/d;!gqpr<G!)dzIf<kK*!
Sju;!giIh<H!! ke<jl;!<<< ouh<hl<! ! hqiqU!;!giIh<H!
!
osb<jg;<<< !
! ouh<hL{<mig<gq! ! Stimulant!
! hsqk<kQk<K~{<c! ! Stomachic!
! ngm<Muib<ugx<xq! ! Carminative 
!
G{l<;<<< Sg<gqeiz<?! osiqbijl?! liIohiqs<sz<?! HtqObh<hl<?! ouh<hl<?! gQp<uib<! Ofib<?!
-jvh<H?!-Vlz<?!gpqs<sz<?!fQOvx<xl<?!Ge<ll<?!ubqx<Xh<hqsl<?!giKg<!Gk<kz<?LgOfib<?!
kjz!Ofib<?!Gjzuzq?!hi{<M?!ubqx<Xg<!Gk<kz<?!JbSvl<!Ohil</!
! !
! $jzlf<kl<!ofR<osiqh<H!OkimOlh<!hl<lpjz!
! &zl<!-jvh<hqVlz<!&g<GfQI.uizgh!
! Okimlkq!sivf<!okimIuik!Ge<lfQIk<!
! Okiml<N!ll<Ohig<GR<!Sg<G/!
! !
! uikh<!hq{qubq!X~kx<!osuquib<!
! ! uzqkjz!uzqjgz!uzqbqV!uqpqfQI!
! sQkk<!okiMuiq!Ohkqh<!hzOvi!
! ! sqglzq!Lglg!Lglqc!ghliI!
! sQks<!Svl<hqiq!Ohiks<!SvOfib<!
! ! okxqhMoleolipq!GuIHuq!keqOz!
! =Kg<!GkUlq!kQKg<!Gkui!
! ! okEl<uqkq!bqjzfu!SXG{!LeOu/!
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4.CHITRAMOOLAM: 
BOTANICAL NAME: Plumbago zeylanica 
FAMILY: Plumbaginaceae 
VERNACULAR NAMES: 
Sanskrit: Chitraka 
English: Ceylon Leadwork 
Telugu: Agnimatha 
Hindi: Chitra 
Bengali: Chita 
Malayam: Vellakotuveri 
HABITAT: This garden plant is growing will in Bengal, UP Southern India and Ceylon. 
This is an allied species and is considered to be a cultivated variety of P Rosea. 
PART USED: Root 
CONSITUTENT: Fluckiger (1889) isolated plumbagin from the root in a porer form, 
Roy &Dutt(1928) have found that “Plumbagin” is present in all the varieties of Plumbago 
with in India. 
“Plumbagin” has the property of setting up irritation of the Skin. 
ACTION: Root is said to increase the digestive power and promote the apptite. 
Kelenka(1931) finds that plumbagin stimulates the central nervous system is small dose 
while with layer closes Paralysiis sets in leading ultimately to Death. The blood pressure 
Should a Slight fall. 
! !
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ogicOuzq– Kodiveli  
Plumbago indica 
OuX!ohbI;! n{qR<sqz<?!nkqgfiiq?!nkqhKr<gq?!npz<?!dkisee<?!wiq?!wPfi?!yzq?!
gVfigl<?! gezq?! giiqjl?! ogiMOuzq?! gieqzqf<kqve<?! gieqzl<?!
ogics<sq?! sqk<kqv&zq?! sqk<kqv&zl<?! sqk<kqvl<?! oRgqpq?! kpz<?! kqg<G?!
kqjsfi?! uR<skivl<?! ue<eq?! ng<eq?! nkqsesq! dkgue<?! skiOuki?!
sqk<kqvgl<?! khee<?! kqgei?! usgl<?! ueli?! ue<eqhiqbl<?! sqk<vgl<?!
ogicue<eq?!uzque<eq?!kquqhqfill</!!
!
ohiKg<! G{l<;!< << << < -keiz<?! gm<c?! H{<?! gpjz?! utqOfib<?! njvbih<Hg<gm<?! Gk<kz<?!
Osijh?!&zOvigl<?!dkqvg<gm<M?!fQOvx<xl<?!ohVubqX!-juOhil</!!
!
! gm<cuqv!{r<gqvf<kq!giz<gt<!njvbih<Hg<!
! gm<cs<$!jzuQg<gr<!gip<&zl<.Lm<cvk<kg<!
! gm<MfQ!Ovx<xr<!gek<k!ohVubqXl<!
! nm<Mr<!ogicOuzq!bil</!!
ou{<ogicOuzq!<<< - Venkodiveli 
Plumbago Zeylanica. Linn 
OuX!ohbI!;ou{<sqk<kqv&zl<?!ou{<ogic&zl<!!
Sju!;giIh<H?!uqXuqXh<H! ! ke<jl!;!<<< ouh<hl<! hqiqU!;!giIh<H!
osb<jg;<<< !
! Ljxouh<hgx<xq! ! Anti-periodic!
! uqbIjuB{<mig<gq! ! Diaphoretic!
!
! uiBuqeiZ{<miGl<?!dml<Hg<Gk<kz<!Ohil</!!
! gVj{&zl<?!njvbih<H?!g{<mlijz/!
 
5.ATHIVIDAYAM: 
BOTANICAL NAME: Aconitum hetrophyllum: 
FAMILY: Ranusculaceae 
VERNACULAR NAMES: 
Sanskrit: Ativisha 
English: Indian atees 
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Telugu: Ativasu 
Hindi: Atis 
Bengali: Ataicha 
HABITAT: Sub-Alpine and Allpine Zones, the Himalayas from Indus to Kumaori. 
Part Used: Dried tuberous roots 
CONSTITUENT: Atisine, Aconitinic acid, Tannic acid, Pectous Substance, Abudant 
starch, a mixture of oleic, Palmitic Stearic glycerides, vegetables mucilage, cane sugar 
and ash 2-percent 
ACTION: Roots are bitter tonic, astringent, Stomachic, antiperiodic and aphrodisiac. 
nkquqmbl<!<<< - Ati-Vidayam 
Aconitum heterophyllum Wall-ex Royle 
OuX!ohbI;.nk<kqv{l<?!hr<Gjv?!likqiq!
h.d! ;! OuI!
Sju! ;! jgh<H!!ke<jl!;<<< !ouh<hl<!!hqiqU!;!giIh<H!
osb<jg;<<< !
! hsqk<kQk<K~{<c! ! Stomachic!
! KuIh<hq! ! ! Astringent!
! ouh<hgx<xq! ! ! Febrifuge!
! N{<jl!ohVg<gq! ! Aphrodisiac!
! dvlig<gq! ! ! Tonic!
! Ljxouh<hgx<xq! ! Antiperiodic!
 
6.MANJAL: 
BOTANICAL NAME: Coscinium fenestraterm 
 FAMILY     : Menispermaceae 
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VERNACULAR NAME: 
Sanskrit: Daru-haridrakam 
English:Tree-Turmeric 
Bengali:Haldi-gack 
Tamil:Mara-Majal 
Telugu:Manu-Pasupes 
HABITAT: In all parts of India, especially Western India. 
PART USED:Stem 
CONSTITUENTS: Stem Contains Berberine and Saponin in small quantities. 
ACTION: Root is bitter, Stomactic, tonic and is a very good substitute for Columba. 
USES: A part of its is applied to the head as a cooling applications and also to bruises, 
Contusions etc. it is very useful in the form of infusion or tincture in continued and 
intermittent fevers, in general debility especially after fevers and in certain forms of 
Dyspepsia, in ulcers and in snake bites. 
lR<st<< << << <- Manjal 
Curcuma longa. Linn 
OuX!ohbI;!niqsel<?!gie<seq?!fqsq?!hQkl<!!
gxqlR<st<! .!gqpr<gqe<! hg<gr<gtqx<!gqjtg<Gl<!uqvx<OhiZt<tjugjt!OuXhMk<kq?!
si{h<hizqz<!Ougjuk<Kh<!hg<Guh<hMk<KuK/!
h/d!;gqpr<G!
Sju;!giIh<H?!jgh<H!! ke<jl!;!<<< ouh<hl<!! hqiqU!;!giIh<H!
osb<jg;!<<< !
! l{&m<c!!
! ngm<Muib<ugx<xq! ! Carminative !
! ouh<hL{<mig<gq! ! Stimulant !
! =vz<Okx<xq! ! ! Hepatic Tonic 
G{l<;<<< !
! dmzqx<!H,sqg<Gtqg<g!dmZg<Gh<!ohie<eqxl<!kVl</!Hziz<!fix<xk<jk!fQr<Gl</!
N{<gt<! lek<jkg<! guvs<osb<Bl<! hsqjbBL{<mig<Gl</! -keiz<! uif<kq?! utq?!
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kQ?Jbg<Gx<xl<?! kjzuiq?! fQOvx<xl<?! out<jt?! &g<GfQIhib<kz<?! Jujguzq?! uQg<gl<?!
u{<Mgc?!ohVl<H{<!-juOhil</!
! ohie<eqxlil<!Oleq!Hzieix<x!Ll<OhiGl<< < < < << < < < << < < < <!
! le<E!HVm!usqblil<!< << << < .!hqe<eqobPl<< << << <!
! uif<kqhqk<k!Okimjlbl<!uikl<Ohif<!kQhlir<< < < < < Q << < < < < Q << < < < < Q <!
! %f<klR<s!tqe<gqpr<Gg<G/< < < < << < < < << < < < < !
! -ke<! l{k<kqx<gigUl<?! fqxk<kqx<gigUl<?! fil<!d{<[l<!d{uqz<!-kjes<!
OsiIh<hK{M/<!
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INTERNAL DRUGS!
 
  KOSTAM                                                                       VETPALAIVIRAI 
                
                       CHUKKU                                                         KODIVELI 
                                            
                         MANJAL                                                    ATHIVIDAYAM 
                  
!
!
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EXTERNAL DRUG: 
1.AAMANAKUENNAI: 
BOTANICAL NAME: Ricinus communis 
FAMILY: Euphorbiaceae 
VERNACULAR NAMES: 
Sanskrit: Eranda 
Hindi: Endi 
Bengali: Verenda 
Telugu: Eramudapu 
Maalayalam: Chittamanakku 
HABITAT: This plant is Common and quite wild in the Jungles of India and is by far the 
largest producer. It is Cultivated throughout India Chiefly in the Madras, Bengal and 
Bombay Presidencies 
Part Used: Oilleaces, wets & Seeds 
CONSTITUENT: The oil Chiefly consist of ricinoleate of glycerol 1 or tri-ricinolein 
with a small quantity of palmittin and Stearin 
OuXohbI;.! !Wv{<ml<?!sqk<kqvl<?!kz'hl<!
osb<jg;<<< !
! lzlqtg<gq! ! ! Laxative!
! uxm<sqbgx<xq!! ! Emollient!
! dmjzh<!ohie<eqxlig<Gl<!
!
! ! Nl{g<G!ofb<biz<!fzL{<mil<!biuIg<Gl<!
! ! H,l{g<G!Oleq!HiqGpOz!.!uib<l{g<gg<!
! ! ogit<tqz<!ubqXuqMr<!OgivLt<t!uiBuXl<!
! ! dt<tqz<uV!Ge<ll<Ohi!OliK/!
! !
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2.MILAGU: 
BOTANICAL NAME: Piper nigrum 
FAMILY: Piperaceae 
VERNACULAR NAME: 
 Sanskrit: Marichaam 
 English: Black pepper 
 Telugu: Miriyalu 
 Malayalam: Keeru- Mulaka 
 Bengali: Kalimirich 
HABITAT: This perennial climbing shrub is indigenous to Malabar and Travancore 
Coats, ie,. Western Coat of India 
Part Used: Dried unique fruits 
CONSITUTENT: A voltaic alkaloid peprine or pipurine 5 to q pc, Piperdine or 
puperidin 5 pc a balsamic voltaic Esstential oil1to 2 pc, 7pc Mesocay Contant Charicin, 
babamic Voltaic oil, Starch, Lignin, Gum, Fat 1 pc, Proteins 7 pc, Ash Containing organic 
Matter 5 pc 
ACTION: Black pepper is acids, Pungent, Hot Carminative also used ad antiperiodic. 
EXTERNALLY: It is rubefacient & stimulant to the skin &resolvent , piperine is a mild 
antipyretic & antiperiodic 
lqtG– Milagu 
Piper nigrum.Linn 
OuX!ohbI;!gzqje?!gxq?gibl<?!Ogitgl<?!kqvr<gz<?!lqiqbz<?!sVlhf<kl<?!ut<tqsl<?!
lisl<?GXlqtG?!ljzbitq/!
h/d;!uqjk?!ogic!
Sju!;jgh<H?!giIh<H!! ke<jl;!<<< ouh<hl<! ! hqiqU!;!giIh<H!
!
!
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osb<jg;!<<< !
! gixZ{<mig<gq! ! Acrid!
! ngm<Muib<ugx<xq! ! Carminative!
! Ljxouh<hgx<xq! ! Antiperiodic!
! kch<H{<mig<gq! ! Rubefacient!
! ouh<hL{<mig<gq! ! stimulant!
! uqg<gr<gjvs<sq! ! Resolvent!
! uiklmg<gq! ! ! Antivatha!
! fs<siq! ! ! ! Antidote!
!
! sQkSvl<!hi{<M!sqOzk<lr<!gqvi{qGe<ll<!
! uikl<!nvsqhqk<kl<!li&zl<!.!YKse<eq!
! bislh^<!livl<!nme<Olgl<!gislqju!
! fisr<!gxqlqtgqeiz<!!
!
! kQbigq!obr<Gl<!kqiqBljk!biuk<K!
! Olibil!ozh<hcB!L{<mig<gix<!.!hibiK!
! Ohif<kqlqIui!kr<gqvf<kq!H{<{Qvl<!l{<{uIg<Gl<!
! gif<kqolb<ui!ks<sZh<jhg<!gib</!!
! ! lqtG?! utq?! kQ?! ghg<Gx<xr<gt<! -ju! njek<jkBl<! fQg<Gl</!
ne<xqBl<?!kqlqIuikl<?!gpjz?!utq?!stq!-jugjtBl<!ngx<Xl</!!
!
3.MANJAL: 
BOTANICAL NAME: Coscinium fenestraterm 
 FAMILY     : Menispermaceae 
           VERNACULAR NAME: 
Sanskrit: Daru-haridrakam 
English:Tree-Turmeric 
Bengali:Haldi-gack 
Tamil:Mara-Majal 
Telugu:Manu-Pasupes 
100 
 
HABITAT: In all parts of India, especially Western India. 
PART USED:Stem 
CONSTITUENTS: Stem Contains Berberine and Saponin in small quantities. 
ACTION: Root is bitter, Stomactic, tonic and is a very good substitute for Columba. 
USES: A part of its is applied to the head as a cooling applications and also to bruises, 
Contusions etc. it is very useful in the form of infusion or tincture in continued and 
intermittent fevers, in general debility especially after fevers and in certain forms of 
Dyspepsia, in ulcers and in snake bites. 
lR<st<< << << <- Manjal 
Curcuma longa. Linn 
OuX!ohbI;!niqsel<?!gie<seq?!fqsq?!hQkl<!!
gxqlR<st<! .!gqpr<gqe<! hg<gr<gtqx<!gqjtg<Gl<!uqvx<OhiZt<tjugjt!OuXhMk<kq?!
si{h<hizqz<!Ougjuk<Kh<!hg<Guh<hMk<KuK/!
h/d!;gqpr<G!
Sju;!giIh<H?!jgh<H!! ke<jl!;!<<< ouh<hl<!! hqiqU!;!giIh<H!
osb<jg;!<<< !
! l{&m<c!!
! ngm<Muib<ugx<xq! ! Carminative !
! ouh<hL{<mig<gq! ! Stimulant !
! =vz<Okx<xq! ! ! Hepatic Tonic 
G{l<;<<< !
! dmzqx<!H,sqg<Gtqg<g!dmZg<Gh<!ohie<eqxl<!kVl</!Hziz<!fix<xk<jk!fQr<Gl</!
N{<gt<! lek<jkg<! guvs<osb<Bl<! hsqjbBL{<mig<Gl</! -keiz<! uif<kq?! utq?!
kQ?Jbg<Gx<xl<?! kjzuiq?! fQOvx<xl<?! out<jt?! &g<GfQIhib<kz<?! Jujguzq?! uQg<gl<?!
u{<Mgc?!ohVl<H{<!-juOhil</!
!
! ohie<eqxlil<!Oleq!Hzieix<x!Ll<OhiGl<!
! le<E!HVm!usqblil<!.!hqe<eqobPl<!
! uif<kqhqk<k!Okimjlbl<!uikl<Ohif<!kQhlir<!
! %If<klR<s!tqe<gqpr<Gg<G/!
!
! -ke<! l{k<kqx<gigUl<?! fqxk<kqx<gigUl<?! fil<!d{<[l<!d{uqz<!-kjes<!
OsiIh<hK{<M/!
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4.VELLAI POONDU: 
BOTANICAL NAME: Allium sativum: 
FAMILY: Liliaceae 
VERNACULAR NAME: 
 Sanskrit: Lasuna 
 English: Garlic 
 Telugu: Tellagaaedda 
 Malayalam: Vellulli 
 Bengali:  Rasun 
HABITAT: Cultivated all over India 
Part Used: Bulb & Oil 
CONSITUTENT: An Acid volatile oil starch, Mucilage, Albumen, Sugar etc 
ACTION: Hot, Stimulant, Carminative, emmenagogue, antirheumatic, anthelmintic and 
alternative 
out<Tt<tq!< << << < – Vellulli 
Allium sativum.Linn 
OuX!ohbI;!-zgel<?gibl<?!dt<tq?!H,{<M?!out<jth<H,{<M?!out<ur<gibl</!!
h/d;!gqpr<G!
Sju;!giIh<H!! ke<jl!;!<<< ouh<hl<! hqiqU!;!giIh<H!
osb<jg;!<<< !
! ngm<Muib<ugx<xq! ! Carminative!
! hsqk<kQk<K~{<c! ! Stomachic 
! dvlig<gq! ! ! Tonic!
! dmx<Oxx<xq! ! ! Alterative 
! ouh<hL{<mig<gq! ! Stimulant!
! Ogijpbgx<xq!! ! Expectorant!
! sqXfQIh<ohVg<gq! ! Diuretic!
! HPg<ogiz<zq!! ! Anthelmintic 
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G{l<;<<< !
! -jks<!sqxqb!gm<cgt<?!osuqM/!fim<hm<m!-Vlz<?!-jvh<H?!ubqx<Xh<HP!
-jugm<Gl<?!Lh<hq{q?!utqOfib<gt<?!Jbk<kjzuzq?!uib<Ofib<?!fQOvx<xl<?!
sQkg<gpqs<sz<?!&zl<!-jugm<Gl<!ogiMg<gzil</!!
! !
! se<eqobiM!uikf<!kjzOfiU!kit<uzq!
! le<equV!fQIg<Ogiju!ue<sQkl<!.!ne<eOl!!
! dt<Tt<tq!g{<hib<!djt&z!OvigLl<!Ohil<!
! out<Tt<tq!ke<eiz<!ouV{<M/!
!
5.KUPPAIMENI  SAARU: 
BOTANICAL NAME: Acalypha indica: 
FAMILY: Euphorbiaceae 
VERNACULAR NAMES: 
 Sanskrit: Arittermanjarie 
 English: Indian Acalypha 
 Telugu: Keippeichhettu 
 Hindi: Keepu 
 Bengali: Muktajjhuri 
HABITAT: Common annual shrub in Indian gardens and waste places throughout the 
plains of India. 
PART USED: Leaves, Root, Stalk & Flowers 
CONSITUENTS: Alkaloids “Acalypus & Acalyphine” 
ACTION: Cathartic anthelmintic, expectorant, enatic anaelyne & hyppotic. 
! !
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Gh<jhOleq<<< !– Kuppai-meni 
Acalypha indica. Linn 
OuX!ohbI;!niqlR<siq?!H,jeu{r<gq?!Oleq/< << << < !
h/d;!-jz?!OuI?s&zl<!
Sju;!jgh<H?!giIh<H! ke<jl<<< !;!ouh<hl<! hqiqU!;!giIh<H!
osb<jg;<<< !
! Kbvmg<gq! !  Anodyne!
! HPg<ogiz<zq!! ! Anthelmintic!
! ohVlzl<Ohig<gq! ! Cathartic!
! sqXFIh<ohVg<gq! ! Diuretic!
! uif<kqB{<mig<gq! ! Emetic!
! Ogijpbgx<xq!! ! Expectorant 
! $kgL{<mig<gq! ! Emmenagogue!
G{l<;<<< !
! -ke<!-jzbiz<?!hz<zc!Ofib<?!kQs<Sm<mh<H{<?!hbqI!ujgbqe<!fR<S?!
ubqx<Xuzq?!utqOfib<?!&zl<?!fjls<sz<?!Gk<kz<?!-jvh<H?!&g<GfQI!hib<kz<?!Ogijp!
Ngqbju!fQr<Gl</!!
! kf<k&!zh<hq{qkQk<!kf<kqMH{<!sIuuqml<!
! df<KGe<ll<!uikl<!dkqv&.zf<kqeU!
! $zR<S!uisl<!okimIhQ!sr<ghl<Ohil<!
Rizr<ogit<!Oleqbk!eiz</!
 
6. KADUGU: 
BOTANICAL NAME: Brassica juncea. 
FAMILY: Cruciferae 
VERNACULAR NAMES: 
Sanskrit: Rajika 
English: Common Indian or brow mustard 
Bengali: Rai sarisha 
Telugu: Avalu 
Malayalam: Kaduka 
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HABITAT: Cultivated in many parts in India 
Part Used: Seeds And Oil 
CONSTITUENT: Seeds contains about do to 25 per cent of oil. An essential oil is also 
produced by the action of water 
ACTION: Whole plant possesses bitter, aperients and tonic properties , Oil in Stimulant 
and counter irritant. A hot mustard batts is an emminaagogue 
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EXTERNAL DRUGS 
 
               AMANAKU OIL                                                        MANJAL     
                
               VELLAIPOONDU                                      KUPPAIMENI SARU 
                
                              KADUGU                                                 MILAGU    
                 
 
! 
! !
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OuXohbI!;Jbuq!
osb<jg;!<<< !
! uif<kqB{<mig<gq! ! Emetic!
! ouh<hL{<mig<gq! ! Stimulant!
! Kch<H{<mig<gq! ! Rubefacient!
! ogih<HtolPh<hq! ! Vesicant!
! osiqh<H{<mig<gq! ! Digestive!
! sqXfQIh<ohVg<gq! ! Diuretic 
G{l<;<<< !
! -K! kjzbqch<jhk<! kvg<%cb! -Vlz<?! &g<GfQI! uckz<! Ogijp?! ouxq?!
gi{iuqmg<! gc?!Gjms<sz<?!Lml<?! lf<kl<?Gpl<hqb!dlqp<fQI?! gpqs<sz<?! ubqx<Xuzq?!
Lh<hq{q?! -jugjt! uqzg<Gl</! OlZl<?! sQkg<gMh<H?! gQz<! uiB?! osiqbijl?! kjz!
Sx<xz<?!uqg<gz<!-jugjtBl<!Ohig<Gl</!!
! !
! -cgis!fisqg<$!iQjtghl<!hqk<kr<!
! gcuik!sQkr<!gMh<Ohi!.!Mmzqx<!
! hMOgim<M!Ofiobe<El<!hr<gqjug!jth<H{<!
! gMOgim<M!Ole<lVf<K!gi{</!
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INTERNAL DRUG – KUSTATHI CHOORNAM 
 
 
!
!
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EXTERNAL DRUG – ERANDA THYLAM 
 
!
!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
! !
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ANNEXURE – II 
BIO – CHEMICAL ANALYSIS 
BIO – CHEMICAL ANALYSIS OF KUSTATHI CHOORNAM 
 
 PREPARATION OF THE EXTRACT 
            5gms of drug was weighed accurately and placed in a 250ml clean beaker. Then 
50ml distilled water was added and dissolved well. Then it was boiled well for about 10 
minutes. It was cooled and filtered in a 100ml volumetric flask and then it was made up to 
100ml with distilled water. This fluid was taken for analysis. 
Qualitative Analysis 
 
S.No 
 
Experiment Observation Inference 
 
1. 
 
Test for calcium: 
2ml of the above prepared extract is 
taken in a clean test tube. To this add 
2 ml of 4% ammonium oxalate 
solution. 
 
No white 
precipitate 
formed. 
Absence of 
calcium. 
 
 
2. 
 
Test for sulphate: 
2ml of the extract is added to 5% 
barium chloride solution. 
 
 
A white 
Precipitate is 
formed. 
 
 
Indicates the 
presence  of 
sulphate. 
 
 
3. 
 
Test for chloride: 
The extract is treated with silver 
nitrate solution. 
 
No  
precipitate  
formed. 
 
 
Absence  of 
chloride. 
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4. 
 
Test for carbonate: 
The substance is treated with 
concentrated Hcl 
 
 
No brisk 
effervescence  
formed. 
 
Absence of 
carbonate. 
 
5. 
Test for Starch: 
The extract is added with weak iodine 
solution. 
 
No Blue colour  
formed 
 
 
Absence  of 
starch. 
 
 
6. 
 
Test for Iron Ferric: 
The extract is treated with 
concentrated glacial acetic acid and 
potassium ferro cyanide. 
 
 
No blue colour  
formed. 
 
 
Absence of 
ferric iron. 
 
 
7. 
 
Test of Iron Ferrous: 
The extract is treated with 
concentrated Nitric acid and 
ammonium thio cyanate solution. 
 
 
Blood red colour 
Is formed. 
 
 
Indicates the 
presence of 
ferrous iron. 
 
 
8. 
 
Test for phosphate: 
The extract is treated with ammonium 
molybdate and concentrated nitric 
acid. 
 
 
No Yellow  
precipitate  
formed. 
 
 
Absence  of 
phosphate. 
 
 
9. 
 
Test for albumin: 
The extract is treated with Esbach’s 
reagent. 
 
 
No yellow 
precipitate  
formed. 
 
 
Absence of 
albumin. 
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10. 
 
Test for Tannic acid: 
The extract is treated with ferric 
chloride reagent. 
 
 
No Blue black 
precipitate  
formed. 
 
 
Absence  of 
Tannic acid. 
 
 
11. 
 
Test for unsaturation: 
Potassium permanganate solution is 
added to the extract. 
 
It gets 
decolorized. 
 
 
Indicates the 
presence of 
unsaturated 
compound. 
 
12. 
 
Test for the reducing sugar: 
5ml of Benedict’s qualitative solution 
is taken in a test tube and allowed to 
boil for 2 minutes and added 8-10 drops 
of the extract and again boil it for 2 
minutes. 
 
 Colour change 
occurs. 
 
Indicates the 
presence  of 
reducing 
sugar. 
 
 
13. 
 
Test for amino acid: 
One or two drops of the extract is 
placed on a filter paper and dried it 
well. After drying, 1% ninhydrin is 
sprayed over the same and dried it 
well. 
 
 
Violet colour 
formed. 
 
 
Indicates the 
presence of 
amino acid. 
 
 
14. 
Test for zinc: 
The extract is treated with Potassium 
ferrocyanide. 
No white 
precipitate is 
formed 
 
 
Absence of zinc. 
 
 
 
Inference: 
 The given sample of “Kustathi choornam” contains sulphate, ferrous iron, amino 
acids, unsaturated compoundand reduced sugars. 
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PHYSIOCHEMICAL ANALYSIS OF –KUSTATHY CHOORANAM 
1. Loss On Drying: 
An accurately weighed 2g of Kustathy Chooranam formulation was taken 
in a tarred glass bottle. The crude drug was heated at 1050C for 6 hours in an oven 
till a constant weight. Percentage moisture content of the sample was calculated 
with reference to the shade dried material. 
2. Determination of total ash: 
Weighed accurately 2g of Kustathy Chooranam formulation was added in 
crucible at a temperature 6000C in a muffle furnace till carbon free ash was 
obtained. It was calculated with reference to the air dried drug.  
3. Determination of acid insoluble ash: 
Ash above obtained, was boiled for 5min with 25ml of 1M Hydrochloric 
acid and filtered using an ash less filter paper. Insoluble matter retained on filter 
paper was washed with hot water and filter paper was burnt to a constant weight 
in a muffler furnace. The percentage of acid insoluble as was calculated with 
reference to the air dried drug. 
4. Determination of water soluble ash: 
Total ash 1g was boiled for 5min with 25ml water and insoluble matter 
collected on an ash less filter paper was washed with hot water and ignited for 15 
min at a temperature not exceeding 4500C in a muffle furnace. The amount of 
soluble ash is determined by drying the filtrate.  
5. Determination of water soluble Extractive: 
5gm of air dried drug, coarsely powered Kustathy Chooranam was 
macerated with 100ml of distilled water in a closed flask for twenty-four hours 
shaking frequently. Solution was filtered and 25 ml of filtrated was evaporated in 
a tarred flat bottom shallow dish, further dried at 1000 C and weighted. The 
percentage of water soluble extractive was calculated with reference to the air 
dried drugs.   
6. Determination of alcohol soluble extractive: 
2.5gm. of air dried drugs, coarsely powdered Kustathy Chooranam was 
macerated with 50 ml. alcohol in closed flask for 24 hrs. With frequent shaking it 
was filtered rapidly taking precaution against loss of alcohol. 10ml of filtrate was 
then evaporated in a tarred flat bottom shallow dish, dried at 1000C and weighted. 
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The percentage of alcohol soluble extractive was calculated with reference to air 
dried drug. 
S.no Parameters Percentage 
1 Loss on drying  5.88% 
2 Total ash value 4.28% 
3 Acid insoluble ash Less than 1% 
4 Water soluble ash Less than 1% 
5 Water soluble extraction 70.01% 
6 Alcohol soluble extraction 12.74% 
     The above stated physiochemical properties for the given sample certified to be 
present. 
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EFFECT OF KUSTATHI CHOORNAM WITH HOT WATER ON 
CARRAGEENAN-INDUCED LOCALISED INFLAMMATORY PAIN IN RATS 
SUMMARY 
  The study plan was developed based on the guidelines of Vogel1 and also it has 
reference to Chao Ma and Jun-Ming Zhang2 and Walker et al. 3, Winter CA, Risley EA, 
Nuss GW. Carrageenin induced edema in hind paw of the rat as an assay for anti-
inflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544–7. 
Objective 
  To study the anti-inflammatory effect of KUSTATHI CHOORNAM were 
prepared with HOT WATER in the rat model of Carrageenan-induced localized 
inflammation.  
Methods: 
Test System 
Species : Rat   
Strain : Albino Wister 
Age : 6-8 weeks at the time of dosing 
Total no. of Rats : 24 
Sex : Male 
Weight                   :    150 gm 
 
 The animals were housed in polypropylene cages with stainless steel top grills 
having facilities for holding pellet food and drinking water in bottle with stainless steel 
sipper tube. Each cage contained 6 rats. All rats had free access to potable water and 
standard pelleted laboratory animal diet ad libitum. Paddy husk was used as bedding 
material. The animals were divided into 5 groups (6 rats/group). Localized inflammatory 
pain was induced in all groups of animals by intraplantar injection of carrageenan (50 µl 
of 3% suspension).  
 One day before the experiment, three basal readings of hind paw in each rat were 
recorded. Group 1 received vehicle orally, Group 2 received a standard drug Diclofenac 
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sodium (10 mg/kg i.p), whereas groups 3,4and 5 received KUSTATHI CHOORNAM. 
The doses of KUSTATHI CHOORNAM were prepared with HOT WATER, whereas 
Diclofenac sodium was dissolved in normal saline. After 30 min, the rats were challenged 
with subcutaneous injection of 0.1 ml of 1% w/v solution of carrageenan into the sub 
plantar region of left paw. The paw was marked with ink at the level of lateral malleolus 
and immersed in mercury up to the mark. The paw volume was measured at 0, 1, 2, 3, 4, 
5 and 6th hr after carrageenin injection using Digital Plethysmometer. The difference 
between initial and subsequent reading gave the actual edema volume.  
 
CONVERSION FORMULA: 
Human dose is 1000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
1000 mg x 2(a) x 0.018 (b) = 18 (c) /150 gm of Rat 
18/1000x150 = 2.7 mg  
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of 
administration 
 
1 Vehicle Control -- 1 ml 
 
2 Therapeutic Dose 2.7 mg /kg 
 
1 ml 
3 Middle  Dose 13.5mg/kg 1 ml 
 
4 High Dose 67.5mg/kg 1 ml 
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EXPERIMENTAL DESIGN: 
Group-I:   Served as a negative control (0.1ml of 1% carrageenin) 
Group-II: Served as standard received Diclofenac sodium (10mg/kg, i.p) + 
                  (0.1ml of 1% carrageenin) 
Group-III: Received KUSTATHI CHOORNAM were prepared with HOT WATER 
        (2.7 mg /kg) + (0.1ml of 1% carrageenin) 
Group IV: Received KUSTATHI CHOORNAM were prepared with HOT WATER 
                   (13.5 mg/kg ) + (0.1ml of 1% carrageenin) 
Group V: Received KUSTATHI CHOORNAM were prepared with HOT WATER 
                   (67.5 mg/kg ) + (0.1ml of 1% carrageenin) 
 
TABLE: EFFECT OF KUSTATHI CHOORNAM WITH HOT WATER ON 
Carrageenin -INDUCED PAW EDEMA IN RATS (BODY WEIGHT in gms) 
 
 
Group 
 
 
Only 
Carrageenan 
 
 
Carrageenan+ 
Diclofenac 
10mg/kg 
 
Carrageenan+ 
L.D 
 
Carrageenan 
+M.D 
Carrageenan+H.D 
INITIAL 
BODY 
WEIGHT 
 
120.667± 
0.3333 
 
117.167± 
2.4441 
 
 
149± 
1.67332 
 
135.5± 
2.09364 
135.333± 
1.22927 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by 
one way ANOVA followed by dunnett’s. ns- not significant **P< 0.05 calculated by 
comparing treated group with control group 
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EFFECT OF KUSTATHI CHOORNAM WITH HOT WATER ON Carrageenin -
INDUCED PAW EDEMA IN RATS  
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by 
one way ANOVA followed by dunnett’s. ns- not significant **P< 0.05 calculated by 
comparing treated group with control group. 
 
 
 
  
 
Group 
Mean 
paw 
volume 
before 
carragee
nan 
injection 
Paw Volume after 
induction with carrageenin 
Increase in paw volume 
(ml) after carrageenan 
injection (mean ± SEM)                 
 
 
Paw Volume after induction with  
carrageenin  
Increase in paw volume (ml) after  
carrageenan injection (mean ± SEM)         
 
0 min 30 min 1hr 2hr 3h 4h 5h 6h 
Only 
Carragee
nan 
 
3.51± 
0.159812 
 
6.85333
± 
0.15272
3 
7.67333
± 
0.14639
4 
7.97333
± 
0.16810
1 
8.19± 
0.16385 
8.11333
± 
0.20452
7 
7.935± 
0.15810
9 
7.81± 
0.14964
4 
 
Carragee
nan + 
Standard 
 
 
3.26667± 
0.067015
8 
 
5.98667
± 
1.20647 
 
6.30667
± 
1.27245 
 
6.19± 
1.24718 
 
6.05± 
1.22018 
 
5.9± 
1.18545
* 
 
 
5.48667
± 
1.10041
* 
 
4.81667
± 
0.97376
8** 
 
Carragee
nan + 
L.D 
 
 
3.33667± 
0.135982 
 
6.70667
± 
0.10666
7 
 
7.26167
± 
0.08174
83 
 
7.10667
± 
0.06168
02 
7.1± 
0.04898
98 
6.84833
± 
0.03970
03 
6.34333
± 
0.06354
35 
5.95333
± 
0.05432
41* 
 
Carragee
nan + 
M.D 
 
3.8± 
0.186619 
 
6.965± 
0.14342
8 
 
7.29333
± 
0.14820
4 
7.15667
± 
0.07163
18 
 
7.05333
± 
0.06606
39 
6.74333
± 
0.08739
44 
 
6.25± 
0.06169
82 
5.77333
± 
0.08604
91* 
 
Carragee
nan + 
H.D 
3.60333± 
0.120268 
3.33167
± 
0.02833
34 
3.38± 
0.07343
93 
3.385± 
0.03703
6 
 
3.46333
± 
0.04848
83 
3.43167
± 
0.08780
34 
 
3.40333
± 
0.06892
83 
3.35333
± 
0.03137
59 
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Carrageenin + H.D
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EFFECT OF KUSTATHI CHOORNAM WITH HOT WATER ON Carrageenin -
INDUCED PAW EDEMA IN RATS 
 
         
                  Only Carrageenin                                        Carrageenin+  STD 
     
          
               Carrageenin + L.D                                                 Carrageenin + M.D 
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EFFECT OF KUSTATHI CHOORNAM WITH HOT WATER ON ACETIC ACID 
INDUCED WRITHING IN MICE1 
1. Kaneria MS, Naik SR, Kohli RK. Anti-inflammatory,antiarthritic and analgesic 
activity of a herbal formulation. Indian J.Experimental Biol. 2007; 45: 279. 
 
       Acetic acid induced writhing method was adopted for evaluation of analgesic 
activity. Writhing is defined as a stretch, tension to one side, extension of hind legs, 
contraction of the abdomen so that the abdomen of mice touches the floor, turning of 
trunk (twist). Any writhing is considered as a positive response. 
 
MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. 
All the animals were obtained from Animal house of the KMCH College of Pharmacy, 
Coimbatore. The animals were housed comfortably in a group of six in a single clean 
plastic cage with a metal frame lid on its top. They were housed under standard 
environmental conditions of temperature (24±1°C) and relative humidity of 30-70 %. A 
12:12 h light dark cycle was followed. All animals had free access to water and standard 
pelletized laboratory animal diet ad libitum. All the experimental procedures and 
protocols used in this study were reviewed and approved via the Approval No. -------------
---------------- by the Institutional Animal Ethical Committee (IAEC) of KMCH College 
of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 
constituted in accordance with the guidelines of the CPCSEA, Government of India. 
DRUGS: 
         Acetic acid (Sigma Chemical Co. Bangalore, India) and Indomethacin  were 
purchased from (Ranbaxy, India). All drugs were dissolved in saline. The different doses 
of KUSTATHI CHOORNAM were prepared WITH HOT WATER.The control group 
received vehicle as control. All drugs were prepared just before use. 
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 PREPARATION OF ACETIC ACID: 
         A solution of acetic acid (1% v/v) in distilled water was prepared. 
 
CONVERSION FORMULA: 
Human dose is 1000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 30 gm of Mice 
1000 mg x 2(a) x 0.018 (b) = 18 (c) /30 gm of Mice 
18/1000x30 = 0.54 mg  
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of 
administration 
 
1 Vehicle Control -- 
1 ml 
 
2 Therapeutic Dose 
0.54 mg /kg 
 
1 ml 
3 Middle  Dose 2.7mg/kg 
1 ml 
 
4 High Dose 13.5mg/kg 1 ml 
 
EXPERIMENTAL PROCEUDRE: 
       GROUP 1 – CONTROL (IP injection of 0.1 ml 1% acetic acid) 
       GROUP 2 -- IP injection of 0.1 ml 1% acetic acid + Indomethacin (5mg/kg, i.p) 
       GROUP 3 -- 0.1 ml 1% acetic acid (ip) + KUSTATHI CHOORNAM  
   WITH HOT WATER 0.54MG /KG(PO)                        
     GROUP 4 -- 0.1 ml 1% acetic acid (ip) + KUSTATHI CHOORNAM WITH HOT  
  WATER 2.7mg/Kg(Po) 
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GROUP 5 -- 0.1 ml 1% acetic acid (ip) + KUSTATHI CHOORNAM WITH                    
HOT WATER 13.5mg/kg(po) 
 
PROCEDURE: 
            Wister albino mice of either sex were divided into five different groups each 
containing  Six animals, the animals were marked individually. Food was withdrawn 12 
hours prior to drug administration till completion of experiment. The animals were 
weighed and numbered appropriately. The test and standard drugs were given orally. After 
60 minutes writhing was induced by intra-peritoneal injection of 1% acetic acid in volume 
of 0.1 ml/10g body weight. The writhing episodes were recorded for 30 minutes; 
stretching movements consisting of arching of the back, elongation of body and extension 
of hind limbs were counted. 
  Anti-nociceptive  activity was expressed as the percentage inhibition of abdominal 
constrictions using the ratio:  
             (Control mean – Treated mean) × 100/Control mean 
 
EFFECT OF KUSTATHI CHOORNAM WITH HOT WATER ON ACETIC ACID 
INDUCED WRITHING IN MICE1 
 
GROUP 
 
No of Writhing (30min) 
 
Inhibition (%) 
 
 
CONTROL 
 
 
45.33±4.807 
 
--- 
 
Indomethacin (5mg/kg, i.p) 
 
 
22.67±1.764*** 
 
49.98 % 
 
K C 0.028mg/kg(po) 
 
 
34.33±1.202** 
 
24.26 % 
 
K C 0.014mg/kg(po) 
 
 
25.33±1.764*** 
 
44.12 % 
 
K C 0.28mg/kg(po) 
 
 
22.33±1.202*** 
 
50.73 % 
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Values are expressed as the mean ± S.D; Statistical significance (p)calculated by 
one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 
0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF KUSTATHI CHOORNAM WITH HOT WATER ON HOT PLATE 
METHOD IN MICE1 
1. Turner RA. Screening methods in pharmacology. In: Turner, R., Hebborn, P. 
(eds.). Academic press, New York. 1965; 100.  
 
            The paws of mice and rats are very sensitive to heat at temperatures which are not                 
damaging the skin. The responses are jumping, withdrawal of the paws and licking of the 
paws. 
 MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. 
All the animals were obtained from Animal house of the KMCH College of Pharmacy, 
Coimbatore. The animals were housed comfortably in a group of six in a single clean 
plastic cage with a metal frame lid on its top. They were housed under standard 
environmental conditions of temperature (24±1°C) and relative humidity of 30-70 %. A 
12:12 h light dark cycle was followed. All animals had free access to water and standard 
pelletized laboratory animal diet ad libitum. All the experimental procedures and 
protocols used in this study were reviewed and approved via the Approval No. -------------
---------------- by the Institutional Animal Ethical Committee (IAEC) of KMCH College 
of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 
constituted in accordance with the guidelines of the CPCSEA, Government of India. 
      The hot plate, which is commercially available, consists of a electrically heated 
surface. The temperature is controlled for 55° to 56 °C. This can be a copper plate or a 
heated glass surface. The animals are placed on the hot plate and the time until either 
licking or jumping occurs is recorded by a stop-watch. 
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EXPERIMENTAL PROCEUDRE: 
 
        GROUP 1 – CONTROL  
       GROUP 2 – Pentazocine (10mg/kg, I.P) 
       GROUP 3 -- KUSTATHI CHOORNAM WITH HOT WATER 
                                   0.54 mg /kg(po)           
              
       GROUP 4 – KUSTATHI CHOORNAM WITH HOT WATER    
                                      2.7mg/kg(po) 
 
      GROUP 5 -- KUSTATHI CHOORNAM WITH HOT WATER    
                                      13.5mg/kg(po) 
 
PROCEUDRE: 
  Mice were screened by placing them on a hot plate maintained at 55±1ºC and 
recording the reaction time in seconds for forepaw licking or jumping. Only mice which 
reacted within 15sec and which did not show large variation when tested on four separate 
occasions, each 15min apart, were taken for the test. The time for forepaw licking or 
jumping on the heated plate of the analgesiometer maintains at 55ºC was taken as the 
reaction time. Prior to treatment, the reaction time of each mouse (licking of the forepaws 
or jumping response) was done at 0- and 10-min interval. The average of the two readings 
was obtained as the initial reaction time (Tb). The reaction time (Ta) following the 
administration of the ---------------, Pentazocine and distilled water was measured at 0.5, 
1, 2, and 3h after latency period of 30min. 
 
The following calculation was:  
          Percentage analgesic activity = Ta-Tb/Tb × 100 
 
 
 
 
  
127 
 
EFFECT OF KUSTATHI CHOORNAM WITH HOT WATER ON HOT PLATE 
METHOD IN MICE1 
 
GROUP 
 
Reaction time in seconds at time (minutes) (mean ± sem) (mean ± sem) 
 
O mints 60 mints 90 mints 120 mints 180 mints 
 
CONTROL 
 
3.467±0.09333 
 
4.257±0.196 
 
4.793±0.096 
 
4.77±0.121 
 
4.56±0.193 
 
 
STANDARD 
 
3.447±0.1299 
 
5.773±0.0693 
 
6.737±0.210 
 
7.62±0.150 
 
7.27±0.206 
 
 
K C + LOW DOSE 
 
3.223±0.02028 
 
7.83±0.0874 
 
8.61±0.167 
 
8.59±0.2401 
 
8.45±0.0779 
 
 
K C + MIDDLE DOSE  
 
3.637±0.05783 
 
7.48±0.1021 
 
7.66±0.165 
 
7.67±0.176 
 
7.47±0.187 
 
 
K C + HIGH DOSE 
 
3.643±0.1943 
 
6.4±0.1528 
 
7.113±0.119 
 
7.2±0.1041 
 
7.20±0.223 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ***P< 0.001, **P < 0.01,*P < 0.05 calculated by 
comparing treated group with CONTROL group. 
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ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF KUSTATHI CHOORNAM WITH HOT WATER 
Table 1. Test substance details 
Name of the test substance 
 
KUSTATHI CHOORNAM WITH 
HOT WATER 
 
Colour of the test substance BROWN 
Nature of the test substance Powder 
 
Table 2. Experimental protocol 
Name of the study Acute toxicity 
Guideline followed OECD 423 method-acute toxic class 
method 
Animals Healthy young adult female wister rats, 
nulliparous, non-pregnant 
Body weight 150-200 g 
Sex female 
Administration of dose and volume 2000 mg/kg in 200g body weight, single dose in 1 ml 
Number of groups and animals 
5 groups and 3 animals in each group 
100mg,250mg,500mg,1000mgand 
2000mg/kg 
Route of administration Oral Cavage (po) 
Vehicle Hot Water 
 
Table3. Housing and feeding conditions 
Room temperature 22°C  ±  3°C 
Humidity 40-60% 
Light 12 h : 12h (light : dark cycle) 
Feed 
Standard laboratory animal food pellets 
with water ad libitum 
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Table 4. Study period and observation parameters 
Initial once observation First 30 minutes and periodically 24 h 
Special attention First 1-4 h after drug administration 
Long term observation Upto 14 days 
Direct observation parameters 
Tremors, convulsions, salivation, diarrhea, 
lethargy, sleep and coma. 
Additional observation parameters 
Skin and fur, eyes and mucous membrane, 
respiratory, circulatory, autonomic and 
central nervous systems, somato motor 
activity and behavior pattern etc. 
  
  The time of death, if any, is recorded. (Complete observations: annexure I). After 
administration of the drug, food is withheld for a further 1-2 hours. 
 
Study procedure 
  Acute oral toxicity was performed as per organization for economic co-operation 
for development (OECD) guideline 423 method. The KUSTATHI CHOORNAM with 
HOT WATER was administered in a single dose by tuberculin syringe. Animals are 
fasted 3 h prior to dosing (food was withheld for 3 h but not water). Following the period 
of fasting animals was weighed and test substance was administered orally at a dose of 
100mg,250mg,500mg,1000mgand 2000mg/kg. After the KUSTATHI CHOORNAM 
with HOT WATER administration, food was withheld 2 h in mice. Animals are 
observed individually after at least once during the first 30 minutes, periodically during 
the first 24 hrs, with special attention given during the first 4 hrs, and daily thereafter, for 
a total of 14 days.  
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REPORT 
Toxicological evaluation of KUSTATHI CHOORNAM with HOT WATER 
Table:5 Effect of KUSTATHI CHOORNAM with HOT WATER on acute toxicity test 
in female rats. 
 
RESULT: 
  From acute toxicity study it was observed that the administration of KUSTATHI 
CHOORNAM with HOT WATER to Female Wister rats did not induce drug-related 
toxicity and mortality in the animals up to 2000mg/kg in 200g female Wister rats. So No-
Observed-Adverse-Effect- Level (NOAEL) of KUSTATHI CHOORNAM with HOT 
WATER is 2000 mg/kg equal to human dose 
 
S.N 
 
 
Response 
Head Body Tail 
Before After Before After Before After 
1 Alertness Normal Normal Normal Normal Normal Normal 
2 Grooming Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response Normal Normal Normal Normal Normal Normal 
5 Pain response Normal Normal Normal Normal Normal Normal 
6 Tremors Absent Absent Absent Absent Absent Absent 
7 Convulsion Absent Absent Absent Absent Absent Absent 
8 Righting reflux Normal Normal Normal Normal Normal Normal 
9 Gripping strength Normal Normal Normal Normal Normal Normal 
10 Pinna reflux Present Present Present Present Present Present 
11 Corneal reflux Present Present Present Present Present Present 
12 Writhing Absent Absent Absent Absent Absent Absent 
13 Pupils Normal Normal Normal Normal Normal Normal 
14 Urination Normal Normal Normal Normal Normal Normal 
15 Salivation Normal Normal Normal Normal Normal Normal 
16 Skin colour Normal Normal Normal Normal Normal Normal 
17 Lacrimation Normal Normal Normal Normal Normal Normal 
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DISCUSSION 
KUSTATHI CHOORNAM with HOT WATER was administered single time 
at the doses of 100mg, 250mg, 500mg, 1000mg and 2000mg/kg to female Wister rats and 
observed for consecutive 14 days after administration. Doses were selected based on the 
pilot study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No mortality 
was observed during the entire period of the study. Data obtained in this study indicated 
no significance physical and behavioral signs of any toxicity due to administration of 
KUSTATHI CHOORNAM with HOT WATER at the doses of 100 mg, 250mg 
,500mg, 1000mg and 2000mg/kg to female Wister rats  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand held 
activity were observed. Home cage activities like Body position, Respiration, Clonic 
involuntary movement, Tonic involuntary movement, Palpebral closure, Approach 
response, Touch response, Pinna reflex, Sound responses, Tail pinch response were 
observed. Handheld activities like Reactivity, Handling, Palpebral closure, Lacrimation, 
Salivation, Piloercetion, Papillary reflex, abdominal tone, Limb tone were observed. 
Functional and behavioral examination was normal in all treated groups. Food 
consumption of all treated animals was found normal as compared to normal group. 
 
SUMMARY & CONCLUSION: 
Summary: 
The present study was conducted to know single dose toxicity of KUSTATHI 
CHOORNAM with HOT WATER on female Wister rats. The study was conducted 
using 15 female Wister rats. The female animals were selected for study of 8- 12 weeks 
old with weight range of within ± 20 % of mean body weight at the time of 
randomization. The groups were numbered as group I, II, III, IV and V and dose with 
100mg, 250mg, 500mg, 1000mg and 2000mg/kg of KUSTATHI CHOORNAM with 
HOT WATER. The drug was administered by oral route single time and observed for 14 
days. Daily the animals were observed for clinical signs and mortality.  
There were no physical and behavioral changes observed in Female Wister rats 
during 14 days. Mortality was not observed in any treatment groups. 
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Conclusion: 
The study shows that KUSTATHI CHOORNAM with HOT WATER did not 
produce any toxic effect at dose of 100mg, 250mg, 500mg, 1000mg and 2000mg/kg to 
rats. So No-Observed-Adverse-Effect-Level (NOAEL) of KUSTATHI CHOORNAM 
with HOT WATER is 2000 mg/kg. 
 
7.0 ABBREVIATIONS 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o  peros 
ML  Milliliter 
%   percentage 
R&D   Research and Development 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD  Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments on  
Animals 
 
 
8.0 REFERENCES: 
1. OECD. Guideline for Testing of Chemicals 423, Acute oral toxicity (acute toxic 
class method). December 2001. 
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SUB-ACUTE TOXICITY STUDY IN WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF KUSTATHI CHOORNAM WITH HOT WATER  
Objective 
  The objective of this study is to evaluate the toxic effects, if any, as a result of the 
repeated once daily oral administration of KUSTATHI CHOORNAM WITH HOT 
WATER to Wister Albino rats for a minimum period of 28 consecutive days. This study 
will provide information on any major toxic effects, target organs and a rationale for 
concluding the No-Observed-Adverse-Effect-Level (NOAEL) and/or No Observed Effect 
Level (NOEL) / LOEL (Low Observed Effect Level) and risk assessment in humans. 
1. Test Guidelines  
This study plan is prepared as per the following guidelines: 
Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
OECD – 407 – Repeated dose 28-day Oral Toxicity Study in Rodents, Adopted 3 
October, 2008. 
1.1. Test System Details 
Species : Rat 
Strain  : Wister Albino  
Source    : Sree Venkateshwara Enterprises Pvt Ltd, Bangalore  
Age : 6-8 weeks  
Sex : Male / Female (nulliparous and non-pregnant) 
Body weight   : 160.0to 180.0 g 
1.2.  Acclimatization 
Animals will be allowed to acclimatize to the experimental room conditions for 
five days prior to the commencement of dosing. During the acclimatization 
period, the animals will be observed daily for any apparent adverse clinical signs. 
Prior to assignment to the study and commencement of treatment, a detailed 
physical health examination will be performed on all animals by a veterinarian 
and animals with any evidence of ill health or poor physical condition will not 
selected for the study. 
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1.3. Randomization and Grouping 
On the starting day of dosing, the animals will be weighed and health examination 
will be performed by veterinarian. Animals will be randomly allocated to different 
groups according to their body weight by using MS-Excel sheet as described in 
the randomization SOP. Animals will be divided into four groups (vehicle control, 
low, intermediate, and high dose). At the initiation of the treatment, the body 
weight variation between the groups did not exceed ±20% of the mean weight of 
each sex. 
1.4. Animal Identification 
In each cage, animals will be identified with numbers by marking at the base of 
the ear. The cages will be identified with an attached colored cage label showing 
study number, study code, group number, sex, dose, strain, species, cage number, 
route of administration and animal number. 
2. Animal Husbandry 
2.1. Animal Welfare and approval 
The study was approved by the IAEC (SLS) and Committee for the Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA registration 
number: Abc14).Their recommendations regarding animal care and handling will 
be followed. 
2.2. Environmental Conditions 
The temperature of the experimental room will be maintained at 22±30C and the 
relative humidity between 30-70 %. The photoperiod will be 12 hours light and 12 
hours dark cycles  
2.3. Housing Conditions 
Two animals will be housed in autoclaved polypropylene rat cages (Size in mm=L 
x W x H: 430 x 290 x 160) using paddy husk as the bedding material. Each cage 
will be fitted with a top grill having provision for keeping rodent pellet feed and 
an autoclaved polypropylene water bottle with stainless steel drinking nozzle. 
Cages will be placed on 3-tier racks and cage rotation will be performed every 
week. Cages will be changed at least twice a week. The cages and water bottles 
will be cleaned and autoclave sterilized. 
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2.4. Sanitation 
Each day, the floor of the animal room will be swept and mopped. Cages and 
bedding material will be changed once in three days and water bottles will be 
changed daily. All the experimental procedures will be done in a clean 
environment. 
2.5. Feed 
The experimental animals will be provided with irradiated rodent pellet feed ad 
libitum supplied from Sai feeds Pvt ltd, Chennai . Feed will be withheld for four 
hours prior to blood collection and necropsy. 
2.6. Drinking Water 
Animals will be provided with filtered drinking water ad libitum  passed through 
water filter system (Aquaguard™) in autoclaved polypropylene bottles. Water 
bottles will be changed daily. Microbial analysis of water will be carried out once 
monthly and the report is maintained in the study file. 
3. Personnel Safety 
All personnel handling animals undergo regular medical examination. Protective 
clothing like apron, face mask, head cap, and gloves will be used to maintain hygienic 
conditions. 
4. Materials and Methods  
4.1. Preparation of Dose formulation 
The dose formulation will be prepared under aseptic conditions as per SLS, SOP.  
4.2. Route of Administration and Justification 
Administration will be by oral gavage, as it is one of the possible routes of 
exposure. 
4.3. Frequency and Duration of Administration  
Once daily for 28 consecutive days 
4.4. Dosing Procedure 
The test item will be administered in once daily by oral gavage using a suitable 
intubation cannula fitted with a graduated syringe. The scheme of dosing and 
sacrifice time points are presented in the below below Table. 
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4.5. Experimental Procedures 
All experimental procedures will be performed in accordance with the Study plan 
and Standard Operating Procedures (SOPs) of SLS. 
CONVERSION FORMULA: 
Human dose is 1000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
1000 mg x 2(a) x 0.018 (b) = 18 (c) /150 gm of Rat 
18/1000x150 = 2.7 mg  
Experimental Doses Calculated as per the standard procedures are 
S.No Groups Dose /kg, weight Volume of 
administration 
1 Vehicle Control -- 1 ml 
2 Therapeutic Dose 2.7 mg /kg 1 ml 
3 Middle  Dose 13.5mg/kg 1 ml 
4 High Dose 67.5mg/kg 1 ml 
 
Experimental Design 
Group 
No. Group 
Dose                          
(mg/kg  
b.wt /day) 
No. of Animals 
Male Female 
G1 Vehicle control HONEY/GHEE 5 5 
G2 
Low dose of  KUSTATHI 
CHOORNAM WITH HOT 
WATER 
2.7mg/kg 5 5 
G3 
Intermediate dose 
KUSTATHI CHOORNAM 
WITH HOT WATER   
13.5mg/kg 5 5 
G4 
High dose  KUSTATHI 
CHOORNAM WITH HOT 
WATER   
67.5mg/kg 5 5 
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5. Observations 
  Animals will be observed daily throughout the treatment period at regular 
intervals. During the treatment period, animals will be observed twice daily for any 
clinical signs of toxicity, morbidity and mortality. All the surviving animals will be 
sacrificed at the end of scheduled period and subjected to gross necropsy and 
histopathological evaluations. 
5.1.Clinical Signs 
  All the animals will be subjected to cage-side (home-cage) observations twice a 
day for any clinical signs of toxicity, preferably at the same time each day and 
considering the peak period of anticipated effect. In addition to home cage 
observations, a detailed clinical examination will be performed once prior to dosing 
and weekly thereafter during treatment period.  
5.2. Morbidity/ Mortality 
All animals will be examined twice a day for mortality and signs of morbidity.  
5.3. Body Weights 
Body weights will be recorded at the beginning of acclimatization, before 
randomization, there after at weekly intervals and at the time of necropsy. 
5.4. Feed Consumption 
Feed consumption will be calculated on a weekly basis throughout the study 
period. 
5.5. Hematology and Clinical Biochemistry  
 Hematology and clinical biochemistry tests will be performed with terminally 
collected blood samples on day-29 from all animals. Animals will be deprived of 
feed overnight and blood samples will be collected by tapping the ear for visibility 
of the vein site and inserted the needle into the marginal ear vein and collected the 
blood into micro centrifuge tube. Approximately 0.5 ml of blood will be collected 
in vials containing 1% EDTA (20µl) as an anticoagulant for hematological 
analysis. 
 Approximately 2 ml blood will be collected from each animal in micro centrifuge 
tubes containing 15µl of heparin (19 units) and the plasma will be separated by 
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centrifugation at 4000 rpm for ten minutes at 4oC. The plasma will be stored at -20 
oC ± 2 and used for all clinical chemistry analysis. 
5.6. Hematology 
Erythrocyte count (RBC), Total Leucocyte count (WBC), Hemoglobin (Hb), 
Hematocrit (HCT), Mean Corpuscular Volume (MCV), Mean Corpuscular 
Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC) and 
Platelet (PLTC). 
5.7. Clinical Biochemistry  
Glucose, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), 
Alkaline phosphatase (ALP), Total protein, Albumin, Creatinine, Urea, 
Cholesterol, Triglycerides, Sodium, Potassium, Calcium, and  Chloride. 
5.8 Pathology 
All animals will be euthanized by CO2 asphyxiation and subjected to necropsy 
under the supervision of the veterinary pathologist. Different tissues/organs of 
thoracic, abdominal and cranial cavities will be examined for any gross 
pathological changes. Tissues from vehicle control and high dose groups will be 
subjected to detailed histopathological analysis (Ovaries/ testes,  kidneys, liver, 
lungs). The organs will be fixed using Bouin’s (reproductive organs) and 10% 
neutral buffered formalin (kidneys, liver, spleen, lungs).Processing of tissue will 
be done by spin tissue processer, embedding of the tissue by tissue embedder. The 
tissues will be initially trimmed to 10-20µ thickness and later 3-6µ to obtain 
thinner tissue sections by using rotary microtome. Haematoxylin and Eosin 
staining will be performed for all tissues. 
5.8. Organ Weights 
Absolute weights of adrenal glands, brain, ovaries/testes, epididymis/uterus, 
heart, kidneys, liver, spleen and lungs will be recorded for all the animals after 
trimming adherent tissue immediately after dissection from the animal. Paired 
organs will be weighed together. Relative weights of these organs against fasting 
animal body weights will be calculated and reported. 
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6. Data Compilation  
Data will be summarised in a tabular form showing the number of animals, 
experimental design, dose groups, dose volume and concentrations, test item and 
vehicle control details. All findings like clinical signs, mortality and morbidity data, 
time of death, body weights, feed consumption, clinical signs, and necropsy and 
pathology observations will be recorded and given in the final report. One original 
copy of the final report is issued to the sponsor.  
7. Statistical Analysis 
All the parameters of treated groups of both sex, viz. body weight, feed consumption, 
organ weights (absolute and relative), biochemical parameters, and hematology 
parameters will be analyzed using SPSS software, version 16.0 by using one-way 
ANOVA test with multiple comparison (vehicle controls treated groups) in the study 
report, and p value < 0.05 is considered as statistically significant.  
8. References 
1. Committee for the Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA) guidelines for Laboratory Animal Facility, The Gazette of 
India, 1998. 
2. Hayes AW, 2000. Principles and Methods of Toxicology, 4
th
 ed., Taylor and 
Francis, London. 
3. Karl-Heinz Diehl, R. H. (2001). A Good Practice Guide to the Administration of 
Substances and Removal of Blood, Including Routes and Volumes. journal of 
applied toxicology , 15-23. 
4. OECD – 407 - Repeated dose 28-day oral Toxicity Study in Rodents, Adopted    
October 3, 2008. 
5. Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
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MATERIALS AND METHODS 
         ESTIMATION OF HEMATOLOGICAL PARAMETERS: 1 
Collection of blood for hematological studies 
  After the treatment period the animals were anaesthetized by ketamine 
hydrochloride and the blood was collected from Retro-orbital sinus by using capillary into 
a centrifugation tube which contains EDTA for haematological parameters The 
haematological parameters like RBC, WBC and Hb percentage, Differential cell count, 
MCV, MCHC, Hematocrit, MCH, platelet count were estimated by the following 
procedures. 
1. ENUMERATION OF RED BLOOD CELLS: 1    Ramnic 2007) 
Reagents : RBC diluting fluid 
 Procedure: 
         Using a red blood cell pipette of haemocytometer, well mixed blood was drawn up 
to 0.5 mark and RBC diluting fluid was taken up to mark II. The fluid blood mixture was 
shaken and transferred onto the counting chamber. The cells were allowed to settle to the 
bottom of the chamber for 2 min. See the fluid does not get dried. Using 45X or high 
power objective the RBC’s were counted uniformly in the larger corner squares.   
The cells were expressed as number of cells x1012/l 
2. ENUMERATION OF WBC: 2    John 1972) 
Reagents: 
  Turk’s fluid: Turk’s fluid was prepared by mixing 2ml of acetic acid with 100 ml 
of distilled water. To this 10 drop of aqueous methylene blue 3 %    w/v) was added. This 
solution haemolysis the red cells due to acidity so that counting of white cells becomes 
easy. 
Procedure:     
              Using a white blood cell pipette of haemocytometer, well mixed blood was 
drawn up to 0.5 mark and WBC diluting fluid was taken up to mark II. The fluid blood 
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mixture was shaken and transferred onto the counting chamber. The cells were allowed to 
settle to the bottom of the chamber for 2 min. See the fluid does not get dried. 
  Using 10X or low power objective the WBC’s were counted uniformly in the larger 
corner squares.  
 The cells were expressed as number of cells/10mm. 
3. DIFFERENTIAL LEUCOCYTE COUNT: 3      John 1972) 
Reagent: 
              Leishmann’s stain: 150mg of powdered leishmann’s stain was dissolved in 
133ml of acetone free methanol. 
Procedure: 
 A blood film stained with leishmann’s stain was examined under oil immersion 
and the different types of WBCs were identified. The percentage distribution of these 
cells was then determined. Smears were made from anticoagulant blood specimens and 
stained with leishmann’s stain. The slides were preserved for counting the number of 
lymphocytes and neutrophils, per 100 cells were noted.  
 From the different Leukocyte count and WBC count, absolute lymphocyte and 
neutrophil count were calculated. 
                                 Number of neutrophils  
 Absolute neutrophil count =   _______________________________   x  TWBC 
                             100  
                                                                  Number of lymphocytes  
 Absolute lymphocyte count =   _______________________________ x TWBC 
                             100 
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DETERMINATION OF BIOCHEMICAL PARAMETERS: 
 
For assessment of biochemical parameters, blood samples were collected from the 
animals by puncturing the retro-orbital plexus and centrifuged. The serum collected after 
centrifugation was analyzed for various biochemical parameters like SGOT, SGPT, 
ALP,TC.TG,HDL All of the above biochemical parameters were estimated using semi 
autoanalyzer (Photometer 5010 V5+, Germany) with enzymatic kits procured from Piramal 
Healthcare limited, Lab Diagnostic Division, Mumbai, India. 
1. Total Cholesterol (TC)  
 Principle 
Determination of cholesterol is done after enzymatic hydrolysis and oxidation. The 
colorimetric indicator is quinoneimine, which is generated from 4-aminoantipyrine and 
phenol by hydrogen peroxide under the catalytic action of peroxidase (trinder’s reaction). 
Cholesterol ester + H2O       CHE       Cholesterol + Fatty acid 
Cholesterol + O2          CHO      Cholesterol-3-one +H2O2 
2H2O2  + 4- Amino antipyrine + Phenol      POD          Quinonelimine + 4 H2O2 
Method  
 CHOD-PAP: Enzymatic photometric test 
Table 6: Reagents 
Goods buffer (pH 6.7) 50 mmol/ l 
Phenol 5 mmol/l 
4-aminoantipyrine 0.3 mmol/l 
Cholesterol estrase >  200 U/l 
Cholesterol oxidase >  100 U/l 
Peroxidase 3 KU/l 
Standard (5.2 mmol/l) 
 
143 
 
Assay procedure 
a. 1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b.  Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C   for 5 min. 
d. Read the test sample. 
 
NORMAL RANGE: < 200 mg/dl in serum.      
1. Deeg R, Ziegenhorn J, Kinetic enzymatic method for automated determination of 
total cholesterol in serum, Clin. Chem., 1983, 29:1798-802. 
2. Triglycerides 
Principle 
Determination of triglycerides (TG) alters enzymatic splitting with lipoprotein lipase. 
Indicator is quinoneimine which is generated from 4-aminoantipyrine and 4- 
chlorophenol by hydrogen peroxidase under the catalytic action of peroxidase. 
Triglycerides              LPL           Glycerol + fatty acid 
Glycerol + ATP              GK            Glycerol-3-phosphate+ ADP 
Glycerol-3-phosphate +O2         GPO         Dihydroxyaceton phosphate + H2O2 
2H2O2  + 4- Amino antipyrine + 4- chlorophenol         POD     Quinonelimine + HCL + 
4H2O2 
Method 
 Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO). 
Reagents 
Components and concentrations in the test Goods buffer pH 7.2, 50 mmol/ l 
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Table 7: Reagents 
4-chloroPhenol 4 mmol/l 
ATP 2 mmol/l 
Mg2+ 15 mmol/l 
Glycerokinase > 0.4 Kµ/l 
Peroxidase > 2 Kµ/l 
Lipoprotein lipase > 4 Kµ/l 
4-aminoantipyrine 0.5 mmol/l 
Glcerol-3-phosphate- oxidase > 1.5Kµ/l 
Standard (2.3 mmol/l) 
 
Assay procedure 
a.  1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b. Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample. 
 Normal Range: < 200 mg/dl in serum. 
1. Cole T.G, Klotzsch S.G, Mcnarmara J, Measurement of triglyceride concentration, 
In Rifai N, Warnick G.R, Dominiczak M.H, Handbook of lipoprotein testing, 
Washington:AACC, Press, 1997, 115-26. 
3. HDL Cholestrol 
 Principle  
Chylomicrons, VLDL and LDL are precipitated by adding phosphotungstic acid and 
magnesium ions to the sample. Centrifugation leaves only the HDL in the supernatant. 
The cholesterol content in it is determined enzymatically. 
Method 
Phosphotungstic acid precipitation method. 
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Table 8: Reagents 
Phosphotungstic acid 0.55 mmol/l 
Magnesium chloride 25 mmol/l 
Assay procedure 
A.  Preparation of supernatant for the HDL-CHL estimation 
     Added 200 µl of serum to the 500 µl of HDL-Cholesterol precipitating reagent 
(from HDL kit) in 1.5 ml centrifuge tube and mixed well. Centrifuged the above solution 
at 4000 rpm for 10 min. 
B. Preparation of test sample for the estimation of HDL-Cholesterol 
a. Taken 1000 µl of reagent-1 (from cholesterol kit) in a 5 ml test tube. 
b. Added, 100 µl of supernatant from above centrifuged solution 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample.  
Normal Range: > 60 mg/dl in serum. 
1. Friedewald W.T, Levy R.T, Frederickson D.S, Estimation of VLDL and LDL 
cholesterol, Clin. Chem., 1972, 18:499-502. 
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4. ESTIMATION OF SERUM GLUTAMATE PYRUVATE 
TRANSAMINASES (SGPT/ ALT) 
1. Determination of aspartate aminotransferase (AST) 
      Aspartate aminotransferase, also known as Glutamate Oxaloacetate Transaminase 
(GOT) catalyses the transamination of L-aspartate and α keto glutarate to form 
oxaloacetate and L- glutamate. Oxaloacetate formed is coupled with 2,4- Dinitrophenyl 
hydrazine to form hydrazone, a brown coloured complex in alkaline medium which can 
be measured colorimetrically. 
Reagents  
  Buffered aspartate  (pH 7.4); 2,4- DNPH reagent;  4N sodium hydroxide;  
working pyruvate standard; solution I (prepared by diluting 1 ml of reagent 3 to 10 ml 
with purified water). 
Procedure  
    Rietman and Frankle method was adopted for the estimation of SGOT. (Reitmann 
S, Frankel S, 1957. A colorimetric method for the determination of serum oxaloacetic and 
glutamic pyruvate transminases. American Journal of Clinical Pathology.28: 56-63.The 
reaction systems used for this study included blank, standard, test (for each serum 
sample) and control (for each serum sample). 0.25 ml of buffered aspartate was added 
into all the test tubes. Then 0.05 ml of serum was added to the test group tubes and 0.05 
ml of working pyruvate standard into the standard tubes. After proper mixing, all the 
tubes were kept for incubation at 37oC for 60 min, after which 0.25 ml each of 2,4- 
DNPH reagent was added into all the tubes. Then, 0.05 ml of distilled water and 0.05 ml 
of each serum sample was added to the blank and the serum control tubes respectively. 
The mixture was allowed to stand at room temperature for 20 min. After incubation, 2.5 
ml of solution I was added to all test tubes. Mixed properly and optical density was 
measured in a spectrophotometer at 505 nm within 15 min. 
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The enzyme activity was calculated as:-  
AST (GOT) activity in IU/L) = [(Absorbance of test - Absorbance of control)/ 
(Absorbance of standard - Absorbance of blank)] x concentration of the standard         
2.  Determination of alanine aminotransferase (ALT) 
 Alanine aminotransferase, also known as Glutathione Peroxidase (GPT) catalyses 
the transamination of L-alanine and α keto glutarate to form pyruvate and L- Glutamate. 
Pyruvate so formed is coupled with 2,4 – Dinitrophenyl hydrazine to form a 
corresponding hydrazone, a brown coloured complex in alkaline medium which can be 
measured colorimetrically. 
Reagents 
  Buffered alanine (pH 7.4), 2,4–DNPH, 4N sodium hydroxide, working pyruvate 
standard, solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with purified water). 
Procedure  
 Rietman and Frankle method was dopted for the estimation of SGPT. The reaction 
systems used for this study included blank, standard, test (for each serum sample) and 
control (for each serum sample). 0.25 ml of buffered alanine was added into all the test 
tubes. This was followed by the addition of 0.05 ml of serum into the test group tubes and 
0.05 ml of working pyruvate standard into the standard tubes. After proper mixing, all the 
tubes were kept for incubation at 37oC for 60 minutes, after which 0.25 ml each of 2,4- 
DNPH reagent was added into all the tubes. Then, 0.05 ml of distilled water and 0.05 ml 
of each serum sample was added to the blank and the serum control tubes respectively. 
The mixture was allowed to stand at room temperature for 20 min. After incubation, 2.5 
ml of solution I was added to all test tubes. Mixed properly and optical density was read 
against purified water in a spectrophotometer at 505 nm within 15 min. 
  The enzyme activity was calculated as:- ALT (GPT) activity in IU/L) = 
[(Absorbance of test - Absorbance of control)/ (Absorbance of standard - Absorbance of 
blank)] x concentration of the standard.        
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3. Determination of alkaline phosphatase (ALP) 
  Alkaline phoshatase from serum converts phenyl phosphate to inorganic 
phosphate and phenol at pH 10.0. Phenol so formed reacts in alkaline medium with 4-
aminoantipyrine in presence of the oxidising agent potassium ferricyanide and forms an 
orange-red coloured complex, which can be measured spectrometrically. The color 
intensity is proportional to the enzyme activity. 
Reagents: 
Buffered substrate 
Chromogen Reagent 
Phenol Standard, 10 mg% 
Procedure: 
  ALP was determined using the method of Kind (Kind PRM, King EJ, 1972. In-
vitro determination of serum alkaline phosphatase. Journal of Clinical Pathology 7: 321-
22\). The working solution was prepared by reconstituting one vial of buffered substrate 
with 2.2 ml of water. 0.5 ml of working buffered substrate and 1.5 ml of purified water 
was dispensed to blank, standard, control and test. Mixed well and incubated at 370C for 3 
min. 0.05 ml each of serum and phenol standard were added to test and standard test tubes 
respectively. Mixed well and incubated for 15 min at 370C. Thereafter, 1 ml of 
chromogen reagent was added to all the test tubes. Then, added 0.05 ml of serum to 
control. Mixed well after addition of each reagent and the O.D of blank, standard, control 
and test were read against purified water at 510 nm. 
  Serum alkaline phosphatase activity in KA units was calculated as follows  
[(O.D. Test-O.D. Control) / (O.D. Standard- O.D. Blank)] x 10 
 
4. Determination of bilirubin  
  In toxic liver, bilirubin levels are elevated. Hyperbilirubinemia can result from 
impaired hepatic uptake of unconjugated bilirubin, such a situation can occur in 
generalized liver cell injury, certain drugs (e.g Rifampin and probenecid) interfere with 
the rat uptake of bilirubin by the liver cell and may produce a mild unconjugated 
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hyperbilirubinemia. Bilirubin level rises in diseases of hepatocytes, obstruction to 
bilirubin excretion into duodenum, in haemolysis and defects of hepatic uptake and 
conjugation of Bilirubin pigment such as Gilbert’s disease.  
Elevation of total serum bilirubin may occur due to:  
1. Excessive haemolysis or destruction of the red blood cells.Eg:Haemolytic disease 
of the new born. 
2. Liver diseases.Eg.Hepatitis and cirrhosis. 
3. Obstruction of the biliary tract.Eg.Gall stones. 
  The method is based on the reaction of Sulfonilic acid with sodium nitrite to form 
azobilirubin which has maximum absorbance at 546nm in the aqueous solution. The 
intensity of the color Produced is directly proportional to the amount of direct or total 
bilurubin concentration present in the sample. 
Reagents 
1. Diazo A-(Reagent-R1) :Ready to use 
2. Diazo B-(Reagent-R2):Ready to use 
3. Bilirubin Activater :Ready to use 
Procedure 
  Kind & King’s method was followed for the estimation of Bilirubin. Five hundred 
µl of working reagent was added to 50 µl of rat serum & incubated for 5 min at 37°C. 
Absorbance was measured AT 546 NM in semi auto analyzer against the standard. 
  The Bilirubin content was calculated using the following equation: 
  Total bilirubin (mg/dt) = Abs of the sample blank x 15. 
  Direct Bilirubin(mg/dt) = Abs of sample blank x 10. 
5. ESTIMATION OF UREA 
Urea is the nitrogen-containing end product of protein catabolism. States 
associated with elevated levels of urea in blood are referred to as hyper uremia or 
azotemia.  
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Method 
  Estimation of urea was done by Urease-GLDH: enzymatic UV test.  
Principle 
Urea + 2H2O     Urease       2NH4 + 2HCO3 
2- Oxoglutarate +NH4+ +NADH      GLDH      L- Glutamate +NAD+ + H2O                                        
Table 14. Reagents 
 
 
 
 
 
 
Procedure 
a. Take 1000 µl of reagent-1 and 250 µl of reagent-2 in 5 ml test tube. 
b. To this, add 10 µl of serum. 
c. Mix well and immediately read the test sample at 340 nm Hg 334 nm Hg 365 nm 
optical path 1 cm against reagent blank (2-point kinetic). 
d. And note down the value. 
Normal range: 10 – 50 mg/dl. 
6. ESTIMATION OF URIC ACID 
Uric acid and its salts are end products of the purine  metabolism. In gout the most 
common complication of  hyperuricemia, ie. Increased serum levels of uric acid lead to 
formation of  monosodium urate crystal around the joints. 
  
R 1 
TRIS pH 7.8 120  mmol/l 
2-Oxoglutarate 7 mmol/l 
ADP 0.6 mmol/l 
Urease ≥ 6 KU/l 
GLDH ≥ 1 KU/l 
R 2 NADH 0.25 mmol 
R 3 Standard 40 mg/dl 
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Method  
  Enzymatic photometric test using  TOOS (N ethyl- N (hydroxyl -3- sulfopropyl)-
m- toluidin) 
Principle  
Uric acid + H2O + O2       uricase         Allantoin +CO2 +H2O2 
TOOS + 4 aminoantipyrine + 2H2O2      POD       Indamine + 3H2O 
Table 15.reagents 
R1 Phosphate buffer pH 7.0 100mmol/l 
TOOS 1mmol/l 
Ascorbate oxidase ≥1 KU/l 
R2 Phosphate buffer pH 7.0 100mmol/l 
4- amino antipyrine 0.3mmol/l 
K4 (Fe( CN)6) 10µmol/l 
Peroxidase ≥1KU/l 
Uricase ≥50U/l 
 
Procedure 
a. Take 800µl of  reagents -1 in a2ml centrifuge tube. 
b. To this add 20µl of serum. 
c. Mix well and incubate at 30°c for 5 minutes. 
d. Then add 200µl of reagent2 
e. Mix well incubate for 5min at 37°c 
f. Measure the not down the values. 
Normal range: 1.9-8.2mg/dl 
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7. ESTIMATION OF CREATININE:  
Principle: 
  Creatinine forms a coloured complex with picrate in alkaline medium.  
  The rate of formation of the complex is measured.  
Reagents: 
Reagent 1    Standard Creatinine (2mg/100ml) 
Reagent 2    Picric acid solution. 
Reagent 3     sodium hydroxide solution  
Procedure: 
 Take 500 µl of reagent -2 and 500 µl of reagent -3 in a 5ml test tube. To this add 
100 µl of serum. Mix well and immediately read the test sample at Hg 492 nm 1cm light 
path and note down the values.  
Normal range is 0.6 -1.1 mg/dl. 
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TABLE: 1   EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF KUSTATHI 
CHOORNAM WITH HOT WATER ON BODY WEIGHT IN Gram (PHYSICAL 
PARAMETER) 
GPs Control Low Dose Middle Dose High Dose 
 Male Female Male Female Male Female Male Female 
1stwk 137.3±3.528 
139.3±2.
404 
146.7±2.
906 
141.3±1.
764 
132±2.30
9 
135.3±2.
404 
145.3±1.7
64 
142.3±2.
728 
2ndw
k 
142.7±2.
906 
143.7±2.
603 
150.7±1.
764 
150±4.16
3 
138±2.64
6 
139.7±2.
186 
153±1.73
2 
148±2.88
7 
3rdwk 151.7± 3.844 
152±4 
 
154± 
3.055 
156.7± 
1.764 
146.7± 
1.453 
147.3± 
2.963 
157±1.52
8 
 
154.3± 
2.728 
 
4thwk 
162± 
2.082 
 
162.7± 
3.528 
 
163.3± 
3.48 
 
166.3± 
0.8819 
 
157.7± 
0.8819 
 
158.7± 
2.603 
 
166±2.08
2 
162± 
2.646 
 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF KUSTATHI CHOORNAM 
WITH HOT WATER  ON FOOD INTAKE In Gram  
Groups Control Low Dose Middle Dose High Dose 
DAY Male Female Male Female Male Female Male Female 
Day 1 34 28 15 10 18 60 12 24 
DAY2 38 62 56 31 28 80 8 58 
DAY3 38 30 44 52 66 32 34 14 
Day 4 56 18 34 24 18 22 42 22 
DAY5 34 10 18 6 44 58 38 26 
Day 6 60 12 58 68 32 38 58 64 
DAY7 50 14 61 88 58 34 62 74 
DAY8 32 44 18 40 26 64 58 62 
Day 9 80 56 22 60 48 56 56 64 
DAY10 74 62 45 56 64 74 24 58 
Day 11 44 54 68 58 30 62 70 56 
DAY12 54 60 38 62 56 64 62 48 
DAY13 72 56 38 44 57 74 54 78 
Day 14 38 19 54 50 16 74 72 56 
DAY15 48 36 64 71 82 56 56 28 
Day 16 56 78 54 42 56 80 56 77 
DAY17 56 78 64 58 44 56 56 74 
DAY18 45 52 34 56 72 64 62 54 
Day 19 50 48 62 56 88 64 64 58 
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DAY20 16 35 20 75 35 56 72 34 
DAY21 34 56 64 68 56 64 45 62 
Day 22 56 34 18 58 64 78 56 42 
DAY23 46 28 64 56 67 58 18 34 
DAY24 54 42 34 78 46 64 30 68 
Day 25 40 80 55 44 88 80 34 64 
DAY26 64 42 56 64 52 46 58 56 
DAY27 68 45 32 38 56 80 56 58 
DAY28 88 36 58 34 24 74 62 61 
 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF KUSTATHI CHOORNAM 
WITH HOT WATER ON WATER INTAKE IN ml 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 70 75 85 140 70 100 50 70 
DAY2 105 60 85 60 50 85 140 105 
DAY3 130 60 85 60 70 150 165 130 
Day 4 70 90 40 55 80 100 90 70 
DAY5 130 210 60 70 130 70 75 60 
Day 6 50 70 90 50 65 60 70 85 
DAY7 70 80 50 130 60 70 90 55 
DAY8 130 60 50 70 75 50 70 55 
Day 9 110 40 80 55 130 20 130 85 
DAY10 65 130 40 130 70 50 60 70 
Day 11 80 60 55 70 60 60 70 30 
DAY12 70 60 75 40 45 80 60 40 
DAY13 50 60 40 65 55 50 30 60 
Day 14 40 40 65 60 85 65 20 70 
DAY15 60 65 20 60 65 80 60 70 
Day 16 45 60 50 65 30 70 60 40 
DAY17 80 60 40 70 30 60 20 55 
DAY18 60 80 65 60 40 90 170 140 
Day 19 70 115 125 120 20 95 185 140 
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DAY20 70 90 95 50 65 60 75 50 
DAY21 70 60 85 130 90 50 95 85 
Day 22 140 40 60 105 70 60 90 60 
DAY23 60 95 60 65 80 95 70 50 
DAY24 110 90 75 60 70 50 60 70 
Day 25 130 60 125 110 85 60 70 60 
DAY26 70 110 90 60 50 70 110 40 
DAY27 70 90 50 70 40 110 60 140 
DAY28 65 50 110 60 85 75 60 125 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF KUSTATHI CHOORNAM 
WITH HOT WATER ON ORGAN WEIGHT in gm 
Values arae expressed as mean ± SEM Statistical significance (p) calculated by 
one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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GROUP CONTROL 
 
Low Dose 
 
Middle Dose 
 
High Dose 
LIVER  
WEIGHT 
7.015±0.380
5 5.468±0.7463 5.987±0.0561 6.24±0.3043 
KIDNEY 
WEIGHT 
L 0.921±0.08582 
0.7613±0.056
74 
0.7443±0.0197
5 0.8363±0.05655 
R 1.165±0.2567 
0.717±0.0327
9 
0.696±0.00907
4 0.8233±0.07304 
HEART 
WEIGHT 
0.8463±0.03
93 
0.8493±0.088
15 
0.7603±0.0339
8 0.972±0.1363 
LUNGS  
WEIGHT 
1.721±0.407
1 
0.8027±0.060
03 1.016±0.2056 1.601±0.4463 
TESTIS WEIGH 2.841±0.383 2.511±0.3985 2.101±0.3407 2.412±0.4074 
UTERUS 0.4477±0.0465 
0.463±0.0457
9 
0.4347±0.0494
4 0.6013±0.1393 
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Kidney weight (L& R)
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KUSTATHI CHOORNAM WITH 
HOT WATER ON HAEMATOLOGICAL PARAMETERS 
Groups Control Low Dose Middle Dose High Dose 
Rbc (X103/µl) 
 5.33±0.8585 6.403±0.289 5.96±0.2173 6.213±0.3619 
Wbc(X106/µl) 11.17±0.8762 11.87±0.8212 13.73±0.636 13.3±0.3606 
 
Hb (g/dl) 
 
16.4±1.29 
 
16.37±1.707 
 
13.5±0.3055 
 
14.37±0.977 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by 
one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 
0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KUSTATHI CHOORNAM WITH 
HOT WATER ON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Total 
Bilirubin(mg/dl) 
0.625±0.125 0.865±0.195 0.79±0.06 1.015±0.055 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by 
one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 
0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KUSTATHI CHOORNAM WITH 
HOT WATER ON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
 
SGOT (U/L) 
 
85.95±9.25 
 
133.2±37.95 
 
77.9±14.9 
 
81.35±3.05 
 
SGPT (U/L) 69.79±15.72 
 
45.4±3.8 
 
48.15±21.85 
 
38.15±3.95 
 
ALP (U/L) 308.2±24.55 
 
321.8±15.75 
 
247.8±10.55 
 
267.3±1.9 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p) calculated by 
one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 
0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KUSTATHI CHOORNAM WITH 
HOT WATER ON BIOCHEMICAL PARAMETER (KIDNEY PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Urea (mg/dl) 26.03±1.01 33.45±0.25 39.08±1.18 26.74±1.13 
Uric acid 
(mg/dl) 
1.615±0.135 1.2±0.04 1.31±0.07 1.64±0.1 
Creatinine 
(mg/dl) 
0.33±0.05 0.275±0.005 0.23±0.02 0.29±0.09 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by 
one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 
0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F KUSTATHI CHOORNAM WITH 
HOT WATER ON BIOCHEMICAL PARAMETER (LIPID PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Total 
cholesterol 
(mg/dl) 
34.3±3.6 44.85±0.75 44.95±8.05 41.2±1.1 
Triglycerides 
(mg/dl) 
101.3±5 71.55±4.85 68.28±2.48 80.4±3.8 
HDL-
Cholesterol 
(mg/dl) 
10.12±0.185 6.625±1.945 6.65±2.05 3.9±0.7 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 
calculate by comparing treated group with CONTROL group.         
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RESULTS: 
CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the dosing   
period of 28 days. 
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Mortality: 
All animals in control and in all the treated dose groups survived throughout the 
dosing period of 28 days. 
 Body weight: 
Results of body weight determination of animals Table-1 from control and 
different dose groups exhibited comparable body weight gain throughout the dosing 
period of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food consumed 
by animals from different dose groups was found to be comparable with that by control 
animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in Table 
No.4 Comparison of organ weights of treated animals with respective control animals on 
day 29 was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations (Table 4) conducted on day 29 
revealed following significant changes in the values of different parameters investigated 
when compared with those of respective controls; however, the increase or decrease in the 
values obtained was within normal biological and laboratory limits or the effect was not 
dose dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on days 29 and recorded in Table 
2 revealed the following significant changes in the values of hepatic serum enzymes 
studied. When compared with those of respective control. However, the increase or 
decrease in the values obtained was within normal biological and laboratory limits. 
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Histopathology: 
In histopathological examination, revealed normal architecture in comparison with 
control and treated animal. 
 DISCUSSION: 
1)  All the animals from control and all the treated dose groups up to 500 mg/kg survived 
throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during the 
dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain with 
that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29, 
revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29 no 
abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was found to be 
comparable with that of respective controls. 
8) Histopathological examination revealed normal architecture in comparison with 
control and treated animal. 
 SUMMARY AND CONCLUSION:  
In conclusion KUSTATHI CHOORNAM WITH HOT WATER can be 
considered safe, as it did not cause either any lethality or adverse changes with general 
behavior of rats and also there were no observable detrimental effects (100 to 300 mg/kg 
body weight) over a period of 28 days. Our results have demonstrated that the 
KUSTATHI CHOORNAM WITH HOT WATER is relatively safe when administered 
orally in rats. 
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9.0 ABBRVIATION 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o.  peros 
mL  Milliliter 
%   percentage 
R&D   Research and Development 
EDTA  Ethylene Diamine Tetra Acetic Acid 
M   Male 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD  Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments on               
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HISTOPATHOLOGY   -  TOXICITY STUDY 
SPECIMEN     : A) Liver.    Group –    : Kustathi choornam. 
 
                                                       
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
    Section from liver shows lobular architecture with interface hepatitis. Individual 
Hepatocytes shows reactive atypia. Portal triad shows no significant pathology. Central 
vein and Sinusoids show dilatation. 
40x shows altere lobular architectuire 40x shows central vein dilatation and 
interface hepatitis 
40x shows interface hepatitis 40x shows reactive atypia 
40x shows altere lobular architectuire 40x shows sinusoidal dilatation 
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SPECIMEN    :  B) spleen. 
Group – :  Kustathi choornam 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
                     Section studied from spleen shows normal white pulp and red pulp. Red pulp 
shows pigment laden macrophages and congested vessels. White pulp shows lymphocytic 
infiltrates forming germinal centre. The pencillar artery shows normal morphology. 
Megakaryocytes 
10x show snormal red and white pulp 10x shows spleen 
40x shows normal pencillar artery 
40x shows pigment laden macrophages with 
lymphocytic infiltrates 
40x shows red pulp shows pigment laden 
macrophages 
40x shows white pulp with lymphocytic 
infilatrates 
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    SPECIMEN  :  C)  Kidney. 
Group – :  Kustathi choornam 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE: 
 
 Section from kidney shows both cortex and medulla. Glomeruli and tubules shows no 
significant pathology. Interstitium shows no significant pathology. Blood vessels show 
congestion. There is no evidence of toxic changes. 
 
10x show snormal cortex and medulla 10x shows cortex 
40x shows blood vessels congestion 
40x shows interstitium 
40x shows normal glomeruli 40x shows normal tubules 
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SPECIMEN  :  D) Testis 
Group – :  Kustathi choornam 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
           Section from testes with seminiferous tubules showing maturation arrest with 
lacking of spermatogenesis.  
 
10x shows focal maturation arrest 10x shows normal tubules with maturation 
arrest 
40x shows normal spermatogenesis with 
maturation arrest 
40x shows spermatogenesis (2) 
40x shows spermatogenesis 40x shows tubules 
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ANNEXURE – IV 
 
ASSESSMENT FORMS 
 
FORM I   –         SCREENING FORM 
FORM II -         CONSENT FORM 
FORM III –       CASE SHEET PROFORMA 
FORM IV -        LABORATORY INVESTIGATIONS 
FORM V –         CLINICAL ASSESSMENT 
FORM VI -        PATIENT WITHDRAWAL FORM 
FORM VII -       DRUG COMPLIANCE FORM 
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GOVERNMENT  SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI. 
POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM. 
AN  OPEN CLINICAL TRIAL ON KUSTATHI CHOORNAM AND ERANDA 
THYLAM FOR THE TREATMENT OF ‘THANDAGAVADHAM’. 
FORM I –SCREENING FORM 
1. OP/ IP No:                                          2. BED No:                        3. Sl. No:  
 4.   NAME:                                             5. AGE:                              6. GENDER:  
 7.   OCCUPATION:                               8. SOCIAL STATUS 
9.  DATE OF ADMISSION:                 10. DATE OF DISCHARGE: 
11. POSTAL ADDRESS: 
INCLUSION CRITERIA: 
• Age : 20-60 yrs 
• Sex : Both male and female 
• Patients having symptoms of Pain in the lumbar region, Radiating pain to 
buttocks and lower limbs ,stiffness present in lumbar region, Exacerbation of 
pain on movements, Pain increased on forward bending, Tingling 
sensation.(Numbness) 
• Patients who are willing   to give  radiological investigation  and provide blood 
for lab investigation. 
• Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 48 days but can option out of the 
trial of his/her own conscious discretion.  
EXCLUSION CRITERIA: 
• Cardiac disease 
• Auto immune diseases like Rheumatoid arthiritis, SLE, Psoriasis, Mixed 
connective tissue disorder. 
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• Spina bifida 
• Liver Disease 
• Pregnancy and lactation 
• Osteo myelitis 
• Renal Disease 
• Tuberculosis in spine 
• Patient with any other serious illness 
• Other systemic illness  
• Dislocation  
 WITHDRAWAL CRITERIA             
                  Intolerance to the drug &development  of adverse reactions during drug trial. 
• Poor patient compliance & defaulters. 
• Patient turned unwilling to continue in the course of clinical trial. 
• Occurrence of any serious illness 
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GOVERNMEN   SIDDHA  MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI. 
POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL ON KUSTATHI CHOORNAM AND ERANDA 
THYLAM’ FOR THE TREATMENT OF ‘THANDAGAVADHAM’ 
 
Form: II CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
  I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient. 
Signature………………….                                                                                                                             
Date………                     Name…………………… 
CONSENT BY PATIENT 
I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions.  
I am aware of my right to opt out of the trial at any time during the course of the 
trial without having to give the reasons for doing so. 
I, exercising my free power of choice, hereby give my consent to be included as a 
subject in the clinical trial of KUSTATHI CHOORNAM (INTERNAL) AND 
ERANDA THYLAM (EXTERNAL) for the treatment of THANDAGAVATHAM. 
                                                                                                                                 
Signature…………………                                                                                
Name…………………….. 
Date………………….. 
!
!
!
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI. 
POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL ON KUSTATHI CHOORNAM AND!ERANDA 
THYLAM FOR THE TREATMENT OF THANDAGAVADHAM. 
CASE PROFORMA 
                                          Dissertation done by : 
I.P. No :                 Occupation  : 
Bed No :     Income : 
Ward  :     Nationality  : 
Name  :     Religion  : 
Age  :     Date of Admission : 
Sex  :     Date of Discharge : 
Permanent Address :                Diagnosis  : 
       Result   : 
       Medical Officer : 
Complaints and duration: 
 
History of  present illness: 
 
History of  Previous Illness: 
Personal History including habits: 
Family History: 
GENERAL CONDITIONS ON EXAMINATION 
1. Consciousness   : 
2. General appearance  : 
3. Stature    : 
4. Nourishment   : 
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5. Skin Changes   : 
6. Face     : 
7. Pallor    : 
8. Jaundice    : 
9. Cyanosis    : 
10. Clubbing              : 
11. Lymphadenopathy : 
12. Abdominal Distension : 
13. Jugular Venous Pulsation : 
14. Engorged veins  : 
15. Koilonychia   : 
16. Pedal oedema   : 
17. Generalised Oedema  : 
18. Temperature   : 
19. Pulse :  Rate   :  /min 
  Rhythm  : 
  Volume  : 
  Character  : 
  Peripheral Pulses : 
  Pulses paradoxus : 
20. Respiratory Rate  : /min 
21. Heart Rate  :          /min 
22. Blood pressure : (mm/Hg) 
    Right   Left        Upper limb 
23. Miscellaneous 
!
! !
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sqk<k!Ljx!OkIU<<< !
2/!fqzl<!
! GxqR<sq!
! Lz<jz!
! lVkl<!
! ofb<kz<!
! hijz!
3/!hVu!gizl<!
! giI!gizl<!! ! )Nu{q!.!Hvm<misq*!
! %kqI!gizl<!!! )Jh<hsq!.!giIk<kqjg*!
! Le<heq! ! )!liIgpq!.!jk!
! hqe<heq! ! )!lisq!.!hr<Geq*!
! -tOueqz<! ! )!sqk<kqjv!.!jugisq*!
! LKOueqz<! ! )!Neq!.!Nc*!
4/!big<jg!)dmz<*!
! uikl<!
! hqk<kl<!
! ghl<!
! gzh<H!
5/!G{l<!
! sk<Kul<!
! -viskl<!
! kilsl<!
6/!hqx!dXh<Hgtqe<!fqjz!
! -Vkbl<! ! ! .!
! Hh<Hsl<! ! .!
! -jvh<jh! ! ! .!
! gz<zQvz<! ! ! .!
! l{<{Qvz<! ! ! .!
! sqXGmz<! ! ! .!
186 
 
! ohVr<Gmz<! ! ! .!
! sqXfQvgl<! ! ! .!
! &jt!! ! .!
! gVh<jh! ! ! .!
7/!dbqI!kiKg<gt<!
)n*! uikl<!! ! .!
! hqvi{e<! ! ! .!
! nhiee<! ! ! .!
! uqbiee<! ! ! .!
! dkiee<! ! ! .!
! sliee<! ! ! .!
! fige<!! ! ! .!
! %Ile<!! ! .!
! gqVgve<! ! ! .!
! Okukk<ke<! ! ! .! !
! keR<osbe<! ! ! .!
)N*!hqk<kl<!
! nex<!hqk<kl<!! ! .!
! -vR<sg!hqk<kl<! ! .!
! sikg!hqk<kl<!! ! .!
! NOzisg!hqk<kl<! ! .!
! hqvisg!hqk<kl<! .!
)-*!ghl<!
! nuzl<hgl<! ! ! .!
! gqOzkgl<! ! ! .!
! Ohikgl<! ! ! .!
! kx<hgl<! ! ! .!
! sf<kqgl<! ! ! .!
8/!dmz<!kiKg<gt<!
! sivl<! ! ! ! .!
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! osf<fQI!! ! ! .!
! D{<! ! ! ! .!
! ogiPh<H! ! ! .!
! we<H! ! ! ! .!
! &jt!! ! .!
! Sg<gqzl<0SOvi{qkl<!.!
9/!w{<!ujgk<OkIUgt<! !
! fic! ! ! ! .!
! ^<hiqsl<! ! ! .!
! fi! ! ! ! .!
! fqxl<! ! ! ! .!
! olipq!! ! .!
! uqpq! ! ! ! .!
lzl<!
! fqxl<! ! ! ! .!
! wjm! ! ! ! .!
! -Xgz<! ! .!
! -tgz<! ! .!
sqXfQI!
2!fQIg<Gxq!
! fqxl<! ! ! ! .!
! l{l<!! ! ! .!
! wjm! ! ! ! .!
! Fjv! ! ! ! .!
! wR<sz<!! ! .!
3/!ofb<g<Gxq 
EXAMINATION OF THE SPINE AND JOINTS 
A) GALS LOCOMOTOR SCREENING 
A(Appearance)  M (Movement) 
         G     
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          A 
          L 
          S 
B) PROVOCATIVE TESTS 
i. Straight leg raising test (SLR) 
ii. Contralateral well leg raising test 
iii. Braggard’s test 
iv. Femoral nerve stretch test 
v. Schobler’s test 
vi. Forward bending to touch the toes 
vii. Flip test 
viii. Lassegue test 
ix. Bowstring sign 
C) INSPECTION 
 Skin over the vertebrae 
            Attitute and Defornity 
 Muscular Wasting 
 Trophic changes 
 Swelling 
 Fasciculation 
 Gait 
D) PALPATION 
 Local temperature 
 Tenderness 
 Rigidity and Deformity 
 Wasting 
 Swelling 
 Lymphadenopathy 
 Cold abscess 
E) GENERAL  MOVEMENTS 
 Painful / Not painful 
           Pain scale used:  Back pain functioning scale. 
 Restricted / Non restricted - Restricted movement assessment scale 
 Excess Mobility in any direction. Present/ Not present 
Examination of CVS 
Examination of RS 
Examination of Abdomen 
Case Summary: 
Differential Diagnosis: 
Diagnosis: 
Follow Up 
Date  
Symptoms 
Drug 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI. 
POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL ON KUSTATHI CHOORNAM AND ERANDA 
THYLAM  FOR THE TREATMENT OF THANDAGAVADHAM. 
Form IV -LABORATORY INVESTIGATIONS 
1. OP/ IP No:                                               2. BED No:                           3. Sl. No:  
 4.   NAME:                                                     5. AGE:                                 6. GENDER:  
 7.   OCCUPATION:                                      8. SOCIAL STATUS 
9.  DATE OF ENROLLMENT:                      10. DATE OF DISCHARGE: 
11. POSTAL ADDRESS: 
 
Date: 
LABORATORY INVESTIGATION 
1. BLOOD 
 TC : Cells / cu.mm 
 DC : P % L% E % M % 
 ESR : 
   1/2 hour  : mm 
   1 hour : mm 
 Hb   : 
 Blood Sugar  : 
 Blood Urea  : 
 Serum Cholesterol : 
 
Lecturer  HOD 
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2. URINE 
 Albumin : 
 Sugar  : 
 Deposits : 
3. Motion 
 Ova   : 
 Cyst   : 
5. RADIOGRAPHIC FINDINGS 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI. 
POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL ON KUSTATHI CHOORNAM AND ERANDA 
THYLAM  FOR THE TREATMENT OF THANDAGAVADHAM. 
FORM - V ASSESSMENT PROFORMA 
1. IP / OP No  2. Sl. No 
4.  Name. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
5. Date of admission  
6. Date of discharge 
CLINICAL ASSESSMENT: 
 
Sl.no Signs and symptoms 10th day 20th day 30th day 
1. Low back ache    
2. Radiating pain to lower 
limbs 
   
3. Restricted movements    
4. Tenderness    
5. Numbness in lower 
limbs  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI. 
POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL ON KUSTATHI CHOORNAM AND ERANDA 
THYLAM FOR THE TREATMENT OF THANDAGAVADHAM. 
FORM - VI PATIENT WITHDRAWAL FORM 
 
1.  OP / IP No                             2. S.No.   3.Date: __________ 
4.  Name                 5. Age  __________      6. Gender ________ 
7.  Postal address: 
 
Complaints and Duration: 
 
Irregular Treatment: 
 
Adverse Reactions: 
 
Other causes: 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI. 
POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL ON KUSTATHI CHOORNAM AND ERANDA 
THYLAM FOR THE TREATMENT OF THANDAGAVADHAM. 
FORM VII - DRUG COMPLIANCE FORM 
Name of the Drug:KUSTATHI CHOORNAM  
Drugs issued: ………grams                        Drugs returned:  ……grams 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                Signature of the HOD 
 
 
S.NO DATE 
MORNING/TIME NIGHT/TIME 
Day 1    
Day 2    
Day 3    
Day 4    
..    
..    
Up to day 30    
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